

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
11 December 2003 (11.12.2003)

PCT

(10) International Publication Number  
**WO 03/102019 A2**

- (51) International Patent Classification<sup>7</sup>: **C07K**
- (21) International Application Number: **PCT/US03/17638**
- (22) International Filing Date: **4 June 2003 (04.06.2003)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**10/161,996** **4 June 2002 (04.06.2002)** **US**
- (71) Applicant (*for all designated States except US*): **ISIS PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **FRIER, Susan, M.** [US/US]; 2946 Renault Street, San Diego, CA 92122 (US). **BAKER, Brenda, F.** [US/US]; 2147 Avenida Toronja, Carlsbad, CA 92009 (US). **DOBIE, Kenneth, W.** [GB/US]; 703 Stratford Ct., #4, Del Mar, CA 92014 (US).
- (74) Agent: **COZEN O'CONNOR P.C.**; 1900 Market Street, Philadelphia, PA 19103 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **ANTISENSE MODULATION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-1 EXPRESSION**

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of sterol regulatory element-binding protein-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding sterol regulatory element-binding protein-1. Methods of using these compounds for modulation of sterol regulatory element-binding protein-1 expression and for treatment of diseases associated with expression of sterol regulatory element-binding protein-1 are provided.

**WO 03/102019 A2**

5           **ANTISENSE MODULATION OF STEROL REGULATORY ELEMENT-BINDING  
                  PROTEIN-1 EXPRESSION**

10   **FIELD OF THE INVENTION**

          The present invention provides compositions and methods for  
modulating the expression of sterol regulatory element-binding  
protein-1. In particular, this invention relates to compounds,  
particularly oligonucleotides, specifically hybridizable with  
15   nucleic acids encoding sterol regulatory element-binding  
protein-1. Such compounds have been shown to modulate the  
expression of sterol regulatory element-binding protein-1.

**BACKGROUND OF THE INVENTION**

20           Cholesterol and fatty acids are primary components of  
cellular membranes. Cholesterol plays several essential roles  
in mammalian cell biology. It modulates the properties of cell  
membranes and serves as the precursor for steroid hormones, bile  
acids, and vitamin D and is required for proper embryonic  
25   patterning. High plasma cholesterol levels contribute to  
atherosclerotic disease, whereas cholesterol deficit causes  
developmental defects, thus cholesterol levels must be carefully  
controlled. Fatty acid synthesis, called lipogenesis, is an  
energy storage system specialized to adipose tissue and the  
30   liver and is also required to support cellular growth.  
Lipogenesis is stimulated primarily by hormones such as insulin  
and the availability of carbohydrates (Shimano, *Prog. Lipid*  
*Res.*, **2001**, *40*, 439-452).

The transcription of genes involved in cholesterol and fatty acid biosynthesis is controlled by the transcription factors known as sterol regulatory element-binding protein-1 and -2. These target genes include, but are not limited to: LDL receptor, HMG CoA synthase, HMG CoA reductase, farnesyl diphosphate synthase, squalene synthase, lanosterol 14a-demethylase, acetyl CoA carboxylase, fatty acid synthase, stearyl CoA desaturase-1 and -2, acetyl CoA binding protein, ATP citrate lyase, malic enzyme, PPAR gamma, Acetyl CoA synthase, glycerol-3-phosphate acyltransferase, lipoprotein lipase, and HCL receptor. The 5' region of these genes contains the sterol regulatory element-1 (SRE-1) or E-box promoters to which the basic helix-loop-helix sterol regulatory element-binding protein-1 binds (Shimano, *Prog. Lipid Res.*, **2001**, *40*, 439-452).

The gene encoding sterol regulatory element-binding protein-1 (also called SREBP-1, SREBP-1a, SREBP-1c, sterol regulatory element BP-1c, sterol regulatory element-binding transcription factor 1, and SREBF1) was cloned in 1993 and two alternatively spliced isoforms exist, termed SREBP-1a and SREBP-1c, with alternative sequences on both the 5' and 3' ends (Yokoyama et al., *Cell*, **1993**, *75*, 187-197). Both of these activate transcription of genes containing SRE-1 promoters, therefore the significance of the alternative splicing is not currently known. Disclosed and claimed in US Patent 5,527,690 is a nucleic acid sequence encoding sterol regulatory element-binding protein-1, as are expression vectors expressing the recombinant DNA, and host cells containing said vectors (Goldstein et al., **1996**).

In a feedback control mechanism, the intracellular cholesterol levels serves as a regulator of transcriptional activity whereby transcription is suppressed when cholesterol levels increase. Sterol regulatory element-binding protein-1 is localized to the endoplasmic reticulum by a C-terminal hydrophobic extension. In sterol-depleted cells, sterol

regulatory element-binding protein-1 is cleaved by sterol regulatory element-binding protein-1 cleavage activating protein (SCAP), a protease which is inhibited by cholesterol. The soluble form of sterol regulatory element-binding protein-1 then  
5 translocates to the nucleus. Upon accumulation of sterols in the cells, sterol regulatory element-binding protein-1 remains bound to the membrane and transcription of sterol regulated genes decreases. (Sakai and Rawson, *Curr. Opin. Lipidol.*, **2001**, 12, 261-266).

10 Sterol regulatory element-binding protein-1 may also play a role in repressing the transcription of some genes with SRE-1 promoters via a postulated mechanism whereby sterol regulatory element-binding protein-1 displaces a positive regulator of the those gene. Repression of caveolin transcription by sterol  
15 regulatory element-binding protein-1 has been observed and this may be another feature of sterol regulation since caveolin is involved in regulating cellular cholesterol content (Bist et al., *Proc. Natl. Acad. Sci. U. S. A.*, **1997**, 94, 10693-10698).

20 Sterol regulatory element-binding protein-1c may a link cholesterol and fatty acid metabolism. The liver X receptors (LXR) are a class of transcription factors that are induced by oxysterols, which mostly arise as metabolic derivatives of cholesterol. One of the target genes transcribed by LXRs is sterol regulatory element-binding protein-1c, the upregulation  
25 of which promotes lipid synthesis to coordinate the homeostatic balance between fatty acids and sterols (Repa et al., *Genes Dev.*, **2000**, 14, 2819-2830).

Glucose and insulin are required for the production of fatty acids via the induction of hepatic lipogenic enzymes.

30 Sterol regulatory element-binding protein-1c is upregulated by insulin *in vivo* and in hepatocyte cultures (Azzout-Marniche et al., *Biochem. J.*, **2000**, 350 Pt 2, 389-393.; Shimomura et al., *Proc. Natl. Acad. Sci. U. S. A.*, **1997**, 94, 12354-12359). Sterol regulatory element-binding protein-1c is also upregulated in the  
5 ob/ob mouse and a transgenic mouse model of lipodystrophy



(Shimomura et al., *Mol. Cell*, 2000, 6, 77-86). The pivotal role sterol regulatory element-binding protein-1 has in lipid metabolism and the action of insulin suggests that sterol regulatory element-binding protein-1c might be involved in pathologies such as type 2 diabetes, obesity, and insulin resistance syndromes and is a potential target for pharmacological manipulation (Ferre et al., *Biochem. Soc. Trans.*, 2001, 29, 547-552).

Growth-factor induced activation of the sterol regulatory element-binding protein-1 pathway has been proposed as one of the mechanisms responsible for upregulation of lipogenic gene expression in a subset of cancer cells. In LNCaP prostate cancer cells, the growth factor EGF stimulates sterol regulatory element-binding protein-1 expression which then leads to upregulation of the expression of fatty acid synthase (FAS). This pathway has been suggested as a target for chemotherapeutic intervention because increased expression of FAS has been observed in certain aggressive cancers such as prostate, breast, ovary, colon, tongue, thyroid, and endometrium (Swinnen et al., *Oncogene*, 2000, 19, 5173-5181).

Upregulation or increase in soluble sterol regulatory element-binding protein-1 may be a side effect of antiretroviral therapy used in AIDS patients. Highly-active antiretroviral therapy (HAART) has dramatically reduced AIDS-related deaths, however long-term HAART has been associated with a unique syndrome of lipodystrophy and other metabolic complications such as hyperlipidemia, insulin resistance, and lactic acidosis. Lipodystrophy observed in AIDS patients has also been observed in a mouse model overexpressing sterol regulatory element-binding protein-1 (Shimomura et al., *Genes Dev.*, 1998, 12, 3182-3194). Thus HAART-associated lipodystrophy has been attributed overexpression or an increase in soluble sterol regulatory element-binding protein-1, which leads to perturbations in the synergistic regulation of genes involved in maintenance of cholesterol homeostasis (Nerurkar et al., *Clin. Biochem.*, 2001,

34, 519-529). Consistent with this hypothesis is the observation that sterol regulatory element-binding protein-1 is upregulated in 3T3-L1 preadipocytes undergoing differentiation enhanced by ritonavir, a protease inhibitor used in HIV therapy.

5 The postulated mechanism involves ritonavir-stimulated inhibition of proteasomal activity, the route through which sterol regulatory element-binding protein-1 is degraded in cells (Nguyen et al., *AIDS*, 2000, 14, 2467-2473).

Transgenic mice overexpressing sterol regulatory element-binding protein-1 in adipose tissue exhibit many of the features of congenital generalized lipodystrophy, an autosomal recessive disorder in humans characterized by profound insulin resistance, hyperinsulinemia, hyperglycemia, a paucity of white fat, and an enlarged fatty liver (Shimomura et al., *Genes Dev.*, 1998, 12, 3182-3194).

Currently, there are no known therapeutic agents which effectively inhibit the synthesis of sterol regulatory element-binding protein-1 and to date, investigative strategies aimed at modulating sterol regulatory element-binding protein-1 function have involved the use of an antisense expression vector. The decreased expression of by an antisense cDNA in HepG2 cells illustrated that sterol regulatory element-binding protein-1 is selectively involved in the signal transduction pathway of insulin and insulin-like growth factor leading to low density lipoprotein receptor gene activation (Streicher et al., *Z Ernahrungswiss*, 1998, 37, 85-87.; Streicher et al., *J. Biol. Chem.*, 1996, 271, 7128-7133).

A natural process in which sterol regulatory element-binding protein-1 expression is suppressed demonstrates the potential benefits of downregulating genes encoding proteins of lipid synthesis. Polyunsaturated fatty acids decrease the nuclear abundance and expression of sterol regulatory element-binding protein-1 and simultaneously upregulate the expression of genes encoding proteins involved in fatty acid oxidation. These beneficial effects associated with oxidation of fatty

acids instead of storage include a reduced risk of heart disease and improvements in the metabolic syndrome such as increased insulin sensitivity (Clarke, *J. Nutr.*, 2001, 131, 1129-1132).

Consequently, there remains a long felt need for agents  
5 capable of effectively inhibiting sterol regulatory element-binding protein-1 function.

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of  
.0 therapeutic, diagnostic, and research applications for the modulation of sterol regulatory element-binding protein-1 expression.

The present invention provides compositions and methods for modulating sterol regulatory element-binding protein-1  
.5 expression.

#### SUMMARY OF THE INVENTION

The present invention is directed to compounds,  
10 particularly antisense oligonucleotides, which are targeted to a nucleic acid encoding sterol regulatory element-binding protein-1, and which modulate the expression of sterol regulatory element-binding protein-1. Pharmaceutical and other compositions comprising the compounds of the invention are also  
15 provided. Further provided are methods of modulating the expression of sterol regulatory element-binding protein-1 in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an  
20 animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of sterol regulatory element-binding protein-1 by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the  
25 invention.

**DETAILED DESCRIPTION OF THE INVENTION**

The present invention employs oligomeric compounds, particularly antisense oligonucleotides, for use in modulating the function of nucleic acid molecules encoding sterol regulatory element-binding protein-1, ultimately modulating the amount of sterol regulatory element-binding protein-1 produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding sterol regulatory element-binding protein-1. As used herein, the terms "target nucleic acid" and "nucleic acid encoding sterol regulatory element-binding protein-1" encompass DNA encoding sterol regulatory element-binding protein-1, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translocation of the RNA to sites within the cell which are distant from the site of RNA synthesis, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of sterol regulatory element-binding protein-1. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

As used herein, the term "oligomeric compound" refers to a compound comprising a plurality of linked nucleases. In some embodiments, oligomeric compounds comprise from about 5 to 100 nucleases. In some embodiments, oligomeric compounds comprise  
5 from about 8 to about 50 nucleobases (i.e. from about 8 to about 50 linked nucleosides), and even more preferably from about 12 to about 30 nucleobases. The present invention is also intended to comprehend other oligomeric compounds from about 8 to about 50 nucleobases in length which hybridize to the nucleic acid  
10 target and which modulate expression of the target. Such compounds include ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other short catalytic RNAs or catalytic oligonucleotides.

In some embodiments, oligomeric compounds are single or  
15 double stranded. In some embodiments, oligomeric compounds of the present invention possess a hairpin structure. In some preferred embodiments, the present invention provides double stranded oligomeric compounds comprising two complementary oligonucleotides, each oligonucleotide comprising from about 8  
20 to about 50 nucleobases. In some embodiments, such oligomeric compounds serve as substrates for double stranded RNases. In other embodiments, the compounds or oligonucleotides serve as substrates for single stranded RNases.

In some embodiments, the oligomeric compound modulates  
25 expression of the sterol regulatory element-binding protein-1 RNA by at least 10%, preferably about 20%, more preferably about 25%, more preferably about 30%, more preferably about 40%, more preferably about 50%, more preferably about 60%, more preferably about 70%, more preferably about 75%, more preferably about 80%,  
30 more preferably about 85%, more preferably about 90%, more preferably about 95%, more preferably about 98%, more preferably about 99%, and most preferably about 100%.

In some embodiments, the double stranded oligomeric compound modulates expression of the sterol regulatory element-  
35 binding protein-1 RNA by at least 10%, preferably about 20%,

more preferably about 25%, more preferably about 30%, more preferably about 40%, more preferably about 50%, more preferably about 60%, more preferably about 70%, more preferably about 75%, more preferably about 80%, more preferably about 85%, more preferably about 90%, more preferably about 95%, more preferably about 98%, more preferably about 99%, and most preferably about 100%.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding sterol regulatory element-binding protein-1. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function *in vivo*. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in

prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used *in vivo* to initiate translation of an mRNA molecule transcribed from a gene encoding sterol regulatory element-binding protein-1, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the

translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. mRNA transcripts produced via the process of splicing of two (or more) mRNAs from different gene sources are known as "fusion transcripts". It has also been found that introns can be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

It is also known in the art that alternative RNA transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as "variants". More specifically, "pre-mRNA variants" are transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in either their start or stop position and contain both intronic and extronic regions.

Upon excision of one or more exon or intron regions or portions thereof during splicing, pre-mRNA variants produce smaller "mRNA variants". Consequently, mRNA variants are



processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as "alternative splice variants". If no splicing of the pre-mRNA variant occurs  
5 then the pre-mRNA variant is identical to the mRNA variant.

It is also known in the art that variants can be produced through the use of alternative signals to start or stop transcription and that pre-mRNAs and mRNAs can possess more than one start codon or stop codon. Variants that originate from a pre-mRNA or mRNA that use alternative start codons are known as  
.0 "alternative start variants" of that pre-mRNA or mRNA. Those transcripts that use an alternative stop codon are known as "alternative stop variants" of that pre-mRNA or mRNA. One specific type of alternative stop variant is the "polyA variant"  
.5 in which the multiple transcripts produced result from the alternative selection of one of the "polyA stop signals" by the transcription machinery, thereby producing transcripts that terminate at unique polyA sites.

Once one or more target sites have been identified,  
20 oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or  
25 reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between two  
30 nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The  
35 oligonucleotide and the DNA or RNA are complementary to each

other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable.

Percent homology, sequence identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison WI), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482-489). In some preferred embodiments, homology, sequence identity or complementarity, between the oligomeric and target is between about 50% to about 60%. In some embodiments, homology, sequence identity or complementarity, is between about 60% to about 70%. In preferred embodiments, homology, sequence identity or complementarity, is between about 70% and about 80%. In more preferred embodiments, homology, sequence identity or complementarity, is between about 80% and about 90%. In some preferred embodiments, homology, sequence identity or complementarity, is about 90%, about 92%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%.

An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic

treatment, and in the case of in vitro assays, under conditions in which the assays are performed. It is preferred that the antisense compounds of the present invention comprise at least 80% sequence complementarity to a target region within the target nucleic acid, moreover that they comprise 90% sequence complementarity and even more comprise 95% sequence complementarity to the target region within the target nucleic acid sequence to which they are targeted. For example, an antisense compound in which 18 of 20 nucleobases of the antisense compound are complementary, and would therefore specifically hybridize, to a target region would represent 90 percent complementarity. Percent complementarity of an antisense compound with a region of a target nucleic acid can be determined routinely using basic local alignment search tools (BLAST programs) (Altschul et al., *J. Mol. Biol.*, **1990**, 215, 403-410; Zhang and Madden, *Genome Res.*, **1997**, 7, 649-656).

Antisense and other compounds of the invention, which hybridize to the target and inhibit expression of the target, are identified through experimentation, and representative sequences of these compounds are hereinbelow identified as preferred embodiments of the invention. The sites to which these preferred antisense compounds are specifically hybridizable are hereinbelow referred to as "preferred target regions" and are therefore preferred sites for targeting. As used herein the term "preferred target region" is defined as at least an 8-nucleobase portion of a target region to which an active antisense compound is targeted. While not wishing to be bound by theory, it is presently believed that these target regions represent regions of the target nucleic acid which are accessible for hybridization.

While the specific sequences of particular preferred target regions are set forth below, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the scope of the present invention.

Additional preferred target regions may be identified by one having ordinary skill.

Target regions 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative preferred target regions are considered to be suitable preferred target regions as well.

Exemplary good preferred target regions include DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 5'-terminus of one of the illustrative preferred target regions (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5'-terminus of the target region and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). Similarly good preferred target regions are represented by DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of one of the illustrative preferred target regions (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of the target region and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). One having skill in the art, once armed with the empirically-derived preferred target regions illustrated herein will be able, without undue experimentation, to identify further preferred target regions. In addition, one having ordinary skill in the art will also be able to identify additional compounds, including oligonucleotide probes and primers, that specifically hybridize to these preferred target regions using techniques available to the ordinary practitioner in the art.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has,

therefore, been harnessed for research use.

For use in kits and diagnostics, the antisense compounds of the present invention, either alone or in combination with other antisense compounds or therapeutics, can be used as tools in  
5 differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

Expression patterns within cells or tissues treated with one or more antisense compounds are compared to control cells or  
0 tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can  
5 be performed on stimulated or unstimulated cells and in the presence or absence of other compounds which affect expression patterns.

Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and Vilo, *FEBS Lett.*, **2000**, 480, 17-24; Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16), SAGE (serial analysis of gene expression) (Madden, et al., *Drug Discov. Today*, **2000**, 5, 415-425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, *Methods Enzymol.*, **1999**, 303, 258-72), TOGA (total gene expression  
5 analysis) (Sutcliffe, et al., *Proc. Natl. Acad. Sci. U. S. A.*, **2000**, 97, 1976-81), protein arrays and proteomics (Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16; Jungblut, et al., *Electrophoresis*, **1999**, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16;  
10 Larsson, et al., *J. Biotechnol.*, **2000**, 80, 143-57), subtractive RNA fingerprinting (SuRF) (Fuchs, et al., *Anal. Biochem.*, **2000**, 286, 91-98; Larson, et al., *Cytometry*, **2000**, 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and Belmont, *Curr. Opin. Microbiol.*, **2000**, 3, 316-21), comparative  
35 genomic hybridization (Carulli, et al., *J. Cell Biochem. Suppl.*,

1998, 31, 286-96), FISH (fluorescent *in situ* hybridization) techniques (Going and Gusterson, *Eur. J. Cancer*, 1999, 35, 1895-904) and mass spectrometry methods (reviewed in To, *Comb. Chem. High Throughput Screen*, 2000, 3, 235-41).

5       The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotide drugs, including ribozymes, have been  
0       safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

5       In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent  
0       internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake,  
5       enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

      While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to  
0       oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 80 nucleobases (i.e. from about 8 to about 80 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides from about 8  
5       to about 50 nucleobases, even more preferably those comprising

from about 12 to about 30 nucleobases. Antisense compounds include ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other short catalytic RNAs or catalytic oligonucleotides which hybridize to the target nucleic acid and modulate its expression.

Antisense compounds 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative antisense compounds are considered to be suitable antisense compounds as well.

Exemplary preferred antisense compounds include DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 5'-terminus of one of the illustrative preferred antisense compounds (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5'-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). Similarly preferred antisense compounds are represented by DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of one of the illustrative preferred antisense compounds (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). One having skill in the art, once armed with the empirically-derived preferred antisense compounds illustrated herein will be able, without undue experimentation, to identify further preferred antisense compounds.

Antisense and other compounds of the invention, which hybridize to the target and inhibit expression of the target, are identified through experimentation, and representative sequences of these compounds are herein identified as preferred embodiments of the invention. While specific sequences of the

antisense compounds are set forth herein, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the scope of the present invention. Additional preferred antisense compounds may be identified by one having ordinary skill.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines.

Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. In addition, linear structures may also have internal nucleobase complementarity and may therefore fold in a manner as to produce a double stranded structure. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.



Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar

portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; 5 methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not 0 limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the 10 nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic 15 acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.

30 Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, **1991**, 254, 1497-1500.

35 Most preferred embodiments of the invention are

oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular -CH<sub>2</sub>-NH-O-CH<sub>2</sub>-, -CH<sub>2</sub>-N(CH<sub>3</sub>)-O-CH<sub>2</sub>- [known as a methylene (methyylimino) or MMI backbone], -CH<sub>2</sub>-O-N(CH<sub>3</sub>)-CH<sub>2</sub>-, -CH<sub>2</sub>-N(CH<sub>3</sub>)-N(CH<sub>3</sub>)-CH<sub>2</sub>- and -O-N(CH<sub>3</sub>)-CH<sub>2</sub>-CH<sub>2</sub>- [wherein the native phosphodiester backbone is represented as -O-P-O-CH<sub>2</sub>-] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C<sub>1</sub> to C<sub>10</sub> alkyl or C<sub>2</sub> to C<sub>10</sub> alkenyl and alkynyl. Particularly preferred are O[(CH<sub>2</sub>)<sub>n</sub>O]<sub>m</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>OCH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>ONH<sub>2</sub>, and O(CH<sub>2</sub>)<sub>n</sub>ON[(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>]<sub>2</sub>, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C<sub>1</sub> to C<sub>10</sub> lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH<sub>3</sub>, OCN, Cl, Br, CN, CF<sub>3</sub>, OCF<sub>3</sub>, SOCH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, ONO<sub>2</sub>, NO<sub>2</sub>, N<sub>3</sub>, NH<sub>2</sub>, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, **1995**, *78*, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminoethoxyethoxy, i.e., a O(CH<sub>2</sub>)<sub>2</sub>ON(CH<sub>3</sub>)<sub>2</sub> group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also

known in the art as 2'-O-dimethyl-amino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O-CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>3</sub>)<sub>2</sub>, also described in examples hereinbelow.

Other preferred modifications include 2'-methoxy (2'-O-CH<sub>3</sub>), 2'-aminopropoxy (2'-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>), 2'-allyl (2'-CH<sub>2</sub>-CH=CH<sub>2</sub>), 2'-O-allyl (2'-O-CH<sub>2</sub>-CH=CH<sub>2</sub>) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

A further preferred modification includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. The linkage is preferably a methylene (-CH<sub>2</sub>-)<sub>n</sub> group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and

uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl ( $-C\equiv C-CH_3$ ) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding

affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine  
5 substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base  
0 methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.:  
5 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, certain of which are commonly owned with the instant  
0 application, and each of which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the  
5 invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. The compounds of the invention can include conjugate groups covalently bound to functional groups such as primary or  
10 secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers.  
35 Typical conjugate groups include cholesterol, lipids, phospho-

lipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion. Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed October 23, 1992 the entire disclosure of which is incorporated herein by reference. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, **1989**, *86*, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1994**, *4*, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, **1992**, *660*, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1993**, *3*, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, **1992**, *20*, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, **1991**, *10*, 1111-1118; Kabanov et al., *FEBS Lett.*, **1990**, *259*, 327-330; Svinarchuk et al., *Biochimie*, **1993**, *75*, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, **1995**, *36*, 3651-3654; Shea et al., *Nucl. Acids Res.*, **1990**, *18*, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, **1995**, *14*, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, **1995**, *36*, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, **1995**, *1264*, 229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, **1996**, *277*, 923-937). Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin,

warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethicin, a  
5 barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in United States Patent Application 09/334,130 (filed June 15, 1999) which is incorporated herein by reference in its entirety.

0 Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802;  
5 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506;  
0 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant  
5 application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single  
10 compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which  
15 contain two or more chemically distinct regions, each made up of



at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, increased stability and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. The cleavage of RNA:RNA hybrids can, in like fashion, be accomplished through the actions of endoribonucleases, such as interferon-induced RNaseL which cleaves both cellular and viral RNA. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption-assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form

(i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl)

5 phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published December 9, 1993 or in WO 94/26764 and U.S. 5,770,713 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the  
0 compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals  
5 or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for  
0 example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by  
5 contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for  
10 purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are  
15 the hydrochlorides, acetates, salicylates, nitrates and

phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylemaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric

acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

0       The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of sterol regulatory element-binding protein-1 is treated by administering  
5       antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or  
10       carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

      The antisense compounds of the invention are useful for  
15       research and diagnostics, because these compounds hybridize to nucleic acids encoding sterol regulatory element-binding protein-1, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid  
30       encoding sterol regulatory element-binding protein-1 can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of  
35       sterol regulatory element-binding protein-1 in a sample may also

be prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Preferred topical formulations include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). Oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively,

oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters include but are not limited arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, 5 tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C<sub>1-10</sub> alkyl ester (e.g. isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt 0 thereof. Topical formulations are described in detail in United States patent application 09/315,298 filed on May 20, 1999 which is incorporated herein by reference in its entirety.

Compositions and formulations for oral administration include powders or granules, microparticulates, 5 nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitables. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Preferred oral formulations are those in which oligonucleotides 0 of the invention are administered in conjunction with one or more penetration enhancers surfactants and chelators. Preferred surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Preferred bile acids/salts include chenodeoxycholic acid (CDCA) and 5 ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucolic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate and sodium glycodihydrofusidate. Preferred fatty acids include arachidonic 0 acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a 5 diglyceride or a pharmaceutically acceptable salt thereof (e.g.

sodium). Also preferred are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly preferred combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the invention may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Particularly preferred complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylamino-methylethylene P(TDAE), polyaminostyrene (e.g. p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcyanoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for oligonucleotides and their preparation are described in detail in United States applications 08/886,829 (filed July 1, 1997), 09/108,673 (filed July 1, 1998), 09/256,515 (filed February 23, 1999), 09/082,624 (filed May 21, 1998) and 09/315,298 (filed May 20, 1999), each of which is incorporated herein by reference in their entirety.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically



acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and

formulation arts and may be applied to the formulation of the compositions of the present invention.

### Emulsions

5       The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1  $\mu\text{m}$  in diameter (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301). Emulsions are often biphasic systems comprising two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be of either the water-in-oil (w/o) or the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase, the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase, the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases, and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide

certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous phase provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in

*Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming

strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of ease of formulation, as well as efficacy from an absorption and bioavailability standpoint (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single

optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that  
5 are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear  
10 dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three  
5 to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and  
0 hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive  
5 knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel  
0 Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions  
5 include, but are not limited to, ionic surfactants, non-ionic

surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprates (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., *Pharmaceutical Research*, 1994, 11, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and

decreased toxicity (Constantinides et al., *Pharmaceutical Research*, 1994, 11, 1385; Ho et al., *J. Pharm. Sci.*, 1996, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature.

- 5 This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the
- 0 microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal
- 5 tract, vagina, buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the

0 absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-

5 surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92). Each of these classes has been discussed above.

### Liposomes

- 10 There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the
- 15 duration of action they offer from the standpoint of drug



delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes and as the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes

present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, **1987**, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled Release*, **1992**, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol,

while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is  
5 formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a  
0 reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., *Journal of Drug Targeting*, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to  
5 the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., *Antiviral Research*, 1992, 18, 259-265).

Non-ionic liposomal systems have also been examined to  
0 determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-  
stearyl ether) and Novasome™ II (glyceryl distearate/  
5 cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, 1994, 4, 6,  
0 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to  
5 liposomes lacking such specialized lipids. Examples of

sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside  $G_{M1}$ , or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., *FEBS Letters*, **1987**, 223, 42; Wu et al., *Cancer Research*, **1993**, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, **1987**, 507, 64) reported the ability of monosialoganglioside  $G_{M1}$ , galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (*Proc. Natl. Acad. Sci. U.S.A.*, **1988**, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside  $G_{M1}$  or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (*Bull. Chem. Soc. Jpn.*, **1980**, 53, 2778) described liposomes comprising a nonionic detergent, 2C<sub>12</sub>15G, that contains a PEG moiety. Illum et al. (*FEBS Lett.*, **1984**, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S.

Patent Nos. 4,426,330 and 4,534,899). Klibanov et al. (*FEBS Lett.*, **1990**, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, **1990**, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Patent Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive

candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

#### Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C<sub>1-10</sub> alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654).



Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*, 1990, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion

for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, **1993**, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), *N*-acyl derivatives of collagen, laureth-9 and *N*-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; Buur et al., *J. Control Rel.*, **1990**, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, **1987**, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as

ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

#### Carriers

5 Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity *per se*) but is recognized as a nucleic acid  
10 by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the  
15 latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially  
20 phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyanostilbene-2,2'-disulfonic acid (Miyao *et al.*, *Antisense Res. Dev.*, **1995**, *5*, 115-121; Takakura *et al.*, *Antisense & Nucl. Acid Drug Dev.*, **1996**, *6*, 177-183).

#### Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable  
30 solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a  
35 nucleic acid and the other components of a given pharmaceutical

composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

### Other Components

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine,

pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-

5 hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The*  
0 *Merck Manual of Diagnosis and Therapy*, 15th Ed. 1987, pp. 1206-1228, Berkow et al., eds., Rahway, N.J. When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by  
5 MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and  
0 antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other  
5 non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds,  
0 particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

5 The formulation of therapeutic compositions and their

subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on  $EC_{50}$ s found to be effective in *in vitro* and *in vivo* animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

**EXAMPLES****Example 1****5 Nucleoside Phosphoramidites for Oligonucleotide Synthesis  
Deoxy and 2'-alkoxy amidites**

2'-Deoxy and 2'-methoxy beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA).  
Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, optimized synthesis cycles were developed that incorporate multiple steps coupling longer wait times relative to standard synthesis cycles.

The following abbreviations are used in the text: thin layer chromatography (TLC), melting point (MP), high pressure liquid chromatography (HPLC), Nuclear Magnetic Resonance (NMR), argon (Ar), methanol (MeOH), dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>), triethylamine (TEA), dimethyl formamide (DMF), ethyl acetate (EtOAc), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF).

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-dC) nucleotides were synthesized according to published methods (Sanghvi, et. al., *Nucleic Acids Research*, **1993**, 21, 3197-3203) using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA) or prepared as follows:

**Preparation of 5'-O-Dimethoxytrityl-thymidine intermediate for  
30 5-methyl dC amidite**

To a 50 L glass reactor equipped with air stirrer and Ar gas line was added thymidine (1.00 kg, 4.13 mol) in anhydrous pyridine (6 L) at ambient temperature. Dimethoxytrityl (DMT) chloride (1.47 kg, 4.34 mol, 1.05 eq) was added as a solid in four portions over 1 h. After 30 min, TLC indicated approx. 95%



product, 2% thymidine, 5% DMT reagent and by-products and 2 %  
3',5'-bis DMT product ( $R_f$  in EtOAc 0.45, 0.05, 0.98, 0.95  
respectively). Saturated sodium bicarbonate (4 L) and  $\text{CH}_2\text{Cl}_2$   
were added with stirring (pH of the aqueous layer 7.5). An  
5 additional 18 L of water was added, the mixture was stirred, the  
phases were separated, and the organic layer was transferred to  
a second 50 L vessel. The aqueous layer was extracted with  
additional  $\text{CH}_2\text{Cl}_2$  (2 x 2 L). The combined organic layer was  
washed with water (10 L) and then concentrated in a rotary  
10 evaporator to approx. 3.6 kg total weight. This was redissolved  
in  $\text{CH}_2\text{Cl}_2$  (3.5 L), added to the reactor followed by water (6 L)  
and hexanes (13 L). The mixture was vigorously stirred and  
seeded to give a fine white suspended solid starting at the  
interface. After stirring for 1 h, the suspension was removed  
15 by suction through a 1/2" diameter teflon tube into a 20 L  
suction flask, poured onto a 25 cm Coors Buchner funnel, washed  
with water (2 x 3 L) and a mixture of hexanes-  $\text{CH}_2\text{Cl}_2$  (4:1, 2x3  
L) and allowed to air dry overnight in pans (1" deep). This was  
further dried in a vacuum oven (75°C, 0.1 mm Hg, 48 h) to a  
20 constant weight of 2072 g (93%) of a white solid, (mp 122-  
124°C). TLC indicated a trace contamination of the bis DMT  
product. NMR spectroscopy also indicated that 1-2 mole percent  
pyridine and about 5 mole percent of hexanes was still present.

25 **Preparation of 5'-O-Dimethoxytrityl-2'-deoxy-5-methylcytidine  
intermediate for 5-methyl-dC amidite**

To a 50 L Schott glass-lined steel reactor equipped with an  
electric stirrer, reagent addition pump (connected to an  
addition funnel), heating/cooling system, internal thermometer  
30 and an Ar gas line was added 5'-O-dimethoxytrityl-thymidine  
(3.00 kg, 5.51 mol), anhydrous acetonitrile (25 L) and TEA (12.3  
L, 88.4 mol, 16 eq). The mixture was chilled with stirring to -  
10°C internal temperature (external -20°C).  
Trimethylsilylchloride (2.1 L, 16.5 mol, 3.0 eq) was added over  
35 30 minutes while maintaining the internal temperature below -

5°C, followed by a wash of anhydrous acetonitrile (1 L). Note: the reaction is mildly exothermic and copious hydrochloric acid fumes form over the course of the addition. The reaction was allowed to warm to 0°C and the reaction progress was confirmed by TLC (EtOAc-hexanes 4:1;  $R_f$  0.43 to 0.84 of starting material and silyl product, respectively). Upon completion, triazole (3.05 kg, 44 mol, 8.0 eq) was added the reaction was cooled to -20°C internal temperature (external -30°C). Phosphorous oxychloride (1035 mL, 11.1 mol, 2.01 eq) was added over 60 min so as to maintain the temperature between -20°C and -10°C during the strongly exothermic process, followed by a wash of anhydrous acetonitrile (1 L). The reaction was warmed to 0 °C and stirred for 1 h. TLC indicated a complete conversion to the triazole product ( $R_f$  0.83 to 0.34 with the product spot glowing in long wavelength UV light). The reaction mixture was a peach-colored thick suspension, which turned darker red upon warming without apparent decomposition. The reaction was cooled to -15°C internal temperature and water (5 L) was slowly added at a rate to maintain the temperature below +10°C in order to quench the reaction and to form a homogenous solution. (Caution: this reaction is initially very strongly exothermic). Approximately one-half of the reaction volume (22 L) was transferred by air pump to another vessel, diluted with EtOAc (12 L) and extracted with water (2 x 8 L). The combined water layers were back-extracted with EtOAc (6 L). The water layer was discarded and the organic layers were concentrated in a 20 L rotary evaporator to an oily foam. The foam was coevaporated with anhydrous acetonitrile (4 L) to remove EtOAc. (note: dioxane may be used instead of anhydrous acetonitrile if dried to a hard foam). The second half of the reaction was treated in the same way. Each residue was dissolved in dioxane (3 L) and concentrated ammonium hydroxide (750 mL) was added. A homogenous solution formed in a few minutes and the reaction was allowed to stand overnight (although the reaction is complete within 1 h).

TLC indicated a complete reaction (product  $R_f$  0.35 in EtOAc-MeOH 4:1). The reaction solution was concentrated on a rotary evaporator to a dense foam. Each foam was slowly redissolved in warm EtOAc (4 L; 50°C), combined in a 50 L glass reactor vessel, and extracted with water (2 x 4L) to remove the triazole by-product. The water was back-extracted with EtOAc (2 L). The organic layers were combined and concentrated to about 8 kg total weight, cooled to 0°C and seeded with crystalline product. After 24 hours, the first crop was collected on a 25 cm Coors Buchner funnel and washed repeatedly with EtOAc (3 x 3L) until a white powder was left and then washed with ethyl ether (2 x 3L). The solid was put in pans (1" deep) and allowed to air dry overnight. The filtrate was concentrated to an oil, then redissolved in EtOAc (2 L), cooled and seeded as before. The second crop was collected and washed as before (with proportional solvents) and the filtrate was first extracted with water (2 x 1L) and then concentrated to an oil. The residue was dissolved in EtOAc (1 L) and yielded a third crop which was treated as above except that more washing was required to remove a yellow oily layer.

After air-drying, the three crops were dried in a vacuum oven (50°C, 0.1 mm Hg, 24 h) to a constant weight (1750, 600 and 200 g, respectively) and combined to afford 2550 g (85%) of a white crystalline product (MP 215-217°C) when TLC and NMR spectroscopy indicated purity. The mother liquor still contained mostly product (as determined by TLC) and a small amount of triazole (as determined by NMR spectroscopy), bis DMT product and unidentified minor impurities. If desired, the mother liquor can be purified by silica gel chromatography using a gradient of MeOH (0-25%) in EtOAc to further increase the yield.

**Preparation of 5'-O-Dimethoxytrityl-2'-deoxy-N4-benzoyl-5-methylcytidine penultimate intermediate for 5-methyl dC amidite**

Crystalline 5'-O-dimethoxytrityl-5-methyl-2'-deoxycytidine (2000 g, 3.68 mol) was dissolved in anhydrous DMF (6.0 kg) at ambient temperature in a 50 L glass reactor vessel equipped with an air stirrer and argon line. Benzoic anhydride (Chem Impex not Aldrich, 874 g, 3.86 mol, 1.05 eq) was added and the reaction was stirred at ambient temperature for 8 h. TLC ( $\text{CH}_2\text{Cl}_2$ -EtOAc;  $\text{CH}_2\text{Cl}_2$ -EtOAc 4:1;  $R_f$  0.25) indicated approx. 92% complete reaction. An additional amount of benzoic anhydride (44 g, 0.19 mol) was added. After a total of 18 h, TLC indicated approx. 96% reaction completion. The solution was diluted with EtOAc (20 L), TEA (1020 mL, 7.36 mol, ca 2.0 eq) was added with stirring, and the mixture was extracted with water (15 L, then 2 x 10 L). The aqueous layer was removed (no back-extraction was needed) and the organic layer was concentrated in 2 x 20 L rotary evaporator flasks until a foam began to form. The residues were coevaporated with acetonitrile (1.5 L each) and dried (0.1 mm Hg, 25°C, 24 h) to 2520 g of a dense foam. High pressure liquid chromatography (HPLC) revealed a contamination of 6.3% of N4, 3'-O-dibenzoyl product, but very little other impurities.

The product was purified by Biotage column chromatography (5 kg Biotage) prepared with 65:35:1 hexanes-EtOAc-TEA (4L). The crude product (800 g), dissolved in  $\text{CH}_2\text{Cl}_2$  (2 L), was applied to the column. The column was washed with the 65:35:1 solvent mixture (20 kg), then 20:80:1 solvent mixture (10 kg), then 99:1 EtOAc:TEA (17kg). The fractions containing the product were collected, and any fractions containing the product and impurities were retained to be resubjected to column chromatography. The column was re-equilibrated with the original 65:35:1 solvent mixture (17 kg). A second batch of crude product (840 g) was applied to the column as before. The column was washed with the following solvent gradients: 65:35:1 (9 kg), 55:45:1 (20 kg), 20:80:1 (10 kg), and 99:1 EtOAc:TEA (15 kg). The column was reequilibrated as above, and a third batch of the crude product (850 g) plus impure fractions recycled from

the two previous columns (28 g) was purified following the procedure for the second batch. The fractions containing pure product combined and concentrated on a 20L rotary evaporator, co-evaporated with acetone (3 L) and dried (0.1 mm Hg, 48 h, 25°C) to a constant weight of 2023 g (85%) of white foam and 20 g of slightly contaminated product from the third run. HPLC indicated a purity of 99.8% with the balance as the diBenzoyl product.

**[5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-deoxy-N<sup>4</sup>-benzoyl-5-methylcytidin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (5-methyl dC amidite)**

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-deoxy-N<sup>4</sup>-benzoyl-5-methylcytidine (998 g, 1.5 mol) was dissolved in anhydrous DMF (2 L). The solution was co-evaporated with toluene (300 ml) at 50°C under reduced pressure, then cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (52.5 g, 0.75 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (15 ml) was added and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (2.5 L) and water (600 ml), and extracted with hexane (3 x 3 L). The mixture was diluted with water (1.2 L) and extracted with a mixture of toluene (7.5 L) and hexane (6 L). The two layers were separated, the upper layer was washed with DMF-water (7:3 v/v, 3 x 2 L) and water (3 x 2 L), and the phases were separated. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and rotary evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried to a constant weight (25 °C, 0.1mm Hg, 40 h) to afford 1250 g an off-white foam solid (96%).

## **2'-Fluoro amidites**

### **2'-Fluorodeoxyadenosine amidites**

2'-fluoro oligonucleotides were synthesized as described

previously [Kawasaki, et. al., *J. Med. Chem.*, **1993**, *36*, 831-841] and United States patent 5,670,633, herein incorporated by reference. The preparation of 2'-fluoropyrimidines containing a 5-methyl substitution are described in US Patent 5,861,493.

5 Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and whereby the 2'-alpha-fluoro atom is introduced by a S<sub>N</sub>2-displacement of a 2'-beta-triflate group. Thus N6-benzoyl-9-  
0 beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite  
5 intermediates.

### **2'-Fluorodeoxyguanosine**

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-  
0 beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate isobutyryl-arabinofuranosylguanosine. Alternatively, isobutyryl-arabinofuranosylguanosine was prepared as described by Ross et al., (*Nucleosides & Nucleosides*, *16*, 1645, **1997**). Deprotection  
5 of the TPDS group was followed by protection of the hydroxyl group with THP to give isobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies  
10 were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

### **2'-Fluorouridine**

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-  
15 anhydro-1-beta-D-arabinofuranosyluracil was treated with 70%

hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

### 2'-Fluorodeoxycytidine

5 2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

### 2'-O-(2-Methoxyethyl) modified amidites

0 2'-O-Methoxyethyl-substituted nucleoside amidites (otherwise known as MOE amidites) are prepared as follows, or alternatively, as per the methods of Martin, P., (Helvetica Chimica Acta, 1995, 78, 486-504).

### Preparation of 2'-O-(2-methoxyethyl)-5-methyluridine intermediate

2,2'-Anhydro-5-methyl-uridine (2000 g, 8.32 mol), tris(2-methoxyethyl)borate (2504 g, 10.60 mol), sodium bicarbonate (60 g, 0.70 mol) and anhydrous 2-methoxyethanol (5 L) were combined in a 12 L three necked flask and heated to 130 °C (internal temp) at atmospheric pressure, under an argon atmosphere with stirring for 21 h. TLC indicated a complete reaction. The solvent was removed under reduced pressure until a sticky gum formed (50-85°C bath temp and 100-11 mm Hg) and the residue was redissolved in water (3 L) and heated to boiling for 30 min in order the hydrolyze the borate esters. The water was removed under reduced pressure until a foam began to form and then the process was repeated. HPLC indicated about 77% product, 15% dimer (5' of product attached to 2' of starting material) and unknown derivatives, and the balance was a single unresolved early eluting peak.

15 The gum was redissolved in brine (3 L), and the flask was rinsed with additional brine (3 L). The combined aqueous solutions were extracted with chloroform (20 L) in a heavier-

than continuous extractor for 70 h. The chloroform layer was concentrated by rotary evaporation in a 20 L flask to a sticky foam (2400 g). This was coevaporated with MeOH (400 mL) and EtOAc (8 L) at 75°C and 0.65 atm until the foam dissolved at which point the vacuum was lowered to about 0.5 atm. After 2.5 L of distillate was collected a precipitate began to form and the flask was removed from the rotary evaporator and stirred until the suspension reached ambient temperature. EtOAc (2 L) was added and the slurry was filtered on a 25 cm table top Buchner funnel and the product was washed with EtOAc (3 x 2 L). The bright white solid was air dried in pans for 24 h then further dried in a vacuum oven (50°C, 0.1 mm Hg, 24 h) to afford 1649 g of a white crystalline solid (mp 115.5-116.5°C).

The brine layer in the 20 L continuous extractor was further extracted for 72 h with recycled chloroform. The chloroform was concentrated to 120 g of oil and this was combined with the mother liquor from the above filtration (225 g), dissolved in brine (250 mL) and extracted once with chloroform (250 mL). The brine solution was continuously extracted and the product was crystallized as described above to afford an additional 178 g of crystalline product containing about 2% of thymine. The combined yield was 1827 g (69.4%). HPLC indicated about 99.5% purity with the balance being the dimer.

#### **Preparation of 5'-O-DMT-2'-O-(2-methoxyethyl)-5-methyluridine penultimate intermediate**

In a 50 L glass-lined steel reactor, 2'-O-(2-methoxyethyl)-5-methyl-uridine (MOE-T, 1500 g, 4.738 mol), lutidine (1015 g, 9.476 mol) were dissolved in anhydrous acetonitrile (15 L). The solution was stirred rapidly and chilled to -10°C (internal temperature). Dimethoxytriphenylmethyl chloride (1765.7 g, 5.21 mol) was added as a solid in one portion. The reaction was allowed to warm to -2°C over 1 h. (Note: The reaction was monitored closely by TLC (EtOAc) to determine when to stop the



reaction so as to not generate the undesired bis-DMT substituted side product). The reaction was allowed to warm from -2 to 3°C over 25 min. then quenched by adding MeOH (300 mL) followed after 10 min by toluene (16 L) and water (16 L). The solution  
5 was transferred to a clear 50 L vessel with a bottom outlet, vigorously stirred for 1 minute, and the layers separated. The aqueous layer was removed and the organic layer was washed successively with 10% aqueous citric acid (8 L) and water (12 L). The product was then extracted into the aqueous phase by  
0 washing the toluene solution with aqueous sodium hydroxide (0.5N, 16 L and 8 L). The combined aqueous layer was overlaid with toluene (12 L) and solid citric acid (8 moles, 1270 g) was added with vigorous stirring to lower the pH of the aqueous layer to 5.5 and extract the product into the toluene. The  
5 organic layer was washed with water (10 L) and TLC of the organic layer indicated a trace of DMT-O-Me, bis DMT and dimer DMT.

The toluene solution was applied to a silica gel column (6 L sintered glass funnel containing approx. 2 kg of silica gel  
0 slurried with toluene (2 L) and TEA(25 mL)) and the fractions were eluted with toluene (12 L) and EtOAc (3 x 4 L) using vacuum applied to a filter flask placed below the column. The first EtOAc fraction containing both the desired product and impurities were resubjected to column chromatography as above.  
5 The clean fractions were combined, rotary evaporated to a foam, coevaporated with acetonitrile (6 L) and dried in a vacuum oven (0.1 mm Hg, 40 h, 40°C) to afford 2850 g of a white crisp foam. NMR spectroscopy indicated a 0.25 mole % remainder of acetonitrile (calculates to be approx. 47 g) to give a true dry  
0 weight of 2803 g (96%). HPLC indicated that the product was 99.41% pure, with the remainder being 0.06 DMT-O-Me, 0.10 unknown, 0.44 bis DMT, and no detectable dimer DMT or 3'-O-DMT.

**Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE T amidite)**

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-  
5-methyluridine (1237 g, 2.0 mol) was dissolved in anhydrous DMF (2.5 L). The solution was co-evaporated with toluene (200 ml) at 50°C under reduced pressure, then cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (900 g, 3.0 mol) and tetrazole (70 g, 1.0 mol) were added. The mixture was  
shaken until all tetrazole was dissolved, N-methylimidazole (20 ml) was added and the solution was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (3.5 L) and water (600 ml) and extracted with hexane (3 x 3L). The mixture was diluted with water (1.6 L) and extracted  
with the mixture of toluene (12 L) and hexanes (9 L). The upper layer was washed with DMF-water (7:3 v/v, 3x3 L) and water (3x3 L). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25°C, 0.1mm Hg, 40 h) to afford 1526 g of an off-white foamy solid (95%).

**Preparation of 5'-O-Dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methylcytidine intermediate**

To a 50 L Schott glass-lined steel reactor equipped with an electric stirrer, reagent addition pump (connected to an addition funnel), heating/cooling system, internal thermometer and argon gas line was added 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methyl-uridine (2.616 kg, 4.23 mol, purified by base extraction only and no scrub column), anhydrous acetonitrile (20 L), and TEA (9.5 L, 67.7 mol, 16 eq). The mixture was chilled with stirring to -10°C internal temperature (external -20°C). Trimethylsilylchloride (1.60 L, 12.7 mol, 3.0 eq) was added over 30 min. while maintaining the internal temperature below -5°C, followed by a wash of anhydrous

acetonitrile (1 L). (Note: the reaction is mildly exothermic and copious hydrochloric acid fumes form over the course of the addition). The reaction was allowed to warm to 0°C and the reaction progress was confirmed by TLC (EtOAc,  $R_f$  0.68 and 0.87 for starting material and silyl product, respectively). Upon completion, triazole (2.34 kg, 33.8 mol, 8.0 eq) was added the reaction was cooled to -20°C internal temperature (external - 30°C). Phosphorous oxychloride (793 mL, 8.51 mol, 2.01 eq) was added slowly over 60 min so as to maintain the temperature between -20°C and -10°C (note: strongly exothermic), followed by a wash of anhydrous acetonitrile (1 L). The reaction was warmed to 0°C and stirred for 1 h, at which point it was an off-white thick suspension. TLC indicated a complete conversion to the triazole product (EtOAc,  $R_f$  0.87 to 0.75 with the product spot glowing in long wavelength UV light). The reaction was cooled to -15°C and water (5 L) was slowly added at a rate to maintain the temperature below +10°C in order to quench the reaction and to form a homogenous solution. (Caution: this reaction is initially very strongly exothermic). Approximately one-half of the reaction volume (22 L) was transferred by air pump to another vessel, diluted with EtOAc (12 L) and extracted with water (2 x 8 L). The second half of the reaction was treated in the same way. The combined aqueous layers were back-extracted with EtOAc (8 L) The organic layers were combined and concentrated in a 20 L rotary evaporator to an oily foam. The foam was coevaporated with anhydrous acetonitrile (4 L) to remove EtOAc. (note: dioxane may be used instead of anhydrous acetonitrile if dried to a hard foam). The residue was dissolved in dioxane (2 L) and concentrated ammonium hydroxide (750 mL) was added. A homogenous solution formed in a few minutes and the reaction was allowed to stand overnight

TLC indicated a complete reaction ( $\text{CH}_2\text{Cl}_2$ -acetone-MeOH, 20:5:3,  $R_f$  0.51). The reaction solution was concentrated on a rotary evaporator to a dense foam and slowly redissolved in warm  $\text{CH}_2\text{Cl}_2$  (4 L, 40°C) and transferred to a 20 L glass extraction

vessel equipped with a air-powered stirrer. The organic layer was extracted with water (2 x 6 L) to remove the triazole by-product. (Note: In the first extraction an emulsion formed which took about 2 h to resolve). The water layer was back-extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 2 L), which in turn was washed with water (3 L). The combined organic layer was concentrated in 2 x 20 L flasks to a gum and then recrystallized from EtOAc seeded with crystalline product. After sitting overnight, the first crop was collected on a 25 cm Coors Buchner funnel and washed repeatedly with EtOAc until a white free-flowing powder was left (about 3 x 3 L). The filtrate was concentrated to an oil recrystallized from EtOAc, and collected as above. The solid was air-dried in pans for 48 h, then further dried in a vacuum oven (50°C, 0.1mm Hg, 17 h) to afford 2248 g of a bright white, dense solid (86%). An HPLC analysis indicated both crops to be 99.4% pure and NMR spectroscopy indicated only a faint trace of EtOAc remained.

**Preparation of 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-N4-benzoyl-5-methyl-cytidine penultimate intermediate:**

Crystalline 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methyl-cytidine (1000 g, 1.62 mol) was suspended in anhydrous DMF (3 kg) at ambient temperature and stirred under an Ar atmosphere. Benzoic anhydride (439.3 g, 1.94 mol) was added in one portion. The solution clarified after 5 hours and was stirred for 16 h. HPLC indicated 0.45% starting material remained (as well as 0.32% N4, 3'-O-bis Benzoyl). An additional amount of benzoic anhydride (6.0 g, 0.0265 mol) was added and after 17 h, HPLC indicated no starting material was present. TEA (450 mL, 3.24 mol) and toluene (6 L) were added with stirring for 1 minute. The solution was washed with water (4 x 4 L), and brine (2 x 4 L). The organic layer was partially evaporated on a 20 L rotary evaporator to remove 4 L of toluene and traces of water. HPLC indicated that the bis benzoyl side product was present as a 6% impurity. The residue was diluted

with toluene (7 L) and anhydrous DMSO (200 mL, 2.82 mol) and sodium hydride (60% in oil, 70 g, 1.75 mol) was added in one portion with stirring at ambient temperature over 1 h. The reaction was quenched by slowly adding then washing with aqueous citric acid (10%, 100 mL over 10 min, then 2 x 4 L), followed by aqueous sodium bicarbonate (2%, 2 L), water (2 x 4 L) and brine (4 L). The organic layer was concentrated on a 20 L rotary evaporator to about 2 L total volume. The residue was purified by silica gel column chromatography (6 L Buchner funnel containing 1.5 kg of silica gel wetted with a solution of EtOAc-hexanes-TEA(70:29:1)). The product was eluted with the same solvent (30 L) followed by straight EtOAc (6 L). The fractions containing the product were combined, concentrated on a rotary evaporator to a foam and then dried in a vacuum oven (50°C, 0.2 mm Hg, 8 h) to afford 1155 g of a crisp, white foam (98%). HPLC indicated a purity of >99.7%.

**Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N<sup>4</sup>-benzoyl-5-methylcytidin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE 5-Me-C amidite)**

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N<sup>4</sup>-benzoyl-5-methylcytidine (1082 g, 1.5 mol) was dissolved in anhydrous DMF (2 L) and co-evaporated with toluene (300 ml) at 50 °C under reduced pressure. The mixture was cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (52.5 g, 0.75 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (1 L) and water (400 ml) and extracted with hexane (3 x 3 L). The mixture was diluted with water (1.2 L) and extracted with a mixture of toluene (9 L) and hexanes (6 L). The two layers were separated and the upper layer was washed with DMF-water (60:40 v/v, 3 x 3 L) and water (3 x 2 L). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and

evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg, 40 h) to afford 1336 g of an off-white foam (97%).

**Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N<sup>6</sup>-benzoyladenoin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE A amidite)**

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N<sup>6</sup>-benzoyladenoin (purchased from Reliable Biopharmaceutical, St. Lois, MO), 1098 g, 1.5 mol) was dissolved in anhydrous DMF (3 L) and co-evaporated with toluene (300 ml) at 50 °C. The mixture was cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (78.8 g, 1.24 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (1 L) and water (400 ml) and extracted with hexanes (3 x 3 L). The mixture was diluted with water (1.4 L) and extracted with the mixture of toluene (9 L) and hexanes (6 L). The two layers were separated and the upper layer was washed with DMF-water (60:40, v/v, 3 x 3 L) and water (3 x 2 L). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and evaporated to a sticky foam. The residue was co-evaporated with acetonitrile (2.5 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg, 40 h) to afford 1350 g of an off-white foam solid (96%).

**Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N<sup>4</sup>-isobutyrylguanosin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE G amidite)**

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N<sup>4</sup>-isobutyrylguanosine (purchased from Reliable Biopharmaceutical, St. Louis, MO, 1426 g, 2.0 mol) was dissolved in anhydrous DMF (2 L). The solution was co-evaporated with toluene (200 ml) at 50 °C, cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (900 g, 3.0 mol) and tetrazole

(68 g, 0.97 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (2 L) and  
5 water (600 ml) and extracted with hexanes (3 x 3 L). The mixture was diluted with water (2 L) and extracted with a mixture of toluene (10 L) and hexanes (5 L). The two layers were separated and the upper layer was washed with DMF-water (60:40, v/v, 3x3 L). EtOAc (4 L) was added and the solution was  
10 washed with water (3 x 4 L). The organic layer was dried ( $\text{Na}_2\text{SO}_4$ ), filtered and evaporated to approx. 4 kg. Hexane (4 L) was added, the mixture was shaken for 10 min, and the supernatant liquid was decanted. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in  
5 a vacuum oven (25 °C, 0.1mm Hg, 40 h) to afford 1660 g of an off-white foamy solid (91%).

**2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites**

0 **2'-(Dimethylaminooxyethoxy) nucleoside amidites**

2'-(Dimethylaminooxyethoxy) nucleoside amidites (also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites) are prepared as described in the following paragraphs.

Adenosine, cytidine and guanosine nucleoside amidites are  
5 prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

10 **5'-O-tert-Butyldiphenylsilyl-O<sup>2</sup>-2'-anhydro-5-methyluridine**

O<sup>2</sup>-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with  
35 mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g,

119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC ( $R_f$  0.22, EtOAc) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between  $\text{CH}_2\text{Cl}_2$  (1 L) and saturated sodium bicarbonate (2 x 1 L) and brine (1 L). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of EtOAc and ethyl ether (600mL) and cooling the solution to -10°C afforded a white crystalline solid which was collected by filtration, washed with ethyl ether (3 x 200 mL) and dried (40°C, 1mm Hg, 24 h) to afford 149g of white solid (74.8%). TLC and NMR spectroscopy were consistent with pure product.

**5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine**

In the fume hood, ethylene glycol (350 mL, excess) was added cautiously with manual stirring to a 2 L stainless steel pressure reactor containing borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). (Caution : evolves hydrogen gas). 5'-O-tert-Butyldiphenylsilyl-O<sup>2</sup>-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient temperature and opened. TLC (EtOAc,  $R_f$  0.67 for desired product and  $R_f$  0.82 for ara-T side product) indicated about 70% conversion to the product. The solution was concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. (Alternatively, once the THF has evaporated the solution can be diluted with water and the product extracted into EtOAc). The residue was purified by column chromatography (2kg silica gel, EtOAc-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined,



evaporated and dried to afford 84 g of a white crisp foam (50%), contaminated starting material (17.4g, 12% recovery) and pure reusable starting material (20g, 13% recovery). TLC and NMR spectroscopy were consistent with 99% pure product.

5

**2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine**

5'-O-tert-Butylidiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol) and dried over P<sub>2</sub>O<sub>5</sub> under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dissolved in dry THF (369.8mL, Aldrich, sure seal bottle). Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture with the rate of addition maintained such that the resulting deep red coloration is just discharged before adding the next drop. The reaction mixture was stirred for 4 hrs., after which time TLC (EtOAc:hexane, 60:40) indicated that the reaction was complete. The solvent was evaporated in vacuo and the residue purified by flash column chromatography (eluted with 60:40 EtOAc:hexane), to yield 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%) upon rotary evaporation.

15

**5'-O-tert-butylidiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine**

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH<sub>2</sub>Cl<sub>2</sub> (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate washed with ice cold CH<sub>2</sub>Cl<sub>2</sub>, and the combined organic phase was washed with water and brine and dried (anhydrous Na<sub>2</sub>SO<sub>4</sub>). The solution was filtered and evaporated to afford 2'-O-(aminooxyethyl)thymidine, which was then dissolved in MeOH (67.5mL). Formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and

the resulting mixture was stirred for 1 h. The solvent was removed under vacuum and the residue was purified by column chromatography to yield 5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95 g, 78%) upon rotary evaporation.

**5'-O-tert-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine**

5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL) and cooled to 10°C under inert atmosphere. Sodium cyanoborohydride (0.39g, 6.13mmol) was added and the reaction mixture was stirred. After 10 minutes the reaction was warmed to room temperature and stirred for 2 h. while the progress of the reaction was monitored by TLC (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>). Aqueous NaHCO<sub>3</sub> solution (5%, 10mL) was added and the product was extracted with EtOAc (2 x 20 mL). The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to dryness. This entire procedure was repeated with the resulting residue, with the exception that formaldehyde (20% w/w, 30 mL, 3.37 mol) was added upon dissolution of the residue in the PPTS/MeOH solution. After the extraction and evaporation, the residue was purified by flash column chromatography and (eluted with 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine as a white foam (14.6g, 80%) upon rotary evaporation.

**2'-O-(dimethylaminooxyethyl)-5-methyluridine**

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and TEA (1.67mL, 12mmol, dry, stored over KOH) and added to 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine (1.40g, 2.4mmol). The reaction was stirred at room temperature for 24 hrs and monitored by TLC (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>). The solvent was removed

under vacuum and the residue purified by flash column chromatography (eluted with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford 2'-O-(dimethylaminooxyethyl)-5-methyluridine (766mg, 92.5%) upon rotary evaporation of the solvent.

5

**5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine**

2'-O-(dimethylaminooxyethyl)-5-methyluridine (750 mg, 2.17 mmol) was dried over P<sub>2</sub>O<sub>5</sub> under high vacuum overnight at 40°C, co-evaporated with anhydrous pyridine (20 mL), and dissolved in pyridine (11 mL) under argon atmosphere. 4-dimethylaminopyridine (26.5 mg, 2.60 mmol) and 4,4'-dimethoxytrityl chloride (880 mg, 2.60 mmol) were added to the pyridine solution and the reaction mixture was stirred at room temperature until all of the starting material had reacted. Pyridine was removed under vacuum and the residue was purified by column chromatography (eluted with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> containing a few drops of pyridine) to yield 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%) upon rotary evaporation.

:0

**5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine (1.08 g, 1.67 mmol) was co-evaporated with toluene (20 mL), N,N-diisopropylamine tetrazonide (0.29 g, 1.67 mmol) was added and the mixture was dried over P<sub>2</sub>O<sub>5</sub> under high vacuum overnight at 40°C. This was dissolved in anhydrous acetonitrile (8.4 mL) and 2-cyanoethyl-N,N,N<sup>1</sup>,N<sup>1</sup>-tetraisopropylphosphoramidite (2.12 mL, 6.08 mmol) was added. The reaction mixture was stirred at ambient temperature for 4 h under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:EtOAc 1:1). The solvent was evaporated, then the residue was dissolved in EtOAc (70mL) and washed with 5% aqueous NaHCO<sub>3</sub> (40mL). The EtOAc layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>,

35

filtered, and concentrated. The residue obtained was purified by column chromatography (EtOAc as eluent) to afford 5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%) upon rotary evaporation.

#### **2'-(Aminooxyethoxy) nucleoside amidites**

2'-(Aminooxyethoxy) nucleoside amidites (also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites) are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

#### **N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-hydroxyethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may be phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-([2-phthalamidoxy]ethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

**2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites**

2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>2</sub>)<sub>2</sub>, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

**2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine**

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) was slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. (Caution: Hydrogen gas evolves as the solid dissolves). 2',3'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) were added and the bomb was sealed, placed in an oil bath and heated to 155°C for 26 h. then cooled to room temperature. The crude solution was concentrated, the residue was diluted with water (200 mL) and extracted with hexanes (200 mL). The product was extracted from the aqueous layer with EtOAc (3 x 200 mL) and the combined organic layers were washed once with water, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (eluted with 5:100:2 MeOH/CH<sub>2</sub>Cl<sub>2</sub>/TEA) as the eluent. The appropriate fractions were combined and evaporated to afford the product as a white solid.

**5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine**

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine in anhydrous pyridine (8 mL), was added TEA (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) and the reaction was stirred for 1 h. The reaction mixture was poured into water (200 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 200 mL). The combined CH<sub>2</sub>Cl<sub>2</sub> layers were washed with saturated NaHCO<sub>3</sub> solution, followed by saturated NaCl solution, dried over anhydrous sodium sulfate, filtered and

evaporated. The residue was purified by silica gel column chromatography (eluted with 5:100:1 MeOH/CH<sub>2</sub>Cl<sub>2</sub>/TEA) to afford the product.

5        **5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)-ethyl]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite**

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) were added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) under an atmosphere of argon. The reaction mixture was stirred overnight and the solvent evaporated. The resulting residue was purified by silica gel column chromatography with EtOAc as the eluent to afford the title compound.

## **Example 2**

### **Oligonucleotide synthesis**

10        Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 394) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized similar to phosphodiester oligonucleotides with the following exceptions: thiation was effected by utilizing a 10% w/v solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the oxidation of the phosphite linkages. The thiation reaction step time was increased to 180 sec and preceded by the normal capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (12-16 hr), the oligonucleotides were recovered by precipitating with >3 volumes of ethanol from a 1 M NH<sub>4</sub>OAc solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 35 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

### Example 3

#### Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated

by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

5 Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

#### **Example 4**

##### **0 PNA Synthesis**

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, **1996**, 4, 5-23.

5 They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

#### **Example 5**

##### **0 Synthesis of Chimeric Oligonucleotides**

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

##### **[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric Phosphorothioate Oligonucleotides**

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated

15



DNA synthesizer Model 394, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by incorporating coupling steps with increased reaction times for the 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite. The fully protected oligonucleotide is cleaved from the support and deprotected in concentrated ammonia (NH<sub>4</sub>OH) for 12-16 hr at 55°C. The deprotected oligo is then recovered by an appropriate method (precipitation, column chromatography, volume reduced *in vacuo* and analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

**[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides**

[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

**[2'-O-(2-Methoxyethyl) Phosphodiester]--[2'-deoxy Phosphorothioate]--[2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides**

[2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidation with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4-dithiolane-2-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center

gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein  
5 incorporated by reference.

#### **Example 6**

##### **Oligonucleotide Isolation**

After cleavage from the controlled pore glass solid support  
0 and deblocking in concentrated ammonium hydroxide at 55°C for 12-16 hours, the oligonucleotides or oligonucleosides are recovered by precipitation out of 1 M NH<sub>4</sub>OAc with >3 volumes of ethanol. Synthesized oligonucleotides were analyzed by electrospray mass spectroscopy (molecular weight determination) and by capillary  
5 gel electrophoresis and judged to be at least 70% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in the synthesis was determined by the ratio of correct molecular weight relative to the -16 amu product (+/-32 +/-48). For some studies oligonucleotides were  
10 purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* **1991**, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

#### **Example 7**

##### **Oligonucleotide Synthesis - 96 Well Plate Format**

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a 96-well format.  
30 Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diiso-  
35 propyl phosphoramidites were purchased from commercial vendors

(e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per standard or patented methods. They are utilized as base protected beta-cyanoethyldiisopropyl phosphoramidites.

5        Oligonucleotides were cleaved from support and deprotected with concentrated  $\text{NH}_4\text{OH}$  at elevated temperature ( $55-60^\circ\text{C}$ ) for 12-16 hours and the released product then dried *in vacuo*. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples  
0        are then diluted utilizing robotic pipettors.

#### Example 8

##### Oligonucleotide Analysis - 96-Well Plate Format

5        The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96-well format (Beckman P/ACE™ MDQ) or, for individually prepared  
0        samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors.  
5        Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

#### Example 9

##### Cell culture and oligonucleotide treatment

10        The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following cell types are  
35        provided for illustrative purposes, but other cell types can be

5 routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, ribonuclease protection assays, or RT-PCR.

5 T-24 cells:

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete  
0 McCoy's 5A basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they  
5 reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and  
10 treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

The human lung carcinoma cell line A549 was obtained from  
15 the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per  
30 mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

35 Human neonatal dermal fibroblast (NHDF) were obtained from

the Clonetics Corporation (Walkersville, MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville, MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

#### HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville, MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville, MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

#### b.END cells:

The mouse brain endothelial cell line b.END was obtained from Dr. Werner Risau at the Max Plank Institute (Bad Nauheim, Germany). b.END cells were routinely cultured in DMEM, high glucose (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 3000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

#### Treatment with antisense compounds:

When cells reached 70% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 100  $\mu$ L OPTI-MEM™-1 reduced-serum medium (Invitrogen Corporation, Carlsbad, CA) and then treated with 130  $\mu$ L of OPTI-MEM™-1 containing 3.75  $\mu$ g/mL LIPOFECTIN™ (Invitrogen

Corporation, Carlsbad, CA) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

5       The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control  
0       oligonucleotide is selected from either ISIS 13920 (**TCCGTCATCGCTCCTCAGGG**, SEQ ID NO: 1) which is targeted to human H-ras, or ISIS 18078, (**GTGCGCGCGAGCCCGAAATC**, SEQ ID NO: 2) which is targeted to human Jun-N-terminal kinase-2 (JNK2). Both controls are 2'-O-methoxyethyl gapmers (2'-O-methoxyethyls shown  
5       in bold) with a phosphorothioate backbone. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, **ATGCATTCTGCCCCCAAGGA**, SEQ ID NO: 3, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The  
0       concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest  
5       concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for  
10       oligonucleotide transfection experiments. The concentrations of antisense oligonucleotides used herein are from 50 nM to 300 nM.

#### Example 10

Analysis of oligonucleotide inhibition of sterol regulatory  
15       element-binding protein-1 expression

Antisense modulation of sterol regulatory element-binding protein-1 expression can be assayed in a variety of ways known in the art. For example, sterol regulatory element-binding protein-1 mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. The preferred method of RNA analysis of the present invention is the use of total cellular RNA as described in other examples herein. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions.

Protein levels of sterol regulatory element-binding protein-1 can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to sterol regulatory element-binding protein-1 can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997). Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997).

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998). Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997). Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991).

#### Example 11

##### Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al., (*Clin. Chem.*, 1996, 42, 1758-1764). Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993). Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200  $\mu$ L cold PBS. 60  $\mu$ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55  $\mu$ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200  $\mu$ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60  $\mu$ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C, was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.



Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

## Example 12

### 5 Total RNA Isolation

Total RNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia, CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and  
0 each well was washed with 200 µL cold PBS. 150 µL Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 150 µL of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate  
5 attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 1 minute. 500 µL of Buffer RW1 was added to each well of the RNEASY 96™ plate and incubated for 15 minutes and the vacuum was again applied for 1 minute. An additional 500 µL of Buffer RW1  
0 was added to each well of the RNEASY 96™ plate and the vacuum was applied for 2 minutes. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 90 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 3 minutes. The plate  
15 was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 170 µL water into each well, incubating 1 minute, and then applying the  
30 vacuum for 3 minutes.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting,

DNase treatment and elution steps are carried out.

### Example 13

#### 5 Real-time Quantitative PCR Analysis of sterol regulatory element-binding protein-1 mRNA Levels

Quantitation of sterol regulatory element-binding protein-1 mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., FAM or JOE, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated.

With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

PCR reagents were obtained from Invitrogen Corporation, (Carlsbad, CA). RT-PCR reactions were carried out by adding 20 µL PCR cocktail (2.5x PCR buffer (-MgCl<sub>2</sub>), 6.6 mM MgCl<sub>2</sub>, 375 µM each of dATP, dCTP, dGTP and dTTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNase inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV reverse transcriptase, and 2.5x ROX dye) to 96-well plates containing 30 µL total RNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the PLATINUM® Taq, 40 cycles of a two-step PCR protocol

were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, OR). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen™ RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreen™ are taught in Jones, L.J., et al, (Analytical Biochemistry, 1998, 265, 368-374).

In this assay, 170 µL of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:350 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 30 µL purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 480nm and emission at 520nm.

Probes and primers to human sterol regulatory element-binding protein-1 were designed to hybridize to a human sterol regulatory element-binding protein-1 sequence, using published sequence information (GenBank accession number U00968.1, incorporated herein as SEQ ID NO:4). For human sterol regulatory element-binding protein-1 the PCR primers were: forward primer: GTCCTGCGTCGAAGCTTTG (SEQ ID NO: 5) reverse primer: AGGTCGAACTGTGGAGGCC (SEQ ID NO: 6) and the PCR probe was: FAM-AGGCCGAAGGCAGTGCAAGAGACTC-TAMRA (SEQ ID NO: 7) where FAM is the fluorescent dye and TAMRA is the quencher dye. For human GAPDH the PCR primers were: forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO:8) reverse primer: GAAGATGGTGATGGGATTTT GGGTCTCGCTCCTGGAAGAT (SEQ ID NO:9) and the PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC- TAMRA 3' (SEQ ID NO: 10) where JOE is the fluorescent reporter dye and TAMRA is the quencher dye.

Probes and primers to mouse sterol regulatory element-

binding protein-1 were designed to hybridize to a mouse sterol regulatory element-binding protein-1 sequence, using published sequence information. A consensus sequence of mouse sterol regulatory element-binding protein-1 was assembled using GenBank  
5 accession numbers AI116616, BF385567, AB017337, AI552487, BF160829, BE553319, NM\_024166 and AW476364, and is incorporated herein as SEQ ID NO:11. For mouse sterol regulatory element-binding protein-1 the PCR primers were:  
forward primer: TTGGCCACAGTACCTTTGGTT (SEQ ID NO:12)  
0 reverse primer: CTGAGCCTAGGGCCTTGCT (SEQ ID NO: 13) and the PCR probe was: FAM-CATCCACCGACTCGCAGCTGG-TAMRA (SEQ ID NO: 14) where FAM is the fluorescent reporter dye and TAMRA is the quencher dye. For mouse GAPDH the PCR primers were:  
5 forward primer: GGCAAATTCAACGGCACAGT (SEQ ID NO:15)  
reverse primer: GGGTCTCGCTCCTGGAAGAT (SEQ ID NO:16) and the PCR probe was: 5' JOE-AAGGCCGAGAATGGGAAGCTTGTCATC-TAMRA 3' (SEQ ID NO: 17) where JOE is the fluorescent reporter dye and TAMRA is the quencher dye.

#### Example 14

##### Northern blot analysis of sterol regulatory element-binding protein-1 mRNA levels

5 Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis  
0 through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-  
15 TEST "B" Inc., Friendswood, TX). RNA transfer was confirmed by

UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer's  
5 recommendations for stringent conditions.

To detect human sterol regulatory element-binding protein-1, a human sterol regulatory element-binding protein-1 specific probe was prepared by PCR using the forward primer  
GTCCTGCGTCGAAGCTTTG (SEQ ID NO: 5) and the reverse primer  
0 AGGTCGAACTGTGGAGGCC (SEQ ID NO: 6). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

To detect mouse sterol regulatory element-binding protein-1, a mouse sterol regulatory element-binding protein-1 specific  
5 probe was prepared by PCR using the forward primer TTGGCCACAGTACCTTTGGTT (SEQ ID NO: 12) and the reverse primer CTGAGCCTAGGGCCTTGCT (SEQ ID NO: 13). To normalize for variations in loading and transfer efficiency membranes were  
10 stripped and probed for mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels  
15 in untreated controls.

### Example 15

**Antisense inhibition of human sterol regulatory element-binding  
30 protein-1 expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap**

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human sterol regulatory element-binding protein-1 RNA, using  
35 published sequences (GenBank accession number U00968.1,

incorporated herein as SEQ ID NO: 4, residues 79000 - 10600 of GenBank accession number NT\_010657.5, incorporated herein as SEQ ID NO: 18, GenBank accession number AV704194.1, incorporated herein as SEQ ID NO: 19, and GenBank accession number

5 NM\_004176.1, incorporated herein as SEQ ID NO: 20). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides  
 .0 in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the  
 .5 oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human sterol regulatory element-binding protein-1 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which A549 cells were treated  
 20 with the antisense oligonucleotides of the present invention. The positive control for each datapoint is identified in the table by sequence ID number. The positive control for each datapoint is identified in the table by sequence ID number. If  
 . present, "N.D." indicates "no data".

25

**Table 1**

**Inhibition of human sterol regulatory element-binding protein-1 mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap**

30

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO	CONTROL SEQ ID NO
166175	Coding	4	981	tgtctgcacagtgggtgccag	60	21	1
166181	Coding	4	1521	ctccgagtcactgccactgc	75	22	1
206245	Exon: Exon Junction	19	90	tgaagcatgtcttcgaaagt	18	23	1
219635	Coding	20	273	gtcactgtcttggttgttga	48	24	1
219636	Coding	20	278	gggaagtcactgtcttggtt	65	25	1

219637	Coding	20	283	ggccagggaagtcaactgtct	84	26	1
219642	Coding	20	893	gagtcctgccttgatgaagt	49	27	1
219644	Coding	20	1088	gccttgctgccagctgcgag	65	28	1
219647	Coding	20	1229	gcagatttattcagctttgc	59	29	1
219648	Coding	20	1234	agacagcagatttattcagc	51	30	1
219649	Coding	20	1239	gcgcaagacagcagatttat	69	31	1
219650	Coding	20	1244	gccttgcgcaagacagcaga	53	32	1
219651	Coding	20	1249	cgatggccttgcgcaagaca	55	33	1
219652	Coding	20	1254	gtagtogatggccttgcgca	65	34	1
219657	Coding	20	1610	aggcgggagcggtccagcat	52	35	1
219667	Coding	20	2440	ggcagagccactgcatggca	65	36	1
219672	Coding	20	2780	gaggcccaccacttggccac	45	37	1
219673	Coding	20	2806	gccagtggatcaccacagct	62	38	1
219675	Coding	20	2928	ccgggcagccttgaaggagt	49	39	1
219678	Coding	20	2994	actggccttctcacagatgg	58	40	1
219679	Coding	20	3004	gcaggtaccactggccttc	80	41	1
219696	3'UTR	20	4091	ctatgaaaataaagtgtgca	58	42	1
220043	Start Codon	18	14369	gccgacttcacctgtcaagg	46	43	1
220046	Intron: Exon Junction	18	18250	ggagggtcttctgcagaaat	42	44	1
220047	Intron: Exon Junction	18	19601	atttattcagctgcacggtg	74	45	1
220048	Intron: Exon Junction	18	21600	gtgcttccttgaaggcaag	0	46	1
220049	Intron	18	22459	gcaccagccttggccaggag	66	47	1
220050	Intron	18	23023	ccctgtggaaggagagagct	24	48	1
220051	Intron: Exon Junction	18	23228	gggtctacgcctgcagaaga	17	49	1
220052	Exon: Intron Junction	18	24407	gggcaactcaccctccgcatg	64	50	1
220053	Coding	19	31	gtccaggccgttggccctac	62	51	1
220054	Coding	19	73	agtgcattccatggctccgc	67	52	1
220055	Exon: Exon Junction	19	97	gataagctgaagcatgtctt	54	53	1
220056	5'UTR	20	33	gtcctgccttggcctcagag	68	54	1
220057	Start Codon	20	159	tggctcgtccatggcgcagc	58	55	1
220058	Coding	20	174	cgcctcgtgaagggtggct	67	56	1
220059	Coding	20	249	ctgaagcatgtcttcgatgt	45	57	1
220060	Coding	20	386	ctcaatgtggcaggaggtgg	59	58	1
220061	Coding	20	597	tgggaagctctgtggcagga	62	59	1
220062	Coding	20	718	ccagtggcaggccaggcagc	67	60	1
220063	Coding	20	998	agggtcggcaaaggccctgt	61	61	1
220064	Coding	20	1074	tgcgagccggttgataggca	47	62	1
220065	Coding	20	1127	gctgtgcgttctctccacg	64	63	1
220066	Coding	20	1204	tgcccaccaccagatccttg	67	64	1
220067	Coding	20	1310	cgcagacttaggttctcctg	74	65	1
220068	Coding	20	1330	tgttttgtggacagcagtg	59	66	1
220069	Coding	20	1364	ctgccacaggccgacaccag	60	67	1
220070	Coding	20	1915	cagcctgcttgcgatgcctc	66	68	1
220071	Coding	20	1927	ccagggtccagggtcagcctgc	49	69	1
220072	Coding	20	2173	gcttatggtagaccagggt	46	70	1
220073	Coding	20	2204	gtgtgcttccccatggtgtg	36	71	1
220074	Coding	20	2310	cgccacatagatctcggcca	72	72	1
220075	Coding	20	2317	atgcagccgccacatagatc	51	73	1



220076	Coding	20	2584	ctcgctctaagagatgttcc	72	74	1
220077	Coding	20	2631	atcagctgacccagggctgg	67	75	1
220078	Coding	20	2655	ggcatccgagaattccttgt	32	76	1
220079	Coding	20	2754	tacgccggtggtggggcca	32	77	1
220080	Coding	20	2966	gctggaccagactctgcctt	64	78	1
220081	Coding	20	3037	agctgctggctggtgtggta	64	79	1
220082	Coding	20	3182	cgcagctcaagggcggaagc	67	80	1
220083	Coding	20	3547	tctgctgacagtcgtgcagc	38	81	1
220084	Coding	20	3560	aggcgcatgagcatctgctg	72	82	1
220086	Coding	20	3585	ggaagtgacagtgggtcccac	59	83	1
220089	Stop Codon	20	3595	gggtctagctggaagtgcaca	66	84	1
220091	3'UTR	20	3643	cacgggaccaaagtggctag	80	85	1
220094	3'UTR	20	3657	caggacagaagctgcacggg	60	86	1
220096	3'UTR	20	3732	ggcacacagcagccgcaggt	75	87	1
220099	3'UTR	20	3745	cttccaccgcgaaggcacac	61	88	1
220101	3'UTR	20	3785	atggccgctgtcttaggggt	24	89	1
220104	3'UTR	20	3795	cagcaccatcatggccgccg	85	90	1
220106	3'UTR	20	3874	ctaaggtgcctgcagagcaa	75	91	1
220109	3'UTR	20	3923	acagggaaatgtacccctct	80	92	1
220111	3'UTR	20	3937	tggcttccgtcagcacagg	53	93	1
220114	3'UTR	20	3953	tccgggaaagccaagttggc	57	94	1
220116	3'UTR	20	4043	tcaggaggctaagcacgctg	63	95	1
220118	3'UTR	20	4079	agtttgcaaaaggcaaaagta	52	96	1
220120	3'UTR	20	4118	ttaattctctgtacaaaact	63	97	1

As shown in Table 1, SEQ ID NOs 21, 22, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 47, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 72, 73, 74, 75, 78, 79, 80, 82, 83, 84, 85, 86, 87, 88, 90, 91, 92, 93, 94, 95, 96 and 97 demonstrated at least 40% inhibition of human sterol regulatory element-binding protein-1 expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "preferred target regions" and are therefore preferred sites for targeting by compounds of the present invention. These preferred target regions are shown in Table 3. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number of the corresponding target nucleic acid. Also shown in Table 3 is the species in which each of the preferred target regions was found.

**Example 16**

**Antisense inhibition of mouse sterol regulatory element-binding protein-1 expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap.**

5 In accordance with the present invention, a second series of oligonucleotides were designed to target different regions of the mouse sterol regulatory element-binding protein-1 RNA, using published sequences (a consensus sequence of mouse sterol regulatory element-binding protein-1 assembled using GenBank  
0 accession numbers AI116616, BF385567, AB017337, AI552487, BF160829, BE553319, NM\_024166 and AW476364, incorporated herein as SEQ ID NO: 11, GenBank accession number AB046200.1, incorporated herein as SEQ ID NO: 98, GenBank accession number AI115845.1, incorporated herein as SEQ ID NO: 99, and a sequence  
5 assembled from ordered contigs from GenBank accession number AC096624.3, incorporated herein as SEQ ID NO: 100). The oligonucleotides are shown in Table 2. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in  
0 Table 2 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside  
15 (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on mouse sterol regulatory element-binding protein-1 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are  
20 averages from two experiments in which b.END cells were treated with the antisense oligonucleotides of the present invention. The positive control for each datapoint is identified in the table by sequence ID number. If present, "N.D." indicates "no data".

35

Table 2

Inhibition of mouse sterol regulatory element-binding protein-1 mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

5

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO	CONTROL SEQ ID NO
206241	Exon: Exon Junction	99	78	tggagcatgtcttcaaagt	29	101	1
219634	Start Codon	11	61	tgtgcaatccatggctccgt	64	102	1
219638	Genomic	11	348	aagagaagctctcaggagag	11	103	1
219639	Genomic	11	396	ccttgggtcctcccaggaag	46	104	1
219640	Genomic	11	416	ggacaaggggtgcaggtgtca	47	105	1
219641	Genomic	11	515	gatggtgagtggcactggct	57	106	1
219643	Coding	11	1026	ggatgggcagtttgtctgtg	88	107	1
219645	Coding	11	1090	gctgtgcgcttctcaccacg	74	108	1
219646	Coding	11	1110	gcttctcaatggcattgtgg	72	109	1
219653	Coding	11	1326	cactgccacaagctgacacc	72	110	1
219654	Coding	11	1350	ccatagacacatctgtgcct	60	111	1
219655	Coding	11	1476	gctcagagtcactgccacca	74	112	1
219656	Exon: Exon Junction	11	1515	gggctttgacctggctatcc	61	113	1
219658	Exon: Exon Junction	11	1711	ttagagccatctctgctctc	27	114	1
219659	Genomic	11	1731	gcagcaaccactgggtccaa	51	115	1
219660	Genomic	11	1759	agtccattggccagccagac	57	116	1
219661	Genomic	11	1779	ccaagcaggccaacactagt	52	117	1
219662	Genomic	11	1854	tgcgatgtctccagaagtgt	64	118	1
219663	Genomic	11	1966	gccagatccagggttgaggt	57	119	1
219664	Genomic	11	2038	tggcctgccagccagcggcc	40	120	1
219665	Exon: Exon Junction	11	2152	gtgtacttgcccatggcatg	43	121	1
219666	Coding	11	2250	agatctctgccagtgttgcc	65	122	1
219668	Genomic	11	2400	gacctacagggtggcagagc	62	123	1
219669	Genomic	11	2478	ctgggttcccagccacgctg	63	124	1
219670	3' UTR	11	2597	ggcatctgagaactccctgt	75	125	1
219671	3' UTR	11	2714	ccacttggccactgggtctg	52	126	1
219674	3' UTR	11	2864	agccttgaaggagtacagag	42	127	1
219676	3' UTR	11	2894	cacctttctgtggtccagca	78	128	1
219677	3' UTR	11	2920	atggccaggctggctgggct	30	129	1
219680	3' UTR	11	3013	tcacacaggagcagctgcat	55	130	1
219681	3' UTR	11	3024	caagaagtagatcacacagg	55	131	1
219682	3' UTR	11	3096	cattgctggtaccgtgagct	63	132	1
219683	3' UTR	11	3119	ctccagagcagaggcctggg	25	133	1
219684	3' UTR	11	3129	aaccacgcagctccagagca	64	134	1
219685	3' UTR	11	3139	tcatgttggaaccacgcag	52	135	1
219686	3' UTR	11	3149	gctgtcagggtcatgttgga	29	136	1
219687	3' UTR	11	3214	gctgtggcctcatgtaggaa	56	137	1
219688	3' UTR	11	3224	catcagccgagctgtggcct	52	138	1
219689	3' UTR	11	3245	ccgggcaggacttgctctctg	36	139	1
219690	3' UTR	11	3299	tttgccactggaacctgccc	56	140	1
219691	3' UTR	11	3349	gtgtgctcccgccatgtggg	60	141	1
219692	3' UTR	11	3497	caggagcatctgctggcagt	24	142	1

219693	Stop Codon	11	3537	gggtctagctggaagtgcg	28	143	1
219694	3' UTR	11	3632	tctgccactagaggtcggca	71	144	1
219695	3' UTR	11	3686	gcctacagagcaagagggtg	66	145	1
219697	3' UTR	11	3825	aaaattttctcaacctatgaa	57	146	1
219698	Genomic	98	32	tgagaacacttggttcaagg	62	147	1
219699	Genomic	98	101	gccaatagctgccttttagat	59	148	1
219700	Genomic	98	227	gtgttcccaccgctgggttcg	34	149	1
219701	Genomic	98	334	ttactggcggtcactgtcgt	50	150	1
219702	Intron	100	4956	ttggccgtacctttgcttca	41	151	1
219703	Intron	100	5918	ccacactattctcagctagc	74	152	1
219704	Intron	100	6071	agaaggcagcatcaggggtg	53	153	1
219705	Intron: Exon Junction	100	6211	ttcagtgtattctgtaggcag	29	154	1
219706	Exon: Intron Junction	100	6426	agagtccaacctggctatcc	43	155	1
219707	Exon: Intron Junction	100	7009	cttaccggtggccaaatccag	44	156	1
219708	Intron	100	7100	gggatgagacagactggaga	21	157	1
219709	Intron: Exon Junction	100	7547	gtgtacttgctgcaaagtg	46	158	1

As shown in Table 2, SEQ ID NOs 102, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 130, 131, 132, 134, 135, 137, 138, 139, 140, 141, 144, 145, 146, 147, 148, 150, 151, 152, 153, 155, 156 and 158 demonstrated at least 35% inhibition of mouse sterol regulatory element-binding protein-1 expression in this experiment and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "preferred target regions" and are therefore preferred sites for targeting by compounds of the present invention. These preferred target regions are shown in Table 3. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number of the corresponding target nucleic acid. Also shown in Table 3 is the species in which each of the preferred target regions was found.

**Table 3**  
**Sequence and position of preferred target regions identified in**  
**sterol regulatory element-binding protein-1.**

SITEID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV COMP OF SEQ ID	ACTIVE IN	SEQ ID NO
81314	4	981	ctggcaccactgtgcagaca	21	<i>H. sapiens</i>	159
81320	4	1521	gcagtggcagtgactcggag	22	<i>H. sapiens</i>	160
136286	20	273	tcaacaaccaagacagtgac	24	<i>H. sapiens</i>	161
136287	20	278	aaccaagacagtgacttccc	25	<i>H. sapiens</i>	162
136288	20	283	agacagtgacttccctggcc	26	<i>H. sapiens</i>	163
136293	20	893	cacttcatcaaggcagactc	27	<i>H. sapiens</i>	164
136295	20	1088	ctcgcagctggcagcaaggc	28	<i>H. sapiens</i>	165
136298	20	1229	gcaaagctgaataaatctgc	29	<i>H. sapiens</i>	166
136299	20	1234	gctgaataaatctgctgtct	30	<i>H. sapiens</i>	167
136300	20	1239	ataaatctgctgtcttgccg	31	<i>H. sapiens</i>	168
136301	20	1244	tctgctgtcttgccgaaggc	32	<i>H. sapiens</i>	169
136302	20	1249	tgtcttgccgaaggccatcg	33	<i>H. sapiens</i>	170
136303	20	1254	tgcgcaaggccatcgactac	34	<i>H. sapiens</i>	171
136308	20	1610	atgctggaccgctcccgcct	35	<i>H. sapiens</i>	172
136318	20	2440	tgccatgcagtggtctgtcc	36	<i>H. sapiens</i>	173
136323	20	2780	gtggccaagtgtgggcctc	37	<i>H. sapiens</i>	174
136324	20	2806	agctgtggtgatccactggc	38	<i>H. sapiens</i>	175
136326	20	2928	actccttcaaggctgcccg	39	<i>H. sapiens</i>	176
136329	20	2994	ccatctgtgagaaggccagt	40	<i>H. sapiens</i>	177
136330	20	3004	gaaggccagtgggtacctgc	41	<i>H. sapiens</i>	178
136347	20	4091	tgcaaaactttattttcatag	42	<i>H. sapiens</i>	179
123906	18	14369	ccttgacaggtgaagtcggc	43	<i>H. sapiens</i>	180
136698	18	18250	atttctgcaggaagccctcc	44	<i>H. sapiens</i>	181
136699	18	19601	caccgtgcagctgaataaat	45	<i>H. sapiens</i>	182
136701	18	22459	ctcctggccaaggctggtgc	47	<i>H. sapiens</i>	183
136704	18	24407	catgcgagggtgagtgcgc	50	<i>H. sapiens</i>	184
136705	19	31	gtagggccaaacggcctggac	51	<i>H. sapiens</i>	185
136706	19	73	gcggagccatggattgcact	52	<i>H. sapiens</i>	186
136707	19	97	aagacatgcttcagcttatc	53	<i>H. sapiens</i>	187
136708	20	33	ctctgaggccagggcaggac	54	<i>H. sapiens</i>	188
136709	20	159	gctgcgccatggacgagcca	55	<i>H. sapiens</i>	189
136710	20	174	agccacccttcagcgaggcg	56	<i>H. sapiens</i>	190
136711	20	249	acatcgaagacatgcttcag	57	<i>H. sapiens</i>	191
136712	20	386	ccacctcctgccacattgag	58	<i>H. sapiens</i>	192
136713	20	597	tcctgccacagagcttcca	59	<i>H. sapiens</i>	193
136714	20	718	gctgcctggcctgccactgg	60	<i>H. sapiens</i>	194
136715	20	998	acagggcctttgccgacct	61	<i>H. sapiens</i>	195
136716	20	1074	tgcctatcaaccggctcgca	62	<i>H. sapiens</i>	196
136717	20	1127	cgtggagagaagcgacagc	63	<i>H. sapiens</i>	197
136718	20	1204	caaggatctggtggtgggca	64	<i>H. sapiens</i>	198
136719	20	1310	caggagaacctaaagtctgcg	65	<i>H. sapiens</i>	199
136720	20	1330	cactgctgtccacaaaagca	66	<i>H. sapiens</i>	200
136721	20	1364	ctggtgtcggcctgtggcag	67	<i>H. sapiens</i>	201
136722	20	1915	gaggcatcgcaagcaggctg	68	<i>H. sapiens</i>	202
136723	20	1927	gcaggctgacctggacctgg	69	<i>H. sapiens</i>	203
136724	20	2173	agccctgggtctaccataagc	70	<i>H. sapiens</i>	204
136726	20	2310	tggccgagatctatgtggcg	72	<i>H. sapiens</i>	205
136727	20	2317	gatctatgtggcggtgcat	73	<i>H. sapiens</i>	206
136728	20	2584	ggaacatctcttagagcgag	74	<i>H. sapiens</i>	207
136729	20	2631	ccagccctgggtcagctgat	75	<i>H. sapiens</i>	208
136732	20	2966	aaggcagagtctggtccagc	78	<i>H. sapiens</i>	209

136733	20	3037	taccacaccagccagcagct	79	<i>H. sapiens</i>	210
136734	20	3182	gcttcgcccttgagctgcg	80	<i>H. sapiens</i>	211
136736	20	3560	cagcagatgctcatgcgct	82	<i>H. sapiens</i>	212
136737	20	3585	gtgggaccactgtcacttcc	83	<i>H. sapiens</i>	213
136738	20	3595	tgctacttccagctagaccc	84	<i>H. sapiens</i>	214
136739	20	3643	ctagccacttttggtcccggtg	85	<i>H. sapiens</i>	215
136740	20	3657	cccgtgcagcttctgtcctg	86	<i>H. sapiens</i>	216
136741	20	3732	acctgcggtgctgtgtgcc	87	<i>H. sapiens</i>	217
136742	20	3745	gtgtgccttcgcggtggaag	88	<i>H. sapiens</i>	218
136744	20	3795	cggcgccatgatggtgctg	90	<i>H. sapiens</i>	219
136745	20	3874	ttgctctgcaggcaccttag	91	<i>H. sapiens</i>	220
136746	20	3923	agaggggtacatttccctgt	92	<i>H. sapiens</i>	221
136747	20	3937	ccctgtgctgacggaagcca	93	<i>H. sapiens</i>	222
136748	20	3953	gccaaacttggtttcccgga	94	<i>H. sapiens</i>	223
136749	20	4043	cagcgtgcttagcctcctga	95	<i>H. sapiens</i>	224
136750	20	4079	tactttgccttttgcaact	96	<i>H. sapiens</i>	225
136751	20	4118	agttttgtacagagaattaa	97	<i>H. sapiens</i>	226
136285	11	61	acggagccatggattgcaca	102	<i>M. musculus</i>	227
136290	11	396	cttcctgggaggacccaagg	104	<i>M. musculus</i>	228
136291	11	416	tgacacctgcaccttgtcc	105	<i>M. musculus</i>	229
136292	11	515	agccagtgccactcaccatc	106	<i>M. musculus</i>	230
136294	11	1026	cacagacaaactgcccatcc	107	<i>M. musculus</i>	231
136296	11	1090	cgtggtgagaagcgacagc	108	<i>M. musculus</i>	232
136297	11	1110	ccacaatgccattgagaagc	109	<i>M. musculus</i>	233
136304	11	1326	ggtgtcagcttgtggcagtg	110	<i>M. musculus</i>	234
136305	11	1350	aggcacagatgtgtctatgg	111	<i>M. musculus</i>	235
136306	11	1476	tggtggcagtgactctgagc	112	<i>M. musculus</i>	236
136307	11	1515	ggatagccaggtcaaagccc	113	<i>M. musculus</i>	237
136310	11	1731	ttggacccagtggtgtctgc	115	<i>M. musculus</i>	238
136311	11	1759	gtctggctggccaatggact	116	<i>M. musculus</i>	239
136312	11	1779	actagtgttggcctgcttgg	117	<i>M. musculus</i>	240
136313	11	1854	acaacttctggagacatcgca	118	<i>M. musculus</i>	241
136314	11	1966	acctcaaacctggatctggc	119	<i>M. musculus</i>	242
136315	11	2038	ggccgctggctggcaggcca	120	<i>M. musculus</i>	243
136316	11	2152	catgccatgggcaagtacac	121	<i>M. musculus</i>	244
136317	11	2250	ggcaacactggcagagatct	122	<i>M. musculus</i>	245
136319	11	2400	gctctgccaccctgtaggctc	123	<i>M. musculus</i>	246
136320	11	2478	cagcgtggctgggaaccag	124	<i>M. musculus</i>	247
136321	11	2597	acagggagttctcagatgcc	125	<i>M. musculus</i>	248
136322	11	2714	cagaccagtggtgccaagtgg	126	<i>M. musculus</i>	249
136325	11	2864	ctctgtactccttcaaggct	127	<i>M. musculus</i>	250
136327	11	2894	tgctggaccacagaagggtg	128	<i>M. musculus</i>	251
136331	11	3013	atgcagctgctcctgtgtga	130	<i>M. musculus</i>	252
136332	11	3024	cctgtgtgatctacttcttg	131	<i>M. musculus</i>	253
136333	11	3096	agctcacggtaccagcaatg	132	<i>M. musculus</i>	254
136335	11	3129	tgctctggagctgcgtgggtt	134	<i>M. musculus</i>	255
136336	11	3139	ctgcgtgggtttccaacatga	135	<i>M. musculus</i>	256
136338	11	3214	ttcctacatgaggccacagc	137	<i>M. musculus</i>	257
136339	11	3224	aggccacagctcggctgatg	138	<i>M. musculus</i>	258
136340	11	3245	caggagcaagtcctgcccg	139	<i>M. musculus</i>	259
136341	11	3299	gggcaggttccagtggcaaa	140	<i>M. musculus</i>	260
136342	11	3349	cccacatggcgggagcacac	141	<i>M. musculus</i>	261
136345	11	3632	tgccgacctctagtggcaga	144	<i>M. musculus</i>	262
136346	11	3686	caccctcttgcctctgtaggc	145	<i>M. musculus</i>	263
136348	11	3825	ttcataggttgagaattttt	146	<i>M. musculus</i>	264
136349	98	32	ccttgaaacaagtgttctca	147	<i>M. musculus</i>	265
136350	98	101	atctaaaggcagctattggc	148	<i>M. musculus</i>	266
136352	98	334	acgacagtgaccgccagtaa	150	<i>M. musculus</i>	267
136353	100	4956	tgaagcaaaggctacggccaa	151	<i>M. musculus</i>	268
136354	100	5918	gctagctgagaatagtgtgg	152	<i>M. musculus</i>	269

136355	100	6071	ccaccctgatgctgccttct	153	<i>M. musculus</i>	270
136357	100	6426	ggatagccaggttgactct	155	<i>M. musculus</i>	271
136358	100	7009	ctggatttgcccggttaag	156	<i>M. musculus</i>	272
136360	100	7547	cactttgcaggcaagtacac	158	<i>M. musculus</i>	273

As these "preferred target regions" have been found by  
 5 experimentation to be open to, and accessible for, hybridization  
 with the antisense compounds of the present invention, one of  
 skill in the art will recognize or be able to ascertain, using  
 no more than routine experimentation, further embodiments of the  
 invention that encompass other compounds that specifically  
 0 hybridize to these sites and consequently inhibit the expression  
 of sterol regulatory element-binding protein-1.

#### Example 17

##### 5 Western blot analysis of sterol regulatory element-binding protein-1 protein levels

Western blot analysis (immunoblot analysis) is carried out  
 using standard methods. Cells are harvested 16-20 h after  
 oligonucleotide treatment, washed once with PBS, suspended in  
 10 Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on  
 a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and  
 transferred to membrane for western blotting. Appropriate  
 primary antibody directed to sterol regulatory element-binding  
 protein-1 is used, with a radiolabeled or fluorescently labeled  
 15 secondary antibody directed against the primary antibody  
 species. Bands are visualized using a PHOSPHORIMAGER™  
 (Molecular Dynamics, Sunnyvale CA).

#### 30 Example 18

##### RNA Synthesis

In general, RNA synthesis chemistry is based on the selective  
 incorporation of various protecting groups at strategic

intermediary reactions. Although one of ordinary skill in the art will understand the use of protecting groups in organic synthesis, a useful class of protecting groups includes silyl ethers. In particular bulky silyl ethers are used to protect the 5'-hydroxyl in combination with an acid-labile orthoester protecting group on the 2'-hydroxyl. This set of protecting groups is then used with standard solid-phase synthesis technology. It is, important to lastly remove the acid labile orthoester protecting group after all other synthetic steps. Moreover, the early use of the silyl protecting groups during synthesis ensures facile removal when desired, without undesired deprotection of 2' hydroxyl.

Following this procedure for the sequential protection of the 5'-hydroxyl in combination with protection of the 2'-hydroxyl by protecting groups that are differentially removed and are differentially chemically labile, RNA oligonucleotides were synthesized.

RNA oligonucleotides are synthesized in a stepwise fashion. Each nucleotide is added sequentially (3'- to 5'-direction) to a solid support-bound oligonucleotide. The first nucleoside at the 3'-end of the chain is covalently attached to a solid support. The nucleotide precursor, a ribonucleoside phosphoramidite, and activator are added, coupling the second base onto the 5'-end of the first nucleoside. The support is washed and any unreacted 5'-hydroxyl groups are capped with acetic anhydride to yield 5'-acetyl moieties. The linkage is then oxidized to the more stable and ultimately desired P(V) linkage. At the end of the nucleotide addition cycle, the 5'-silyl group is cleaved with fluoride. The cycle is repeated for each subsequent nucleotide.

Following synthesis, the methyl protecting groups on the phosphates are cleaved in 30 minutes utilizing 1 M disodium-2-carbamoyl-2-cyanoethylene-1,1-dithiolate trihydrate ( $S_2Na_2$ ) in DMF. The deprotection solution is washed from the solid support-bound oligonucleotide using water. The support is then treated with 40% methylamine in water for 10 minutes at 55°C. This



releases the RNA oligonucleotides into solution, deprotects the exocyclic amines, and modifies the 2'- groups. The oligonucleotides can be analyzed by anion exchange HPLC at this stage.

5       The 2'-orthoester groups are the last protecting groups to be removed. The ethylene glycol monoacetate orthoester protecting group developed by Dharmacon Research (Lafayette, CO), is one example of a useful orthoester protecting group which, has the following important properties. It is stable to the conditions  
0 of nucleoside phosphoramidite synthesis and oligonucleotide synthesis. However, after oligonucleotide synthesis the oligonucleotide is treated with methylamine which not only cleaves the oligonucleotide from the solid support but also removes the acetyl groups from the orthoesters. The resulting 2-  
5 ethyl-hydroxyl substituents on the orthoester are less electron withdrawing than the acetylated precursor. As a result, the modified orthoester becomes more labile to acid-catalyzed hydrolysis.

Specifically, the rate of cleavage is approximately 10 times  
0 faster after the acetyl groups are removed. Therefore, this orthoester possesses sufficient stability in order to be compatible with oligonucleotide synthesis and yet, when subsequently modified, permits deprotection to be carried out under relatively mild aqueous conditions compatible with the  
5 final RNA oligonucleotide product.

Additionally, methods of RNA synthesis are well known in the art (Scaringe, S. A. Ph.D. Thesis, University of Colorado, 1996; Scaringe, S. A., et al., J. Am. Chem. Soc., 1998, 120, 11820-11821; Matteucci, M. D. and Caruthers, M. H. J. Am. Chem. Soc.,  
10 1981, 103, 3185-3191; Beaucage, S. L. and Caruthers, M. H. Tetrahedron Lett., 1981, 22, 1859-1862; Dahl, B. J., et al., Acta Chem. Scand., 1990, 44, 639-641; Reddy, M. P., et al., Tetrahedron Lett., 1994, 25, 4311-4314; Wincott, F. et al., Nucleic Acids Res., 1995, 23, 2677-2684; Griffin, B. E., et al.,

Tetrahedron, 1967, 23, 2301-2313; Griffin, B. E., et al.,  
Tetrahedron, 1967, 23, 2315-2331).

RNA compounds (RNA oligonucleotides) of the present invention  
can be synthesized by the methods herein or purchased from  
5 Dharmacon Research, Inc (Boulder, CO). Once synthesized,  
complementary RNA compounds can then be annealed by methods  
known in the art to form double stranded (duplexed) oligomeric  
compounds. For example, duplexes can be formed by combining 30  
µl of each of the complementary strands of RNA oligonucleotides  
0 (50 µM RNA oligonucleotide solution) and 15 µl of 5X annealing  
buffer (100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM  
magnesium acetate) followed by heating for 1 minute at 90°C,  
then 1 hour at 37°C. The resulting duplexed compounds can be  
used in kits, assays, screens, or other methods to investigate  
5 the role of a target nucleic acid.

#### **Example 19**

##### **Design of double stranded oligomeric compounds targeting sterol regulatory element-binding protein-1**

0 In accordance with the present invention, a series of  
22 nucleotide oligomeric compounds, in this case duplex RNAs, is  
designed to target sterol regulatory element-binding protein-1  
mRNA (e.g., Genbank accession no. U00968.1, NT\_010657.5,  
AV704194.1 and/or NM\_004176.1). The nucleobase sequence of the  
5 antisense strand of the duplex is identical to the 20 nucleobase  
oligonucleotides in Table 2 with followed by a two-nucleobase  
overhang of deoxythymidine (T), TT, on the 3' end. The sense  
strand of the dsRNA is designed and synthesized as the  
complement of the antisense strand and also contains the two-  
10 nucleobase overhang on the 3' end making both strands of the  
dsRNA duplex complementary over the central 20 nucleobases and  
each having a two-base overhang on the 3' end.

For example, the dsRNA having ISIS 220078 (SEQ ID NO:  
76) as the antisense strand is:

ggcattccgagaattccttgtTT    ISIS 220078  
 |||||  
 TTccgtaggctcttaaggaaca    Complement  
                                  of ISIS 220078

5

Both strands of the dsRNAs may be purchased from Dharmacon Research Inc. (Lafayette, CO), shipped lyophilized and annealed on-site using the manufacturer's protocol.

Briefly, each RNA oligonucleotide is aliquoted and  
 0 diluted to a concentration of 50  $\mu$ M. Once diluted, 30  $\mu$ L of  
 each strand is combined with 15 $\mu$ L of a 5X solution of annealing  
 buffer. The final concentration of said buffer is 100 mM  
 potassium acetate, 30 mM HEPES-KOH pH 7.4, and 2mM magnesium  
 acetate. The final volume is 75  $\mu$ L. This solution is incubated  
 5 for 1 minute at 90°C and then centrifuged for 15 seconds. The  
 tube is allowed to sit for 1 hour at 37°C at which time the  
 dsRNA duplexes are used in experimentation. The final  
 concentration of the dsRNA duplex is 20  $\mu$ M. This solution can  
 be stored frozen (-20°C) and freeze-thawed up to 5 times.

0

#### Example 20

#### **Inhibition of sterol regulatory element-binding protein-1 expression by double stranded RNA (dsRNA)**

In accordance with the present invention, a series of double  
 5 stranded oligomeric compounds targeted to sterol regulatory  
 element-binding protein-1 may be evaluated for their ability to  
 modulate sterol regulatory element-binding protein-1 expression  
 in T-24 cells compared to treatment with the single-stranded  
 oligonucleotides of the present invention listed in Table 2.

.0 When cells reach 80% confluency, they are treated with dsRNA  
 or single stranded oligonucleotide. For cells grown in 96-well  
 plates, wells are washed once with 200  $\mu$ L OPTI-MEM-1 reduced-  
 serum medium (Gibco BRL) and then treated with 130  $\mu$ L of OPTI-  
 MEM-1 containing 12  $\mu$ g/mL LIPOFECTIN™ (Gibco BRL) and the  
 15 desired dsRNA at a final concentration of 200 nM. After 5 hours  
 of treatment, the medium is replaced with fresh medium. Cells  
 are harvested 16 hours after dsRNA or single-stranded

oligonucleotide treatment, at which time RNA is isolated and target reduction measured by RT-PCR.

**What is claimed is:**

1. A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding sterol regulatory element-binding protein-1, wherein said compound specifically hybridizes with said nucleic acid molecule encoding sterol regulatory element-binding protein-1 and inhibits the expression of sterol regulatory element-binding protein-1.
2. The compound of claim 1 which is an antisense oligonucleotide.
3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
4. The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.
5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
6. The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
8. The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.
9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
10. A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding sterol regulatory element-binding protein-1.
11. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
12. The composition of claim 11 further comprising a colloidal dispersion system.
13. The composition of claim 11 wherein the compound is

an antisense oligonucleotide.

14. A method of inhibiting the expression of sterol regulatory element-binding protein-1 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of sterol regulatory element-binding protein-1 is inhibited.

15. A method of treating an animal having a disease or condition associated with sterol regulatory element-binding protein-1 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of sterol regulatory element-binding protein-1 is inhibited.

16. The method of claim 15 wherein the disease or condition is a metabolic disorder.

17. The method of claim 16 wherein the metabolic disorder is diabetes.

18. The method of claim 15 wherein the disease or condition is cardiovascular disease.

19. The method of claim 15 wherein the disease or condition is atherosclerosis.

20. The method of claim 15 wherein the disease or condition is a hyperlipidemia.

<110> Susan M. Freier  
Brenda F. Baker  
Kenneth W. Dobie

<120> ANTISENSE MODULATION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-1  
EXPRESSION

<130> ISIS0046-500

<150> US 10/161996

<151> 2002/06/04

<160> 273

<210> 1  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 1  
tccgtcatcg ctcctcaggg 20

<210> 2  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 2  
gtgcgcgcga gcccgaaatc 20

<210> 3  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 3  
atgcattctg cccccaagga 20

<210> 4  
<211> 4154  
<212> DNA  
<213> H. sapiens

<220>

&lt;221&gt; CDS

&lt;222&gt; (167)...(3610)

&lt;400&gt; 4

taacgaggaa cttttcgccg gcgcccggcc gcctctgagg ccagggcagg acacgaacgc	60
gcggagcggc ggcggcgact gagagccggg gccgcggcgg cgctccctag gaagggccgt	120
acgaggcggc gggcccggcg ggcctcccgg aggaggcggc tgcgcc atg gac gag	175
Met Asp Glu	
1	
cca ccc ttc agc gag gcg gct ttg gag cag gcg ctg ggc gag ccg tgc	223
Pro Pro Phe Ser Glu Ala Ala Leu Glu Gln Ala Leu Gly Glu Pro Cys	
5 10 15	
gat ctg gac gcg gcg ctg ctg acc gac atc gaa gac atg ctt cag ctt	271
Asp Leu Asp Ala Ala Leu Leu Thr Asp Ile Glu Asp Met Leu Gln Leu	
20 25 30 35	
atc aac aac caa gac agt gac ttc cct ggc cta ttt gac cca ccc tat	319
Ile Asn Asn Gln Asp Ser Asp Phe Pro Gly Leu Phe Asp Pro Pro Tyr	
40 45 50	
gct ggg agt ggg gca ggg ggc aca gac cct gcc agc ccc gat acc agc	367
Ala Gly Ser Gly Ala Gly Gly Thr Asp Pro Ala Ser Pro Asp Thr Ser	
55 60 65	
tcc cca ggc agc ttg tct cca cct cct gcc aca ttg agc tcc tct ctt	415
Ser Pro Gly Ser Leu Ser Pro Pro Pro Ala Thr Leu Ser Ser Ser Leu	
70 75 80	
gaa gcc ttc ctg agc ggg ccg cag gca gcg ccc tca ccc ctg tcc cct	463
Glu Ala Phe Leu Ser Gly Pro Gln Ala Ala Pro Ser Pro Leu Ser Pro	
85 90 95	
ccc cag cct gca ccc act cca ttg aag atg tac ccg tcc atg ccc gct	511
Pro Gln Pro Ala Pro Thr Pro Leu Lys Met Tyr Pro Ser Met Pro Ala	
100 105 110 115	
ttc tcc cct ggg cct ggt atc aag gaa gag tca gtg cca ctg agc atc	559
Phe Ser Pro Gly Pro Gly Ile Lys Glu Glu Ser Val Pro Leu Ser Ile	
120 125 130	
ctg cag acc ccc acc cca cag ccc ctg cca ggg gcc ctc ctg cca cag	607
Leu Gln Thr Pro Thr Pro Gln Pro Leu Pro Gly Ala Leu Leu Pro Gln	
135 140 145	
agc ttc cca gcc cca gcc cca ccg cag ttc agc tcc acc cct gtg tta	655
Ser Phe Pro Ala Pro Ala Pro Pro Gln Phe Ser Ser Thr Pro Val Leu	
150 155 160	
ggc tac ccc agc cct ccg gga ggc ttc tct aca gga agc cct ccc ggg	703
Gly Tyr Pro Ser Pro Pro Gly Gly Phe Ser Thr Gly Ser Pro Pro Gly	
165 170 175	
aac acc cag cag ccg ctg cct ggc ctg cca ctg gct tcc ccg cca ggg	751
Asn Thr Gln Gln Pro Leu Pro Gly Leu Pro Leu Ala Ser Pro Pro Gly	
180 185 190 195	
gtc ccg ccc gtc tcc ttg cac acc cag gtc cag agt gtg gtc ccc cag	799
Val Pro Pro Val Ser Leu His Thr Gln Val Gln Ser Val Val Pro Gln	
200 205 210	



3/90

cag cta ctg aca gtc aca gct gcc ccc acg gca gcc cct gta acg acc	847
Gln Leu Leu Thr Val Thr Ala Ala Pro Thr Ala Ala Pro Val Thr Thr	
215 220 225	
act gtg acc tcg cag atc cag cag gtc ccg gtc ctg ctg cag ccc cac	895
Thr Val Thr Ser Gln Ile Gln Gln Val Pro Val Leu Leu Gln Pro His	
230 235 240	
ttc atc aag gca gac tcg ctg ctt ctg aca gcc atg aag aca gac gga	943
Phe Ile Lys Ala Asp Ser Leu Leu Thr Ala Met Lys Thr Asp Gly	
245 250 255	
gcc act gtg aag gcg gca ggt ctc agt ccc ctg gtc tct ggc acc act	991
Ala Thr Val Lys Ala Ala Gly Leu Ser Pro Leu Val Ser Gly Thr Thr	
260 265 270 275	
gtg cag aca ggg cct ttg ccg acc ctg gtg agt ggc gga acc atc ttg	1039
Val Gln Thr Gly Pro Leu Pro Thr Leu Val Ser Gly Gly Thr Ile Leu	
280 285 290	
gca aca gtc cca ctg gtc gta gat gcg gag aag ctg cct atc aac cgg	1087
Ala Thr Val Pro Leu Val Val Asp Ala Glu Lys Leu Pro Ile Asn Arg	
295 300 305	
ctc gca gct ggc agc aag gcc ccg gcc tct gcc cag agc cgt gga gag	1135
Leu Ala Ala Gly Ser Lys Ala Pro Ala Ser Ala Gln Ser Arg Gly Glu	
310 315 320	
aag cgc aca gcc cac aac gcc att gag aag cgc tac cgc tcc tcc atc	1183
Lys Arg Thr Ala His Asn Ala Ile Glu Lys Arg Tyr Arg Ser Ser Ile	
325 330 335	
aat gac aaa atc att gag ctc aag gat ctg gtg gtg ggc act gag gca	1231
Asn Asp Lys Ile Ile Glu Leu Lys Asp Leu Val Val Gly Thr Glu Ala	
340 345 350 355	
aag ctg aat aaa tct gct gtc ttg cgc aag gcc atc gac tac att cgc	1279
Lys Leu Asn Lys Ser Ala Val Leu Arg Lys Ala Ile Asp Tyr Ile Arg	
360 365 370	
ttt ctg caa cac agc aac cag aaa ctc aag cag gag aac cta agt ctg	1327
Phe Leu Gln His Ser Asn Gln Lys Leu Lys Gln Glu Asn Leu Ser Leu	
375 380 385	
cgc act gct gtc cac aaa agc aaa tct ctg aag gat ctg gtg tcg gcc	1375
Arg Thr Ala Val His Lys Ser Lys Ser Leu Lys Asp Leu Val Ser Ala	
390 395 400	
tgt ggc agt gga ggg aac aca gac gtg ctc atg gag ggc gtg aag act	1423
Cys Gly Ser Gly Gly Asn Thr Asp Val Leu Met Glu Gly Val Lys Thr	
405 410 415	
gag gtg gag gac aca ctg acc cca ccc ccc tcg gat gct ggc tca cct	1471
Glu Val Glu Asp Thr Leu Thr Pro Pro Pro Ser Asp Ala Gly Ser Pro	
420 425 430 435	
ttc cag agc agc ccc ttg tcc ctt ggc agc agg ggc agt ggc agc ggt	1519
Phe Gln Ser Ser Pro Leu Ser Leu Gly Ser Arg Gly Ser Gly Ser Gly	
440 445 450	
ggc agt ggc agt gac tcg gag cct gac agc cca gtc ttt gag gac agc	1567
Gly Ser Gly Ser Asp Ser Glu Pro Asp Ser Pro Val Phe Glu Asp Ser	
455 460 465	

aag gca aag cca gag cag cgg ccg tct ctg cac agc cgg ggc atg ctg	1615
Lys Ala Lys Pro Glu Gln Arg Pro Ser Leu His Ser Arg Gly Met Leu	
470 475 480	
gac cgc tcc cgc ctg gcc ctg tgc acg ctc gtc ttc ctc tgc ctg tcc	1663
Asp Arg Ser Arg Leu Ala Leu Cys Thr Leu Val Phe Leu Cys Leu Ser	
485 490 495	
tgc aac ccc ttg gcc tcc ttg ctg ggg gcc cgg ggg ctt ccc agc ccc	1711
Cys Asn Pro Leu Ala Ser Leu Leu Gly Ala Arg Gly Leu Pro Ser Pro	
500 505 510 515	
tca gat acc acc agc gtc tac cat agc cct ggg cgc aac gtg ctg ggc	1759
Ser Asp Thr Thr Ser Val Tyr His Ser Pro Gly Arg Asn Val Leu Gly	
520 525 530	
acc gag agc aga gat ggc cct ggc tgg gcc cag tgg ctg ctg ccc cca	1807
Thr Glu Ser Arg Asp Gly Pro Gly Trp Ala Gln Trp Leu Leu Pro Pro	
535 540 545	
gtg gtc tgg ctg ctc aat ggg ctg ttg gtg ctc gtc tcc ttg gtg ctt	1855
Val Val Trp Leu Leu Asn Gly Leu Leu Val Leu Val Ser Leu Val Leu	
550 555 560	
ctc ttt gtc tac ggt gag cca gtc aca cgg ccc cac tca ggc ccc gcc	1903
Leu Phe Val Tyr Gly Glu Pro Val Thr Arg Pro His Ser Gly Pro Ala	
565 570 575	
gtg tac ttc tgg agg cat cgc aag cag gct gac ctg gac ctg gcc cgg	1951
Val Tyr Phe Trp Arg His Arg Lys Gln Ala Asp Leu Asp Leu Ala Arg	
580 585 590 595	
gga gac ttt gcc cag gct gcc cag cag ctg tgg ctg gcc ctg cgg gca	1999
Gly Asp Phe Ala Gln Ala Ala Gln Gln Leu Trp Leu Ala Leu Arg Ala	
600 605 610	
ctg ggc cgg ccc ctg ccc acc tcc cac ctg gac ctg gct tgt agc ctc	2047
Leu Gly Arg Pro Leu Pro Thr Ser His Leu Asp Leu Ala Cys Ser Leu	
615 620 625	
ctc tgg aac ctc atc cgt cac ctg ctg cag cgt ctc tgg gtg ggc cgc	2095
Leu Trp Asn Leu Ile Arg His Leu Leu Gln Arg Leu Trp Val Gly Arg	
630 635 640	
tgg ctg gca ggc cgg gca ggg ggc ctg cag cag gac tgt gct ctg cga	2143
Trp Leu Ala Gly Arg Ala Gly Gly Leu Gln Gln Asp Cys Ala Leu Arg	
645 650 655	
gtg gat gct agc gcc agc gcc cga gac gca gcc ctg gtc tac cat aag	2191
Val Asp Ala Ser Ala Ser Ala Arg Asp Ala Ala Leu Val Tyr His Lys	
660 665 670 675	
ctg cac cag ctg cac acc atg ggg aag cac aca ggc ggg cac ctc act	2239
Leu His Gln Leu His Thr Met Gly Lys His Thr Gly Gly His Leu Thr	
680 685 690	
gcc acc aac ctg gcg ctg agt gcc ctg aac ctg gca gag tgt gca ggg	2287
Ala Thr Asn Leu Ala Leu Ser Ala Leu Asn Leu Ala Glu Cys Ala Gly	
695 700 705	
gat gcc gtg tct gtg gcg acg ctg gcc gag atc tat gtg gcg gct gca	2335
Asp Ala Val Ser Val Ala Thr Leu Ala Glu Ile Tyr Val Ala Ala Ala	
710 715 720	

5/90

ttg aga gtg aag acc agt ctc cca cgg gcc ttg cat ttt ctg aca cgc Leu Arg Val Lys Thr Ser Leu Pro Arg Ala Leu His Phe Leu Thr Arg 725 730 735	2383
ttc ttc ctg agc agt gcc cgc cag gcc tgc ctg gca cag agt ggc tca Phe Phe Leu Ser Ser Ala Arg Gln Ala Cys Leu Ala Gln Ser Gly Ser 740 745 750 755	2431
gtg cct cct gcc atg cag tgg ctc tgc cac ccc gtg ggc cac cgt ttc Val Pro Pro Ala Met Gln Trp Leu Cys His Pro Val Gly His Arg Phe 760 765 770	2479
ttc gtg gat ggg gac tgg tcc gtg ctc agt acc cca tgg gag agc ctg Phe Val Asp Gly Asp Trp Ser Val Leu Ser Thr Pro Trp Glu Ser Leu 775 780 785	2527
tac agc ttg gcc ggg aac cca gtg gac ccc ctg gcc cag gtg act cag Tyr Ser Leu Ala Gly Asn Pro Val Asp Pro Leu Ala Gln Val Thr Gln 790 795 800	2575
cta ttc cgg gaa cat ctc tta gag cga gca ctg aac tgt gtg acc cag Leu Phe Arg Glu His Leu Leu Glu Arg Ala Leu Asn Cys Val Thr Gln 805 810 815	2623
ccc aac ccc agc cct ggg tca gct gat ggg gac aag gaa ttc tcg gat Pro Asn Pro Ser Pro Gly Ser Ala Asp Gly Asp Lys Glu Phe Ser Asp 820 825 830 835	2671
gcc ctc ggg tac ctg cag ctg ctg aac agc tgt tct gat gct gcg ggg Ala Leu Gly Tyr Leu Gln Leu Leu Asn Ser Cys Ser Asp Ala Ala Gly 840 845 850	2719
gct cct gcc tac agc ttc tcc atc agt tcc agc atg gcc acc acc acc Ala Pro Ala Tyr Ser Phe Ser Ile Ser Ser Ser Met Ala Thr Thr Thr 855 860 865	2767
ggc gta gac ccg gtg gcc aag tgg tgg gcc tct ctg aca gct gtg gtg Gly Val Asp Pro Val Ala Lys Trp Trp Ala Ser Leu Thr Ala Val Val 870 875 880	2815
atc cac tgg ctg cgg cgg gat gag gag gcg gct gag cgg ctg tgc ccg Ile His Trp Leu Arg Arg Asp Glu Glu Ala Ala Glu Arg Leu Cys Pro 885 890 895	2863
ctg gtg gag cac ctg ccc cgg gtg ctg cag gag tct gag aga ccc ctg Leu Val Glu His Leu Pro Arg Val Leu Gln Glu Ser Glu Arg Pro Leu 900 905 910 915	2911
ccc agg gca gct ctg cac tcc ttc aag gct gcc cgg gcc ctg ctg ggc Pro Arg Ala Ala Leu His Ser Phe Lys Ala Ala Arg Ala Leu Leu Gly 920 925 930	2959
tgt gcc aag gca gag tct ggt cca gcc agc ctg acc atc tgt gag aag Cys Ala Lys Ala Glu Ser Gly Pro Ala Ser Leu Thr Ile Cys Glu Lys 935 940 945	3007
gcc agt ggg tac ctg cag gac agc ctg gct acc aca cca gcc agc agc Ala Ser Gly Tyr Leu Gln Asp Ser Leu Ala Thr Thr Pro Ala Ser Ser 950 955 960	3055
tcc att gac aag gcc gtg cag ctg ttc ctg tgt gac ctg ctt ctt gtg Ser Ile Asp Lys Ala Val Gln Leu Phe Leu Cys Asp Leu Leu Leu Val 965 970 975	3103

6/90

gtg cgc acc agc ctg tgg cgg cag cag cag ccc ccg gcc ccg gcc cca	3151
Val Arg Thr Ser Leu Trp Arg Gln Gln Gln Pro Pro Ala Pro Ala Pro	
980 985 990 995	
gca gcc cag ggc gcc agc agc agg ccc cag gct tcc gcc ctt gag ctg	3199
Ala Ala Gln Gly Ala Ser Ser Arg Pro Gln Ala Ser Ala Leu Glu Leu	
1000 1005 1010	
cgt ggc ttc caa cgg gac ctg agc agc ctg agg cgg ctg gca cag agc	3247
Arg Gly Phe Gln Arg Asp Leu Ser Ser Leu Arg Arg Leu Ala Gln Ser	
1015 1020 1025	
ttc cgg ccc gcc atg cgg agg gtg ttc cta cat gag gcc acg gcc cgg	3295
Phe Arg Pro Ala Met Arg Arg Val Phe Leu His Glu Ala Thr Ala Arg	
1030 1035 1040	
ctg atg gcg ggg gcc agc ccc aca cgg aca cac cag ctc ctc gac cgc	3343
Leu Met Ala Gly Ala Ser Pro Thr Arg Thr His Gln Leu Leu Asp Arg	
1045 1050 1055	
agt ctg agg cgg cgg gca ggc ccc ggt ggc aaa gga ggc gcg gtg gcg	3391
Ser Leu Arg Arg Arg Ala Gly Pro Gly Gly Lys Gly Gly Ala Val Ala	
1060 1065 1070 1075	
gag ctg gag ccg cgg ccc acg cgg cgg gag cac gcg gag gcc ttg.ctg	3439
Glu Leu Glu Pro Arg Pro Thr Arg Arg Glu His Ala Glu Ala Leu Leu	
1080 1085 1090	
ctg gcc tcc tgc tac ctg ccc ccc ggc ttc ctg tcg gcg ccc ggg cag	3487
Leu Ala Ser Cys Tyr Leu Pro Pro Gly Phe Leu Ser Ala Pro Gly Gln	
1095 1100 1105	
cgc gtg ggc atg ctg gct gag gcg gcg cgc aca ctc gag aag ctt ggc	3535
Arg Val Gly Met Leu Ala Glu Ala Ala Arg Thr Leu Glu Lys Leu Gly	
1110 1115 1120	
gat cgc cgg ctg ctg cac gac tgt cag cag atg ctc atg cgc ctg ggc	3583
Asp Arg Arg Leu Leu His Asp Cys Gln Gln Met Leu Met Arg Leu Gly	
1125 1130 1135	
ggt ggg acc act gtc act tcc agc tag accccgtgtc ccgggcctca	3630
Gly Gly Thr Thr Val Thr Ser Ser	
1140 1145	
gcacccctgt ctctagccac ttggtcccg tgcagcttct gtcctgcgtc gaagctttga	3690
aggccgaagg cagtgaaga gactctggcc tccacagttc gacctgcggc tgctgtgtgc	3750
cttcgcggtg gaaggcccga ggggcgcgat cttgacccta agaccggcgg ccatgatggt	3810
gctgacctct ggtggccgat cggggcactg caggggcccga gccatttttg ggggcccccc	3870
tccttgctct gcaggcacct tagtggtttt tttcctcctg tgtacaggga agagaggggt	3930
acatttcctt gtgctgacgg aagccaactt ggctttcccg gactgcaagc agggctctgc	3990
cccagaggcc tctctctccg tcgtgggaga gagacgtgta catagtgtag gtcagcgtgc	4050
ttagcctcct gacctgaggc tcctgtgcta ctttgccctt tgcaaacttt attttcatag	4110
attgagaagt tttgtacaga gaattaaaaa tgaaattatt tata	4154

<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 5  
gtcctgcgtc gaagctttg 19

<210> 6  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 6  
aggtcgaact gtggaggcc 19

<210> 7  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 7  
aggccgaagg cagtgaaga gactc 25

<210> 8  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 8  
gaaggtgaag gtcggagtc 19

<210> 9  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 9  
gaagatggtg atgggatttc 20

<210> 10  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 10  
caagcttccc gttctcagcc

20

<210> 11  
<211> 3891  
<212> DNA  
<213> M. musculus

<220>

<400> 11  
aaaatcggcg cggaagctgt cggggtagcg tctgcacgcc ctaggggagg ggcgcggacc 60  
acggagccat ggattgcaca tttcccagtt tccggggaac ttttccttaa cgtgggccta 120  
gtccgaagcc ggggtgggagc cggcgccatg gacgagctgg ccttcgggtga ggcgggctctg 180  
gaacagacac tggccgagat gtgcgaactg gacacagcgg ttttgaacga catcgaagac 240  
atgctccagc tcatcaacaa ccaagacagt gacttccttg gcctgtttga cgtcccctat 300  
gctgggggtg agacagggga cacaggcccc agcagcccag gtgccaactc tcctgagagc 360  
ttctcttctg cttctctggc ctctctctg gaagccttcc tgggaggacc caaggtgaca 420  
cctgcaccct tgtcccctcc accatcgga cccgctgctt taaagatgta cccgtccgtg 480  
tccccctttt cccctgggac tgggatcaaa gaggagccag tgccactcac catcctacag 540  
cctgcagcgc cacagccgtc accggggacc ctctgcctc cgagcttccc cgcaccacc 600  
gtacagctca gccctgcgcc cgtgctgggt tactcgagcc tgccttcagg cttctcaggg 660  
acccttccag gaaacactca gcagccacca tctagcctgc cgctggcccc tgcaccagga 720  
gtcttgccca cccctgccct gcacaccag gtccaaagct tggcctccca gcagccgtg 780  
ccagcctcag cagcccctag aacaaacact gtgacctac aggtccagca ggtcccagtt 840  
gtactgcagc cacacttcat caaggcagac tctactgtgc tgacagctgt gaagacagat 900  
gcaggagcca ccgtgaagac tgcaggcatc agcaccctgg ctctggcac agccgtgcag 960  
gcagggtccc tgcagaccct ggtgagtga gggaccatct tggccacagt acctttggtt 1020  
gtggacacag acaaactgcc catccaccga ctgcagctg gcagcaaggc cctaggctca 1080  
gctcagagcc gtggtgagaa gcgcacagcc cacaatgcca ttgagaagcg ctaccggtct 1140  
tctatcaatg acaagattgt ggagctcaaa gacctgggtg tgggactga agcaaagctg 1200  
aataaatctg ctgtcttgcg caaggccatc gactacatcc gcttcttgca gcacagcaac 1260  
cagaagctca agcaggagaa cctgacccta ctttgtgcac acaaaagcaa atcactgaag 1320

gacctggtgt cagcttgtgg cagtggagga ggcacagatg tgtctatgga gggcatgaaa 1380  
cccgaagtgg tggagacgct taccctcca ccctcagacg ccggctcacc ctcccagagt 1440  
agccccttgt cttttggcag cagagctagc agcagtgggtg gcagtgactc tgagcccgac 1500  
agtccagcct ttgaggatag ccaggtcaaa gccagcggc tgccttcaca cagccgagggc 1560  
atgctggacc gctcccgctt ggccctgtgt gtactggcct ttctgtgtct gacctgcaat 1620  
cctttggcct cgctgttcgg ctggggcatt ctactccct ctgatgctac gggtagacac 1680  
cgtagttctg ggcgcagcat gctggaggca gagagcagag atggctctaa ttggaccag 1740  
tggttgctgc caccctagt ctggctggcc aatggactac tagtggtggc ctgcttggct 1800  
cttctctatg tctatgggga acctgtgact aggccacact ctggcccagc tgtacacttc 1860  
tgagagacatc gcaaacaagc tgacctgaat ttggcccggg gagatgttcg ccagctgct 1920  
caacagctgt ggctagccct gcaagcgctt ggccggcccc tgcccacctc aaacctggat 1980  
ctggcctgca gtctgctttg gaacctcatc cgccacctgc tccagcgtct ctgggtgggc 2040  
cgctggctgg caggccaggg cgggggcctg ctgagggacc gtgggctgag aaaggatgcc 2100  
cgtgccagtg cccgggatgc ggctgttgct taccataagc tgcaccagct gcatgccatg 2160  
ggcaagtaca caggaggaca tcttgctgct tctaacctgg cactaagtgc cctcaacctg 2220  
gctgagtgcg caggagatgc tatctccatg gcaacactgg cagagatcta tgtggcagcg 2280  
tgcctgaggg tcaaaaccag cctcccaaga gccctgcact tcttgacacg tttcttctg 2340  
agcagcggcc gccaggcctg cctagcacag agcggctcgg tgcctcttgc catgcagtgg 2400  
ctctgccacc ctgtaggtca ccgtttcttt gtggacgggg actgggccgt gcacggtgcc 2460  
ccccggaga gcctgtacag cgtggctggg aaccagtggt atccgctggc ccaggtgacc 2520  
cggctattcc gtgaacatct cctagagcga gcgttgaact gtattgctca gccagccca 2580  
ggggcagctg acggagacag ggagttctca gatgcccttg gatctctgca gttgctaaat 2640  
agctgttctg atgctgccgg ggctcctgctg tgcagtttct ctgtcagctc cagcatggct 2700  
gccaccactg gccagacccc agtggccaag tgggtggcct cactgacagc tgtggtgatc 2760  
cactggctga ggcgggatga agaggcagct gagcgcttgt acccactggg agagcatatc 2820  
ccccagggtg tgcaggacac tgagagaccc ctgccaggg cagctctgta ctcttcaag 2880  
gctgcccggg ctctgctgga ccacagaaag gtggaatcta gccagccag cctggccatc 2940  
tgtgagaagg ccagtgggta cctgcgggac agcttagcct ctacaccaac tggcagttcc 3000  
attgacaagg ccatgcagct gctcctgtgt gatctacttc ttgtggcccg taccagtctg 3060  
tggcagcggc agcagtcacc agcttcagtc caggtagctc acgggtaccag caatggaccc 3120  
caggcctctg ctctggagct gcgtggtttc caacatgacc tgagcagcct gcggcggttg 3180  
gcacagagct tccggcctgc tatgaggagg gtattcctac atgaggccac agctcggctg 3240

atggcaggag caagtcctgc ccggacacac cagctcctgg atcgcagtct gaggaggagg 3300  
gcaggttcca gtggcaaaagg aggcactaca gctgagctgg agccacggcc cacatggcgg 3360  
gagcacaccg aggccctgct gttggcatcc tgctatctgc cccctgcctt cctgtcggct 3420  
cctgggcagc gaatgagcat gctggccgag gcggcacgca ccgtagagaa gcttggcgat 3480  
caccggctac tgctggactg ccagcagatg ctccctgcgcc tgggcggcgg aaccaccgtc 3540  
acttccagct agaccccaaa gctttccctt gaggaccttt gtcattggct gtggtcttcc 3600  
agaggggtgag cctgacaagc aatcaggacc atgccgacct ctagtggcag atctggaaat 3660  
tgacagaggct gcactggccc gatggcacc tcttgctctg taggcacctt agtggctttt 3720  
ccctagctga ggctcaccct gggagacctg tacatagtgt agatccggct gggcctggct 3780  
ccagggcagg cccatgtact actttgactt ttgcaaactt tattttcata ggttgagaaa 3840  
ttttgtacag aatattaaaa aatgaaatta ttataaaaa aaaaaaaaaa a 3891

<210> 12

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 12

ttggccacag tacctttggt t

21

<210> 13

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 13

ctgagcctag ggccttgct

19

<210> 14

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 14

catccaccga ctgcagctg g

21

<210> 15



<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 15  
ggcaaattca acggcacagt

20

<210> 16  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 16  
gggtctcgct cctggaagat

20

<210> 17  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 17  
aaggccgaga atgggaagct tgtcatc

27

<210> 18  
<211> 27001  
<212> DNA  
<213> H. sapiens

<220>

<400> 18  
ttaattctgg tttatttcaa cccacctcat tgggaccct tccctccttc ctgccccacc 60  
tggctctgtc cctaggccac agaaccaggt tcggtttcca gccctcttct caacagggct 120  
gcctgctctg atctagtccc agcttgtgat gatccagggc agcctggctc tgatctaaag 180  
cacagctacc tcttccttgc ggcccctatc ctggctgctc ctgggaataa gtgccaaatc 240  
tggggtcaga cagccctggg gccagtcttc cttgggtact ggcttcctcc ttcaggagct 300  
gcactgggcc cactggtatc ctatccctac agctggatct gggaggaaac cagatgacga 360  
aattccagcc tctttctttg gccactcctg tcctcaagag gccaatcttc tggtttcttt 420  
gcagagaggg ggcaggctga tctcacaggt catgctcccc tccacattgt cactagcctc 480  
ccagcctgcc cgtgagaaa catcattagg cccatgttac aaatgaggaa aattgaggca 540

gagtgatgta actggcccag cagttacatc aggcctgctc acaacacagc aggcctggga 600  
cccctataac ttggatcctg gtctgtcttg ttctaaagag tcaaactctag gaaatgagga 660  
aatgaagttt gggatgggccc caggcctggg gcttccactc ggcttccttg cttggtgctg 720  
gagaaacaga ggcccagaga gggggctcgg cttgcccgcg ttcccgagc agccggccag 780  
aggccgctgc cattgtgcgc gaggctggat aaaatgaatg actggagggc gctctggagg 840  
aggggcccggc tgaggggaga tttgtggcgc agaccgggga tcaggggtcc cccgctctct 900  
caaggtgggg cggggccgtc tatctgggag ggcgggtcct ccccgaaagg cccgcctcc 960  
gcctcgaccg cccagcagag ctgcggccgg gggaaccag tttccgagga acttttcgcc 1020  
ggcgcccggc cgctctgag gccagggcag gacaggaacg cgcgagcgcg cggcggcgac 1080  
tgagagccgg ggccgcggcg gcgctcccta ggaagggccg tacgagggcg cgggcccggc 1140  
gggcctcccg gaggaggcg ctgcgccatg gacgagccac ccttcagcga ggcggctttg 1200  
gagcaggcgc tgggcgagcc gtgcgatctg gacgcggcgc tgctgaccga catcgaaggt 1260  
gcgtcagggc gggcagggct tgaagctgcg ccgggtggcg cgagtagggg gcgcgcaggt 1320  
gtctccctgg ctttgtctc cccacgggc gccagctccg tgctgtgctc gcgcgggact 1380  
tcccgtgtc tctgagctcg gtgtcccgag cctcaccgag cctccctggg tccgcgcta 1440  
gcgtctcggg ccgcgcgctt gtgggtgagg gctcctgggc cgggcccggg tcccttggcg 1500  
gctccgggcc gggacacgtg cgctctacg cgtcccaggc cgggtgccg ccgaccggtg 1560  
actctccagc cctgtgatgg ccacggctga agctggggac ccaggcgtcg ccgaagctcc 1620  
gccccagccc cagccgtgac gtaattgcga ggttactcac ggtcattccc tccggcccga 1680  
gagttcagct cggcgctcgga gctcttgccg atgcgcatgg gcgctgcctc gcgcccttcc 1740  
cccgctcgt gtggggttct cccggtctgc gacgggcaca gcctccgcac tcattcactg 1800  
acatccaccg aatgccaggc cccgtcttag gcaccgaggg ttacagaca gacctgggta 1860  
ccccctcttt tagggaacac aaaaatctcc cgggaaacca aacgggtatt tagttgtacc 1920  
ttgggtggag cgaggctggg ggagggcagg gatgtggcta ctttgggtag agcggtcagg 1980  
gacttctaag ctgagacctg agggtcaccc ccaggaccag caaggaaaga tgttttccag 2040  
gccacggcaa ggaaggga aaggcctcga ggcagggcct aagtgtgagg agttagaggc 2100  
ttgcaaagga gtgaggtcag ggaggaggag gacgcaaacc gacttggtcg gccagggaaa 2160  
gggcggagca gaacagtggc accggcttcc atctttggag catcaccctg gctgtgatga 2220  
gaaggggttt ggggccaatg gtggcaccaa gtgccaatta ggaggcccgt tgcttccatt 2280  
ttgtagatag agcaaacgga agcccctagc aaattgcctg catggtttct gtgcaggagt 2340  
tttagcagca ctagctaagt tgcacttggt tgatgaggaa actgaggcca aggtcgcagg 2400  
aacaagatgc ctagactcac agcctgaatg gacatgtcca tggaaccctg ggccaccctg 2460

gggttggaac aacagatata tctatgccac caccactcct gccctactgc agccttgag 2520  
atgagcccag ctggttgcca gcccagaag cttccagcc ctccctcctt cccctgggg 2580  
ctgggctagg ggaggacccc agaggagagg ccctgattgt gaggcttttc caaacagcc 2640  
tcccctatcc ctggcacgag gggttgctct tctactgccct ctggagtgat gaaccctgaa 2700  
atcccaagcc ctagggagat ctgggcctga ctcaactacc agttccacat cactggggccc 2760  
agtgagtgtg gtcccaagag gcaacgtgac caagccagga ggacatgcgc tttgggggtca 2820  
gaacttgaa ctggacactc ctcaattcct ttgtcatcct gctcaagccc tctcacccctc 2880  
taaaccttag tttccacctc cagaaaaatg atgcaaaccc tcccttcctg ggcaagttgg 2940  
acaacagaa ccgttctggg ccacaggtct gatacagacc tttgtttgtt tgtttgtttg 3000  
ttttctgag tggcgcaatt ttggctcact gcaagctcct cctcctgggt tcacgccatt 3060  
ctcctgcctt agtctcccaa gtagctggga ctacaggcgc cagccaccac gcctgggctaa 3120  
ttttttgtat ttttagtaga gacgggggtt cactgtgcta gccaggatgg tctcgatctc 3180  
ctgaccttgt gatccgccg cctcagcctc ccaaagtgtt gggattacag gtgtgagcca 3240  
ccgtcccgag ccagacctt tcttactgac agaattctgt ctgggccaga ggtctgatac 3300  
agacctttct tactgactca tggataaaaa cattgtctct ccagaaccaa aggccaggca 3360  
tgggcagcca tgtggcccaa ggtctagtct atgagagagt gggggcagtc ccagcccctt 3420  
gaagactggg ggcagcccct tctcactagg cagggtcag ctttaccac ttcagtagag 3480  
gatttttcag tttttattca aacttctgt ttttcttccc aattacacac atcttttttc 3540  
attgtagaaa acttagaaaa tgcaagttag caaaaagaag aaaataaaat ctttagacct 3600  
ggggtggtgg ctcacaccta taatccagc acttgggagg tcgaagcaag aggatgactt 3660  
gtgtccagga gtttgagacc agcctgggca acatgacaaa atcctgtctc tacaaaaata 3720  
aaaaattagc tgggtgtggg tgacatgtgc ctgtagtctc agctactctg gaggtgaag 3780  
tgggaggatt gcttgagcct ggacttagag gctgcagtga gctataacca tgccgttgca 3840  
ctcagcctgg atgacagagt gagattctgt ttcaaaaaaa actttaaac taccaccag 3900  
agataagccc tgctaattat gtgaaagagc ttttcttctc tctctctctc tctctctgtg 3960  
tgtttatatg tgtttgggga tgggtgcaca ctcttcataa actttttttt ttttgagaca 4020  
gggtctcgct cttttgccc tgctgtagtc cagtggcatg atctcagctc actgcaaact 4080  
ctgcctctca ggttcaagag attctccagc tccaagtag ctgggattac agtcatgcac 4140  
cgccacgcct ggttaaattt tgtattttta gtagagatgg ccatgttggc caggctggtc 4200  
tcgaactcct gagctcaggt gatctgccc cctcagcctc tcaaaagtgc tgggattaca 4260  
gggcatgaac caccatgccc ggccttcctc aattttttta aaacgacttt attgaggtat 4320  
actttatgta tcacaaaatt taccatttt tagtatatca ttcaatgatt tttagttaac 4380

tttttgagtt gtgtgacaat tactagctgt cgaacatttt tatcacacag tgagatccct 4440  
tatacttctt tagtcagttc ctgttcctgc tcccagcccc gggcagctgt ggatctgtat 4500  
gtgtgtgtgt atatatatat atatatatat atattttttt tttttttttt 4560  
ttttgagacg gagtcttgct ctgtcgccca ggctggagtg cagtgggtgcg atcttggtctc 4620  
actgcaagct ccgcctccca ggttcaaaca gttctgcctc agcctcccga gtagctggga 4680  
ttacaggcac ctgccaccac gcccggctaa tttttttgta ttttttagtag agatgggggtt 4740  
tcaccatgtt agccaggatg gtctcgatct cctgacctg tgatctgccc acctcggcct 4800  
cccaacgttc tggaattaca ggctgagcc accgcgcccg gctggatctg tatttttata 4860  
aattaaaata gggctcattg gttcacagct gattggaatc tgcttggttc catgtcaaca 4920  
gccagacgac agtaaggttt cctcttatta cccacctgat tccctgtcga tggacacct 4980  
ggttgtttta tctttataaa ctgctgcagt ggacactgag gccggttttt ttctttgttt 5040  
ttttttttt gtttgtttgt ttttgagaca gagtcttgct ctgtcaccca ggctggagtg 5100  
cagtggcgcg atctcggtc actgcaaact ccgcctcccg ggttcacacc attctcctgc 5160  
ctcagcctcc cgagtagctt gggactatag gtgcgtgcca ccatgcctgg ctaattttt 5220  
gtatttttag tagagacggg gtttcaccgt gttagccagg atggtctcga tctcctgacc 5280  
tcatgatctg cccgcctcgg cctcccaaag tgctgggatt acaggcgtga gccactgtgc 5340  
ctggccactg aggccagtct ttgcccgat cctcactgtg ttcttaggat gaggttctgg 5400  
gaggggaatt gctggtcaga ggtcgagcct gcttttgaag cttcttctac caggagtgga 5460  
gctgagcagg ttgataagg tctgaagatt tgggggtgga aatgccaggc cccttgagag 5520  
acatgaggga taagaggggg ccaggctggc cttgagtgcc agagtgcaga gctgggctag 5580  
atgtgaggac agtcgggggt cagagcaggg gcacaccgag cttcagttcc ctctggctgc 5640  
ttggatggag gatcgtaatg tgaacagaaa acactaattg agtacttact gtgtttcaga 5700  
cagtgtgttg ataatccac ttaatcccct gacaacccca agtaggtaga catatgatga 5760  
agatgacggc cttgaggacc agagaggtta agtgatttgc ctgagatcac acagccagat 5820  
gatggcaaag ccagaattca aaccaggct gtgggctcca gagcctagct cttagctct 5880  
taagcactgg gctcctaaga atggggatga ggggttgagg gaggtcctc cacaggggct 5940  
actctggggg cctggaagtg ggtcacagag gggtcagagg ctatgtggct acctcccat 6000  
cccagtccag agcagtgttt gagtcatatg actgggaacc agccctgggtg agccagccaa 6060  
gggccttggg ccccatccgg tccctgtgcc tgccacagcc aaactcttgt catgtgaatg 6120  
gatttgggga tggagctgcc tccatgagtc cttgcatctg tgggtgaagg cactgccctg 6180  
gctatagtgt ccctgggttt gagtccctgca tctgcaccaa gacctcaggt gagcctgtct 6240  
ccttctgggc ctacagagtac cttgcagctg tcgggggagg atggatcagg agatggccct 6300

gtacctgtgt tggggattat tgtaagccc gtggcagtct tcacctccct gctgaggatt 6360  
aatatatcca attttgcaca agcttatgag tgcagaagag gcagacggaa acagagttct 6420  
ggccaagagc ctggaacagg gcctcggggt ctctttccta tgcctggacc ccgtcatgtc 6480  
tgctctttgt ctgtcggacc ccagatgtct gccaaagccc gtcagaggct gcttcccaga 6540  
aagcccttct ggggtgtcacc ttgccccgag cagtgcgttc tcagagttct cccgccctga 6600  
tgtccctccc agcatgccc gccagccac aacagggcct tgcttctagt catgtgtctg 6660  
gctgtttgt ggggtccaggc cagccctggg agggcacaat gggggcccgc tctgccaccc 6720  
catacctctc ccaggatat ctcatgcccc agttctctcc ctagtccac caagcactgg 6780  
cactccttag aaaacacagc tctagactag ttactgcct agcttacagc acagaactcc 6840  
cctggtctcc aaccattcat ggctccctag tgctccaaga taaagttccc ttgtctcagc 6900  
cgggttggga gttaccttct gcccaacatt cacctagctg gacacaaaca tcctgagtga 6960  
cccgtcagc tccaggcagg agtcactgcc agcagaggcc tgggatctgg actttgcctg 7020  
ctgacaggtg gagcccaggc cggccagagg aagtgcctct gaccttgtct cctagcagcc 7080  
acgggcatg tggacatgcc ttttgaccct gggcactgac agtgtgtgac agcctgcacc 7140  
atgtgctcca caggggaggc tgtgtgtgtc gggggtgagg tggggaaagc cttaactggc 7200  
tcaggggtga gaggtcaggg agccattgag actggctcca ggtgtgggtc ccctgctggg 7260  
ttggggcttg tgggaggtg gacggggctg ggggtccatc cccctagggg gaatttgtgg 7320  
cctaccccga accctgtttg agtcctttc ctaactgact ccccgctccct gcacctgtct 7380  
cccagcaggc ctgctctctg catgctgcc ctgccaggct ctgggggtccc tgtgctccct 7440  
gcagctagaa ggctgggatc aggggtctta acaagcagcc ctactgtatg acctggaca 7500  
agtccaagaa ccttcagggt cttaacaatg taaaggagc agtactaaa gcagcttctt 7560  
ggaattgtgg ggatccgatg agtgaaggct taagcagtgc atggcacata gtaggcctg 7620  
aaccaatgcc agttagtgtt attattatca ccathtagcc agatgcagtg gctcacgcct 7680  
ataatcttat tgactttaga ggctgagggt ggaggattgc ttgagaccag gagttcaaga 7740  
ccagcctggg caacatagca aggccctgtt tgttttagag aaaacaaaca aatcaccatt 7800  
tagagcacct aaccagtacc tggcacgcga taggttttagc tcaacaaatg ttagcagcaa 7860  
ttaccaagg agcctgtgct ggaagtttct aggatgtacc aggctatggt tccaagttct 7920  
gagcatctac catgtggtgg tctggagttg gtgagagaca ggatggggct gactaggcca 7980  
gtggggagca cccccgcca tggggaacaa gcaccctatc cttggcttcc atggaagata 8040  
attgatgctg ggcacagtgg ctcacgcctg taatcccagc actttgggag gctgaggcag 8100  
ggggatcgct tgagtctggg agttcaagac cagcctgggc aacattgtga gacccaaact 8160  
aaaaaaatta gcttggcatg gtggagtgtg cctgtcgtcc cagctactca ggaggctgag 8220

gctaaagctg gaggattgct tgagcccagg aggttgaggc tgcagtgagc catgatcata 8280  
ccactacact ccagcctggg caacatagtg aggcctgtc tcaaaacaaa caaacaaaaa 8340  
gaacctgctg aggaagcagt gtttctggct gggggaggac gggcagagtg gccatctggc 8400  
cacagatggc ggtttctgtg caaacacat caaggcagcc ttggaaatgt gagtgaagc 8460  
accttcaaag ttctggtcac agccttggga ctaagcaaag ccaccaaaaag tacataaaaag 8520  
acaatgacca tcacccagtg ccggtgatgc tagaaggaaa gggaatacgt tgtagggaag 8580  
gttgtaaagg gctttatctt ttccagactg gagcctggca gctcgaaaac atcttgctgc 8640  
cttcatatga gctttaaacc aagctgcaga gaaacaactc aagagggaga aatatatata 8700  
tatatgtgtg tgtgtgtgta tgtgtgagtg tgtgtgtgtg tgtgtatata tatatatata 8760  
tatatatata tatatatatt tttttttttt tttaagatgg agtctcgttc tgtcaccagg 8820  
ctggagtgc gtggtacaat ctgggtcac tgcaacctcc gcctcctggg ttcaaagtat 8880  
tctcctgcgt cagcctccca agcagctggg actataggca cataccacca cgcccagcta 8940  
atttttgtat ttttagtaga ggctggattt caccatgttg gccaggatgg ttttgatctc 9000  
ctgacctcgt gatctgcctg ccttagcctc ccaaagtgtt gggattacag gcgtgagcca 9060  
gtttgttttt agagacgggg tcttgctctg tcacccaggc tggaatacca tggcacaatc 9120  
acagctcgt gcaatgttga actcccgggt tcaagggatc ctcccacctc agcctccaga 9180  
gtaatggaga ctacaggctc atgccaccat gccagctat ttttaaaact ttgtagagat 9240  
ggggccttgc tacattgccc aggttggtct tgaactcctg ggctcaagtg atctgcctgc 9300  
ctttgcctcc caaagtgctg ttattacagg tgtgagcccc tgcgcctaac cttagcactg 9360  
ccattttgac tgaaaacagg tgcccagcag caggggctac tcccagaatt gccactgcat 9420  
caggcccgtg ggttgttttc agctgccagt gataagtatg tgccctgggc cacctctcgg 9480  
acaagggtgc tgaattgggt ccgaccagca tcacatgtaa ttgccatctc gcagggtgctg 9540  
ctgagggtaa ttccgcacac ctgtagctcc gggaagagcc tagtggggag gaggaaacgt 9600  
ggctctgagg tttatagggt cagacggtca gtatgttggg agctggcatg tggaggggca 9660  
cagacaaggg aagaatggga ggtggcatca gagcaagttt tgatggagga ataggaattc 9720  
accagggtga aagggcattc ctggtggagg gaacagcctg gccttcaata gcttggtggtg 9780  
ttcagaaagc aggcaggga agggaggccc agggagacac cagttagggg atgggggtgg 9840  
aggcagacga ggggtggagg agccatggct ggagtctgca cggcctctga ctgggggtccc 9900  
tgctgtggtc agccctgtgc tgggtgaggc tggggtcaca gctggttcag gccctgacag 9960  
gaggggcccc cagctgaggc ccagcctcta atttggcagg gcagggtgat aggtctgggg 10020  
gggtggtggt taggaagcct ccaggaggag gcagtgccgg agctgagcct taaagagctt 10080  
cgtgttgctc tctctgtctt tgcactctgc acacactcac tgaactgcga caaatgagga 10140

tagctggtca gggcagagggc aggccggagt tggggctcac tgctgtcccc cacaggctgg 10200  
ggctgaaggg caggctctgg ggccgcagaa tggggtttgt gtaccagatt cttcatatgg 10260  
cagctgtggg actttgggca cgaggcctcc gtctgagcct tagtttcctc aagaggacct 10320  
gcgcccaggt gcacctgggg ctccagccat ggggtgcgtcc cattccggga agagctggca 10380  
cacacttgtg cccccggggc agccatgagt gcacaaaggg cagcctgtgc cactgctgga 10440  
tacacgacca gctgagaaca cgaggaccgc cgactccagt taggaggatc aaggaagtgc 10500  
ctgggtgggag cagaacagca ggtgggggtgc agccagctc cctggaggga tgggtgggcac 10560  
ccatcctcac cctgctgcct ccattagcag gccgagaggg tgtgctctgg aatcccatga 10620  
gcacctgtgc cacatcctcc cctgtggctg acccttcttc acagttagtg cagctttgtg 10680  
gtctgtagtg cagggatcaa ttggcaaadc cctttccac ccattccctg gagaattggg 10740  
gtccttgggt cagatgacag accaacctga gttggaatcc cagctccttg gtggccgtcc 10800  
tggcctccac cccctcactg cctccgtcc tcctatcctg cccacgcca ctgcagggcc 10860  
tttgacaca ctgtttcttc tgccctccct tccggccac tccctcatat cattcagtcc 10920  
tcctttcaga tgtcacctcc taagatgggc tgccctgacc acctcatcta taatggcccc 10980  
agtgcctggc acaggattgg cacacagtag atattgtcag agatggatct gggttctgtg 11040  
gacaaggctg tgggggcagg tgaagagctc cctcttcag gaggttgttt ggggttcaag 11100  
gccttgtttg ggttgtaggc ttctgtgctg gtcagcgttg ggccctacaa gcgcatgcca 11160  
tgaggcctgc ccaggatttc cctcatggcc tcacagaata catcggccag agtcattaaa 11220  
ggg'gcctgc atctgccttc agagagaggt ttgaaggtag aactggggag ggatgccagg 11280  
tgggggttca ggtttcctgt tgggtcctga tagaatcagg gcaggagagg aagaagaaga 11340  
gggaagagga ggaaccaggg cttggggagg ggtggcaggg cttcacaagc ctggggaagg 11400  
tgaactaggg agcagttggg gccaccatgg ccagagctct atgcctctc ttccttctg 11460  
tgttcagagt gtgtgtggga accacaaggg ccttctcagt gttcataggg aagcccgtt 11520  
cacccatggg tgggcccga tttgggtgcc acagtgagcc cctagagacc agctctcca 11580  
gcttccagga cagggactag gggaggcaag agaggctctt ccttaaattg tgcaccaag 11640  
gtgcctcagc tgccttactc tagactggcc ccgttaactc cccttaaaaa aaaaaaaaaa 11700  
aagactcagt cgaatggtaa tggagctcca acgtgaatac tgcaagtatc aggcaactca 11760  
ctacctgact ttccagttct aaaccattct aattgctgta gagagaacta acctttgttg 11820  
agactgttga gtgatggatg ttttacacac ttgctttccc agaattccca cctctggaga 11880  
tcgtaggtgt gggagctcag aggggtggga gtggactgtc cccatcacac agcaaggag 11940  
gggctaaagg aagagcaggg cctggcatgc agcccagat agcccacttg ggtgtgtctc 12000  
tgagggaggg tgcagggctg gctctagagt ttcctttttc agtcttaacc tggtgaccag 12060

cttccacaga aattggcacg gtgactcatg cctgtaatcg caacacattg ggaggccgag 12120  
gtgggaggat cacctgaggt caggagttag agaccagcct ggccaacgtg gtgaaaccct 12180  
gtctctacta aaaatacaaa aattacattt cattacaggt gtggtggcgc acacctgtaa 12240  
tcccagctac tcaggaggct gaggcaggag agtcacttga acccgaggag tagaggttgc 12300  
agtgagctga gatcgtgtca ctgcactcca gcctgggtga cagagccaga ctctgtctca 12360  
aaaaaaaaa aaaaaaaaaa agaaattggc cagtagatca gccccagggg agagtgaacc 12420  
agggtttggc caggccttga gtttcagagg ctggccatgg ccagtggcac ccaggccctt 12480  
cccccttcct cggggcatct tagcttagtc tgtgccctct gcccaagggc cagccctctg 12540  
ttcccaggtc acaccccctc ctcttggaag gcccccccg cccaccccc atcagagtct 12600  
ttaatgactc tgctgcccct ggggctcaga gagcaaccgc cctctcccat cgcgcttcct 12660  
cagtgggatg ggagggggtt agagcaggaa gatgagacaa ataaagacac aataagaggc 12720  
aggaatatgt ggtaaagcca agatgggtaa ggggagggga caggcttgac tgttcacagt 12780  
ggccctggcc ctgctgtctc aggctagtat ctgcttggtg gtctcaccac attctaggct 12840  
cagaaactgg ggagcaaagt aatgaaagaa ccaggctggg aggccatggg gaactcatgc 12900  
ctggagtca gctctcagt tgcttttggg tcaaggacgc ttccctgtct taagtcactc 12960  
atgtcagagc ctttgccaag agcaatgctg tgttttgttt tgggggtgag ggaacacccg 13020  
cgggctgagg ggaggggttg gccatgctag agaggccgtc tgttgtcctt gaacctccca 13080  
aagctgggaa ataaggccct gggctggacg gcggtggcga ggacagggtg cgagagagac 13140  
atggctgggt tttcttgctt agggctcctga atagagagca aggttgaggc cgcagggacc 13200  
ccagccccca atggactgct gagtcgctgg gtctgcccag ggttcaggca ccctctcagg 13260  
ttgcagccaa ctgggggtgtg gaccaggcag aggcgctggc ctgcagtttg gggcagaggc 13320  
aggctttgct ggtggtctac ttggctgcaa aatcaactgg ccaggctctg atcactttgt 13380  
gtgtgtgtgt gtgtgtaact ttacctttg aaaaagagg gaagacaggc ccaggcacct 13440  
cctcaaaaga accctagagc ctgtcacccc ttccctaccc atcttctgtc ctagggactg 13500  
cagcccttcc tggcttccca gggccctaca atgaatagtg ggtcgggact cacttggtga 13560  
ctgctgggtt gtgaggcctt gagggggagg ggcagacttc acccatctgg cagagggaca 13620  
tcggtgctgg cagtcaggaa acccttatct ccaggcctca gtttcccgga agtgacctgt 13680  
tttcaggagt ggctcatcc cagaccatca gccccgtgt ggtgaggggt ggccccctcc 13740  
tggggctgcc ctagaagggg gaggtccctg caccacccgc agctgccact cggcagccct 13800  
tggccttaat taaacgcttc ttgcgtacta agtgctgcac ccatattatc tcccttctac 13860  
cattcgacgc caggagagata atgactgtcc tgttttctgg aggagtaaac ggaggggttg 13920  
agcggttaag gctcgtcag ggtgccagcg aaccagtgat ttcgaacaca gagttctggt 13980



gtgttggggcc aggacttctc tgctttgacc ctttaacgaa gggggcgggga gctgagggcc 14040  
agtgaccgcc agtaaccccg gcagacgctg gcaccgagcg ggttaaaggc ggacgtccgc 14100  
tagtaacccc aaccccatte agcgccgcgg ggtgaaactc gagccccgc cgccgtgggg 14160  
aggtggggcg gggggccggg ccggggcccta gcgaggcggc agcgcgcccg ctgattggcc 14220  
gcgcgcgctc accccatgcc cggcccgag ccccgaaagg cggggcgggg cgggacctgc 14280  
aggcggggcg gggctggggc ggggctgggg gcggggcggg gcggggcggg cgcgccgcag 14340  
cgctcaacgg cttcaaaaat ccgccgcgcc ttgacaggtg aagtcggcgc ggggaggggt 14400  
agggccaacg gcctggacgc cccaagggcg ggcgcagatc gcggagccat ggattgcact 14460  
ttogaaggta tttttggagg cctccccacc agccctttat acaatgcctc cgtctcctgc 14520  
aggttctcct ggggtgggcg ggcatgcggg ctacgcaact tgagcaggaa agagcccctt 14580  
cccaggggag aaggtgtgac agttaccagc tcgctgggga agtggagggc tacctccaac 14640  
caaattagtg tcccctgcaa ctcaagggg aagggtttgc ttagagacct aaaagcagca 14700  
tcccgcacta agagggttg gagggagagg gtggtcttct ctacattctc tgcacccgct 14760  
ttgggacagg accaggagga agcaggagg agggcccgtt gtccctctgc cacagcgctc 14820  
gccctattca gcaccctgc ctattgtggg catcttagac ttttcaggaa gacagtggga 14880  
gccctagatt gtcaaaattg tcagttttct tttcaggcct cagtttcccc catctatcga 14940  
agaggctcac acggactggg gtaaagggat gggaaaccct gcagttgaaa gtccattatg 15000  
acttgatgac ttgtgacctg ggggggtccac aaaccaggag agtttctact tgagaagcca 15060  
ggaagactgg ggctgccacc ccatcctgtt ctgccactg ctctaggaaa tttcccctcct 15120  
gcagtagctt ccctgcctgg gtacctgtca gtaggcaatg ttgggtctcc actcggtgcc 15180  
agctgcctgc caagcaaagc ctggggcagc cgtacaaaaa ggggtttagt cttttctgtt 15240  
gtacagatga ggaaactggg gccagtgaga ggaggctgtt ggtccaggct ccacttcaag 15300  
ctgggtgggg gcagggctgg gagctcaggc tggggatcct gagagcactg gaggccccca 15360  
tgggtcctgt agagcattct gaccagtggt gtgccaccac gagtgggtta gagggccctg 15420  
ggctgagcca gataggctgc tagtcaccag ctgggggaga gggcccttgg ccagggtggg 15480  
ctgagggtgg agtgtgtccc agtctgtatg aggaggaagg agtcaggaca gacagcactt 15540  
gcttttacag agatgaaatc aaagccctga gtggccaggc ctgggtcttg aggctacttg 15600  
gctgcaggca aagcctggac ttgagcccag aactctacac agagacacac tggttggcca 15660  
tgtggccagc agctggcttg gccctaagcc ttgggtctgt ccactgagta atgggttgg 15720  
gatggcagcc tggctcttgg cttcttagtg gggcaagaaa aggcagagag acaatagatt 15780  
tgggattttg tagacctggg tttgaacccc actgcatgct cttgggctgc ttgtggctcct 15840  
ccctgagcct cagtgtcttt tcttgtctcc aagatgaggt gagctaactt tttgaggtag 15900

tctagggtag tggccagtgg ttggggcatt ggagtcaaaa tagggctctgg actcagttga 15960  
gtctctgact ctataagaac ttaggccagt aagtcacctc tctacagctc agtttcttca 16020  
cgtgtagaat gggggccaatg atcacatcac cctctcagct gtgggtgagg attaggggtc 16080  
tagcctggcc ccatcaatgt gggtagcccc acagcggggc tggcttttgg accagaccca 16140  
cccttctgac atggggcccc acccttagag tccttctagt gtggatgagg accctgctct 16200  
gatctgggggt cctcttgggg gacttccttg tctgccattc tctttgggga tcctgcgctg 16260  
ccctaggaag agtggggcca ggctgcacag ttggtccttg gtcacagagg atcccaccac 16320  
ttcttcaggg cctcaaggca atcctgcctc tctctgcacc cctcttcccc ctgtaaactg 16380  
aggggagggg aaaatcacc cctcctcagc agtttctaag ttgctttgtc aaattcagtg 16440  
cccagaggat cctgctgggg gtgcgtttta ggatgagacc aggagtggcc aatggtgggg 16500  
tgtggggccc atcgctccta tatgaagacc ccctctgccc tagactgctc ctccctcccc 16560  
atccccatct ccatcccaaa gactggagct gctggatctg tggatggagg cgtgcccccc 16620  
gtttcacaca ttgagaaaca ggccccaagt ggagccaggg aaggctgcac ctgggcctct 16680  
ggattccttt tgttctgtgt ggggttgggg gtgatggact gtggagaggg caggagagct 16740  
gtctggaagg gttggtcacc tcatgggcaa atgcttgaa gctggtctga gtccacggtg 16800  
cagtgtgtat gtgtgtgtgt gtgtgtgtgt gtatgtgtgt ggactcagag gtggatgtct 16860  
tgtagaatgc atgccccatg aagacaggag taaaagttta ccaccatcca catcaagcta 16920  
caggacactc ccagctcccc agaaagtgtc ttagttctag gcagggatit cccttattca 16980  
cagccgggag cagtgcctgg catagtgtgg gcactcagca ctcagcacat gctcactgga 17040  
tgagtgaatg aatgtgagcc tgctgtttgc tgtggactaa ggatgtttct agatgtttgg 17100  
gcaaataccg gatggtggga agagctcagg ctctgaagtc tgcagtcttg ggcccgacct 17160  
tgggctcagc ccagcctag ctgtggggca agattgtgag ccttgtggtg ccaccttgt 17220  
ccaggtattg tgatgcactc gcagcagcag gcattgcttt agacagcaca ggtgctcgca 17280  
aaatggctgt atgtccggga acaccagctc ctgtgggtgg ctttctgtcc tgggtggcatt 17340  
gccacacat acagctgtgt gccaacaagg gttgtgcaaa taaggttgtg tttggatgtg 17400  
tgtgatgcc tgtttggggg tcagtctctg cctcactcac gcacctctt ctcttttca 17460  
cagacatgct tcagcttata aacaaccaag acagtgactt ccctggccta tttgaccac 17520  
cctatgctgg gagtggggca gggggcacag accctgccag ccccgatacc agctcccag 17580  
gcagcttgtc tccacctcct gccacattga gtcctctct tgaagccttc ctgagcgggc 17640  
cgcaggcagc gccctcacc ctgtccctc cccagcctgc acccactcca ttgaagatgt 17700  
accggtccat gcccgctttc tcccctgggc ctggtatcaa ggaagagtca gtgccactga 17760  
gcacctgca gacccccacc ccacagcccc tgccaggggc cctcctgcca cagagcttcc 17820

cagccccagc cccaccgcag ttcagctcca cccctgtgtt aggctacccc agccctccgg 17880  
gaggcttctc tacaggtaag ggggatgtgt ggcgggaggg gacaccggg gtggggcttc 17940  
caggagcaca ggaagaagct tctgctgtga tgtgagtaga ggtctgtgca ggcttttagaa 18000  
actggggctc cactcggctg cttgagatgc cctgttacta gcagtcctgg tgtgcttgtt 18060  
gccggggtag gcgcaacctc gcactggagg cctggcttga agccagtga tttgcatcag 18120  
agcccaggca gggactgtcc ataggaagcc acatggggca atgactcatc caaggccagt 18180  
cggtgataga gacctgaaga gcaggttgaa agtgggagag ggaggtctgt gtctgcagcc 18240  
ccatgcttta tttctgcagg aagccctccc gggaacaccc agcagccgct gcctggcctg 18300  
ccactggctt ccccgccagg ggtcccggcc gtctccttgc acaccagggt ccagagtgtg 18360  
gtccccagc agctactgac agtcacagct gccccacgg cagcccctgt aacgaccact 18420  
gtgacctcgc agatccagca ggtcccgtg agggggtctg gccaggggtt ggggaggggg 18480  
cagccccagc ccagacacac agcttacagc caagcctctc ccaccctcag gtcctgctgc 18540  
agccccactt catcaaggca gactcgctgc ttctgacagc catgaagaca gacggagcca 18600  
ctgtgaaggc ggcaggtctc agtcccctgg tctctggcac cactgtgcag acagggcctt 18660  
tgccggtggg tgacgtgggc agggcataag ggagtgggggt ctacacacac acacacatgc 18720  
ccacctggtg acatgtgcct ggccctgcag accctggtga gtggcggaac catcttggca 18780  
acagtccac tggctgtaga tgcggagaag ctgcctatca accggctcgc agctggcagc 18840  
aaggccccgg cctctgcca gagccgtgga gagaagcgca cagcccacaa cgccattgag 18900  
aagcgctacc gtcctccat caatgacaaa atcattgagc tcaaggatct ggtggtgggc 18960  
actgaggcaa aggtgtggag aggcctgcag gggcacagac cggggtgtcc ctaggaagga 19020  
acagatcagg ggcaactgga aggaagagag ggagtgcagc tgagcctgga caagcaggga 19080  
attggaattc agcctcccca ggccctggca gcctcgctta tttagttaaa ctgggtttgca 19140  
ggcctcttca ataaaggtgg ggctgtgcta ggcattgggg atgcagcaat gaacaagaca 19200  
gacaaaaatt gtccctcaaa gaagagccga ccttctggtg ggggagatgg acagtaggca 19260  
ggatgaataa gtgctcgaga ccaccacgtt tggctcgttg cagagaaagc aggaagagga 19320  
tggtaggggt cccctggtgg tagccaggga aggcctccct gagatggcgg caggcacagc 19380  
agcagctagc cagaccctgc tgtctgcac ttacattcta accctatgcc cggcctggga 19440  
ggtgggtgct actaggcgag gaacggttca ggtagaagga acaagtcaa aggtcctgag 19500  
gcagtaatgt tgcaaagcag ctccgcaccc ccttgctagg gctctccaac ccacaaccc 19560  
ccgacctgac aggccacctg tgcgctcccc ctccctccca caccgtgcag ctgaataaat 19620  
ctgctgtctt gcgcaaggcc atcgactaca ttcgctttct gcaacacagc aaccagaaac 19680  
tcaagcagga gaacctaat ctgcgcactg ctgtccacaa aagcagtgcg tcctggcttt 19740

attgagctcc agtctggcct cttctctagc cttgctccac ctcccggccc caccocatcc 19800  
ctagccccac cccacccttg gttctggccc accctctgcc ctgccacct cacccttggc 19860  
tgtagccctg cattcagctc tagtcccttg gttacctctg gtcctgaaag agacctggtg 19920  
cctccctttg gccctaacce agcccatca aagcgtcctg ggctagcttt aggagctaca 19980  
gtagtcccta ggctccaag ggctaggct ctgatttggg gtcacatata cagcctttac 20040  
tcctggctct gttcctttcg gccacagaa tctctgaagg atctggtgtc ggctgtggc 20100  
agtggaggga acacagacgt gctcatggag ggcgtgaaga ctgagggtga ggaacactg 20160  
acccacccc cctcgatgc tggctcacct ttccagagca gcccttgtc ccttggcagc 20220  
aggggcagtg gcagcgggtg cagtggcagt gactcggagc ctgacagccc agtctttgag 20280  
gacagcaagg ttgggccctg ccacggtgcc cccttcccca ctcccagcca tatcctctga 20340  
gcctcatgac agggccggga agaccctaac agatcctacc tcccatttca tagacagaat 20400  
aactgaggcc tggagccacg tgggggtcca cagtaagggtg ggcagaatcc tgaccccccc 20460  
cttcccagcc ccatgtcttc tgggggtcct cagattctgc cctcaccacc ctgccaacc 20520  
ccaccaggca aagccagagc agcggccgtc tctgcacagc cggggcatgc tggaccgctc 20580  
ccgcctggcc ctgtgcacgc tcgtcttctc ctgcctgtcc tgcaaccctt tggcctcctt 20640  
gctggggggc cgggggcttc ccagccctc agataccacc agcgtctacc atagccctgg 20700  
gcgcaacgtg ctgggcaccg agagcagagg tgggaccggc cagcctgggc atctttggga 20760  
gggacactcg gggtagccc ccaggcttgt gaacttgggg ctctggattt cctgggagct 20820  
gtgtccccag ctttccctct gtccatagat ggccctggct gggcccagtg gctgctgcc 20880  
ccagtggctt ggctgctcaa tgggctgttg gtgctcgtct ccttgggtgt tctctttgtc 20940  
tacggtgagc cagtcacacg gcccactca gggccggccg tgtacttctg gaggcacgc 21000  
aagcaggctg acctggacct ggcccgggta aggggctggc cccggcagag tgggcagggc 21060  
agggaccca ggctgtgaag gtgctgggtg tcaacccttg ttctgtctcc ctgtgcacac 21120  
catgaatctg tcccgctctc cctgtgccta gccacgcac cgcagacccc caccaccct 21180  
ccagagcctg ctgtggacgg ctcttctgag ctttggggca gctgctctga cctactttt 21240  
ctcacctgga aaacctcat ccacaggag actttgcca ggctgccag cagctgtggc 21300  
tggccctgcg ggcactgggc cggcccctgc ccacctcca cctggacctg gcttgtagcc 21360  
tcctctggaa cctcatccgt cacctgtgc agcgtctctg ggtgggcccg tggctggcag 21420  
gccgggcagg gggcctgcag caggactgtg ctctgcgagt ggatgctagc gccagcggc 21480  
gagacgcagc cctggtctac cataagctgc accagctgca caccatgggt aggactgagc 21540  
gtggggcggtg ctccgaggtg ctccctgtc cctgtgtctc accacagcc tcatgcctgc 21600  
ttgccttcca gggaagcaca caggcgggca cctactgcc accaacctgg cgctgagtgc 21660

cctgaacctg gcagagtgtg caggggatgc cgtgtctgtg gcgacgctgg ccgagatcta 21720  
tgtggcggct gcattgagag tgaagaccag tctccacagg gccttgcat tcttgacagt 21780  
gagtgggttg gggggatggc gggagtggg aggggtgggc gcctgaggct ccctgggtaa 21840  
gagctacacg ggatgtggca gtggttacca gggggactcc aggccaagct gggactcggc 21900  
ccggggtctg gccccaggct gtgtccactg tgacagccca gtaccacccc ctacagcgct 21960  
tcttcctgag cagtggccgc caggcctgcc tggcacagag tggctcagtg cctcctgcca 22020  
tgcagtggct ctgccacccc gtgggccacc gtttcttcgt ggatggggac tggctcgtgc 22080  
tcagtacccc atgggagagc ctgtacagct tggccgggaa cccagggtgt ctcttacccc 22140  
ttccctgtcc cctctcctgt ccctcatcct cattcctgtc ctgtcccttg tcgcctgaat 22200  
ctctggctgt ctctggccac cccagtcctt ctccctgcca tgggttggtg ctgtgggggt 22260  
tgcaggaagg gaaaggcctg ggtgcctctc gttccattg gggctttcag aagcacatgc 22320  
agggattgat gggcagatgg ctaattggag aagtgacccc aggcagtgcc gctgtggagt 22380  
aaggaagcgg agccaacaat ggcatcttct caagtcgggtt ttcctttgga agcagtgtag 22440  
ggcaggcctc agtggtgtct cctggccaag gctgggtgct gtgatagtta tgtccacccg 22500  
ctttcccctg tccttggcag gggctgcacc caggggcatg ccggcacttc ccagtggccc 22560  
taggtgtggc cccagccac ccaggaaaaa gcccttagct tggagaggag ggtggggccc 22620  
tgctccccc cccactcacc tcctcctctc cacagtggac cccctggccc aggtgactca 22680  
gctattccgg gaacatctct tagagcgagc actgaactgt gtgaccacg ccaaccccag 22740  
ccctgggtca gctgatggg acaagtaagt gtcgttgtgc cctcctccag gcaaggcccc 22800  
tccggcggga ttctgagaat agctctggc tcaaccctgt ggagagagcc cagagctggg 22860  
ctaccgtgcg tgccatgcac gcttcattcc tctctgagtt tcctctcccc accagcctgt 22920  
gggaggagac agtggcactt tgcagagcca ggggccaggc tgtactctgg agggcagggtg 22980  
gggagcacc tcctaggacc cctgccatct gttccgacag ccagctctct ccttcacag 23040  
ggaattctcg gatgccctcg ggtacctgca gctgctgaac agctgttctg atgctgcggg 23100  
ggctcctgcc tacagcttct ccatcagttc cagcatggcc accaccaccg gtgagtcccc 23160  
ggccccgtc ctggctccct tctcagctcc cccgtgcagc gtgactgagg gttcagggga 23220  
ccctccctct tctgcaggcg tagaccgggt ggccaagtgg tgggcctctc tgacagctgt 23280  
ggtgatccac tggctgcggc gggatgagga ggcggctgag cggctgtgcc cgctggtgga 23340  
gcacctgcc cgggtgctgc aggagtctga gtgagtgcac ggcaggttcc tcctgcctgg 23400  
tccccggctc agccttcctc atcccctggg cactgtgcct cactcagcct ttgttctgtg 23460  
caggaggagt caccaccttt tttcctcagg gaactcgagc cagggaagtg gggggcactc 23520  
agccagggt tgtggactgg tctgactggc actcttctgc cctggtccca acaggagacc 23580

cctgcccagg gcagctctgc actccttcaa ggctgcccgg gccctgctgg gctgtgccaa 23640  
ggcagagtct ggtccagcca gcctgaccat ctgtgagaag gccagtgggt acctgcagga 23700  
cagcctggct accacaccag ccagcagctc cattgacaag gtgaggggtg gggtcagggg 23760  
cctggcaggg ctgggggatt cagctttcca ttccctgggt cctctcccca gccccaggg 23820  
gctgcagaag accatgggggt tagcccaagc agcacaggat aggggggtcca gcagaccctg 23880  
ctttttggct aaggcttctg tccagaggag aggggttgcc cctatctggc ctgagtttcc 23940  
ccatccctgg gaggaggggg gtggatggtg tggtaggata cctttggagg ccctgcatca 24000  
ggagggctgg acagctgctc ccgggcccgt ggccgggtgtg ggggccgaga gaggcgggcg 24060  
gccccgcggg gcattgctgt tgcattgcac gtgtgtgagg cgggtgcagt gcctcggcag 24120  
tgcagcccgg agccggcccc tggcaccacg gggcccatc ctgcccctcc cagagctgga 24180  
gccctggtga cccctgccct gcctgccacc cccaggccgt gcagctgttc ctgtgtgacc 24240  
tgcttcttgt ggtgcgacac agcctgtggc ggcagcagca gccccggcc ccggccccag 24300  
cagcccaggg caccagcagc agggccccag ctccgccct tgagctgcgt ggcttccaac 24360  
gggacctgag cagcctgagg cggctggcac agagcttccg gcccgccatg cggaggggtga 24420  
gtgcccgatg gccctgtcct caagacgggg agtcaggcag tgggtggagat ggagagccct 24480  
gagcctccac tctcctggcc cccaggtgtt cctacatgag gccacggccc ggctgatggc 24540  
ggggggcagc cccacacgga cacaccagct cctcgaccgc agtctgaggc ggcgggcagg 24600  
ccccggtggc aaaggagggt agggggcagc tgctgaccag ggatgtgctg tctgctcagc 24660  
agggaagggc gcacatggga tgtgatacca agggaggctg tgtgtgtgtc agacgggaca 24720  
gacaggcctg gcgcagtggc tcacacctag cactttggga ggctcagttg ggaggacagc 24780  
ttgagcccag gagttggagg ccgcagtgag cctgagtga agggagagtc cctgtctcaa 24840  
aaaaaaaaaa agaccaagca tcttcttgat ggttacctga tgacaattcc tttcacaagg 24900  
aatcagtggg gtgactgtca tttgtgggat acatgactgc acgtgcgtga ctgagctgtg 24960  
ggactttgtg tgtgggctga gactaggggt gggagagggg aaccgcagc gccccgcca 25020  
ggtacctgtg tgccaggtag aggcggctgg tgccgtggct tgtgtgtggg cagggtccc 25080  
gggggggcgt ggccagcttg agacccatcc ctgacacatc ctggtgtgcg caggcgcggt 25140  
ggcggagctg gagccgcggc ccacgcggcg ggagcacgcg gaggccttgc tgctggcctc 25200  
ctgctacctg cccccggct tcctgtcggc gcccgggcag cgcgtgggca tgctggctga 25260  
ggcggcgcgc aactcgaga agcttggcga tcgccggctg ctgcacgact gtcagcagat 25320  
gctcatgcgc ctgggcgggt ggaccactgt cacttcagc tagacccgt gtccccggcc 25380  
tcagcacccc tgtctctagc cactttggtc ccgtgcagct tctgtcctgc gtogaagctt 25440  
tgaaggccga aggcagtga agagactctg gcctccacag ttcgacctgc ggctgctgtg 25500

tgccttcgcg gtggaaggcc cgaggggcg gatcttgacc ctaagaccgg cggccatgat 25560  
gggtgtgacc tctggtggcc gatcggggca ctgcaggggc cgagccattt tggggggccc 25620  
ccctccttgc tctgcaggca ccttagtggc ttttttcctc ctgtgtacag ggaagagagg 25680  
gggtacatttc cctgtgctga cggaagccaa cttggctttc cgggactgca agcagggctc 25740  
tgccccagag gcctctctct ccgtcgtggg agagagacgt gtacatagtg taggtcagcg 25800  
tgcttagcct cctgacctga ggctcctgtg ctactttgcc ttttgcaaac tttattttca 25860  
tagattgaga agttttgtac agagaattaa aaatgaaatt atttataatc tgggttttgt 25920  
gtcttcagct gatggatgtg ctgactagtg agagtgttg ggccctcccc cagcacctag 25980  
ggaaaggctt ccctccccc tccggccaca aggtacacaa cttttaactt agctcttccc 26040  
gatgtttgtt tgtagtgagg aggagtgagg agggctggct gtatggcctc cagcctacct 26100  
gttccccctg ctcccagggc acatgggttg gctgtgtcaa cccttagggc ctccatgggg 26160  
tcagttgtcc cttctcacct ccagctctg tcccatcag gtccctgggt ggcacgggag 26220  
gatggactga cttccaggac ctgttgtgtg acaggagcta cagcttgggt ctccctgcaa 26280  
gaagtctggc acgtctcacc tccccatcc cggcccttg tcatctcaca gcaaagaagc 26340  
ctcctccctc ccgacctgcc gccacactgg agagggggca caggggaggg ggaggtttcc 26400  
tgttctgtga aaggccgact cctgactcc attcatgcc cccccccag ccctccctt 26460  
cattccatt cccaacctt aagcctggc cggctcccag ctgaatctgg tcggaatcca 26520  
cgggctgcag attttccaaa acaatcgtt tatctttatt gacttttttt tttttttttt 26580  
tctgaatgca atgactgttt tttactctta aggaaaataa acatctttta gaaacagctc 26640  
gatacacaca atcttcagt tgaagcaata tactaataag aacactagtc gtcttaacat 26700  
ttacagtctt catatatatt atatatatgt atatgtatac atatataac actatataac 26760  
gaggccagat ataatacaca cgtttaccat tttacagtca tatgtacagg aagttgctag 26820  
ggcggccctg ggctgggggc tgcgtcaggc ctatcgaagc gtggacagag ctgaggacac 26880  
ggacggacag gcggacggac tggcagggac tggccgggc cgggtggtggc tgcgtggaca 26940  
agtggcgtcg cggtagcccc ttaccggca aaggccgggt tggggctctg ttgcgggcgc 27000  
a 27001

<210> 19  
<211> 698  
<212> DNA  
<213> H. sapiens

<220>

<400> 19  
ccttgacagg tgaagtcggc gcggggaggg gtagggccaa cggcctggac gcccgaaggg 60  
cgggcgcaga tcgcggagcc atggattgca ctttgaaga catgcttcag cttatcaaca 120

```

accaagacag tgacttccct ggcctatttg acccacccta tgctgggagt ggggcagggg 180
gcacagaccc tgccagcccc gataccagct cccagggcag ctagtctcca cctcctgcc 240
cattgagctc ctctcttgaa gccttcctga gcggggccgca ggcagcgccc tcacccctgt 300
cccctcccca gcctgcaccc actccattga agatgtaccc gtccatgccc gctttctccc 360
ctgggcctgg tatcaaggaa gagtcagtgc cactgagcat cctgcagacc cccaccccac 420
agcccctgcc agggggccctc ctgccacaga gcttcccagc cccagcccca cctgagttca 480
gctccacccc tgtgttaggc taccocagcc ctccctggagg ctactctaca ggaagccctc 540
ccgggaacac ccagcagccg ctgcctggcc tgccactggc ttccccgaca ggggtcccgc 600
ccgtctcctt gcacaccggg gtccagagtg tgggtcccca gtagctactg acagtcacag 660
ctggcccccac tgcagcccct tgaacgacca ctgtgact 698

```

<210> 20  
 <211> 4154  
 <212> DNA  
 <213> H. sapiens

<220>

<221> CDS  
 <222> (167)...(3610)

```

<400> 20
taacgaggaa cttttcgccg gcgcggggcc gcctctgagg ccagggcagg acacgaacgc 60
gcggagcggc ggcggcgact gagagccggg gccgcggcgg cgctccctag gaagggccgt 120
acgagggcggc gggcccggcg ggccctcccg aggagggcggc tgcgcc atg gac gag 175
                                     Met Asp Glu
                                     1
cca ccc ttc agc gag gcg gct ttg gag cag gcg ctg ggc gag ccg tgc 223
Pro Pro Phe Ser Glu Ala Ala Leu Glu Gln Ala Leu Gly Glu Pro Cys
      5                10                15
gat ctg gac gcg gcg ctg ctg acc gac atc gaa gac atg ctt cag ctt 271
Asp Leu Asp Ala Ala Leu Leu Thr Asp Ile Glu Asp Met Leu Gln Leu
      20                25                30                35
atc aac aac caa gac agt gac ttc cct ggc cta ttt gac cca ccc tat 319
Ile Asn Asn Gln Asp Ser Asp Phe Pro Gly Leu Phe Asp Pro Pro Tyr
      40                45                50
gct ggg agt ggg gca ggg ggc aca gac cct gcc agc ccc gat acc agc 367
Ala Gly Ser Gly Ala Gly Gly Thr Asp Pro Ala Ser Pro Asp Thr Ser
      55                60                65
tcc cca ggc agc ttg tct cca cct cct gcc aca ttg agc tcc tct ctt 415
Ser Pro Gly Ser Leu Ser Pro Pro Pro Ala Thr Leu Ser Ser Ser Leu
      70                75                80
gaa gcc ttc ctg agc ggg ccg cag gca gcg ccc tca ccc ctg tcc cct 463
Glu Ala Phe Leu Ser Gly Pro Gln Ala Ala Pro Ser Pro Leu Ser Pro
      85                90                95

```



ccc cag cct gca ccc act cca ttg aag atg tac ccg tcc atg ccc gct	511
Pro Gln Pro Ala Pro Thr Pro Leu Lys Met Tyr Pro Ser Met Pro Ala	
100 105 110 115	
ttc tcc cct ggg cct ggt atc aag gaa gag tca gtg cca ctg agc atc	559
Phe Ser Pro Gly Pro Gly Ile Lys Glu Glu Ser Val Pro Leu Ser Ile	
120 125 130	
ctg cag acc ccc acc cca cag ccc ctg cca ggg gcc ctc ctg cca cag	607
Leu Gln Thr Pro Thr Pro Gln Pro Leu Pro Gly Ala Leu Leu Pro Gln	
135 140 145	
agc ttc cca gcc cca gcc cca ccg cag ttc agc tcc acc cct gtg tta	655
Ser Phe Pro Ala Pro Ala Pro Pro Gln Phe Ser Ser Thr Pro Val Leu	
150 155 160	
ggc tac ccc agc cct ccg gga ggc ttc tct aca gga agc cct ccc ggg	703
Gly Tyr Pro Ser Pro Pro Gly Gly Phe Ser Thr Gly Ser Pro Pro Gly	
165 170 175	
aac acc cag cag ccg ctg cct ggc ctg cca ctg gct tcc ccg cca ggg	751
Asn Thr Gln Gln Pro Leu Pro Gly Leu Pro Leu Ala Ser Pro Pro Gly	
180 185 190 195	
gtc ccg ccc gtc tcc ttg cac acc cag gtc cag agt gtg gtc ccc cag	799
Val Pro Pro Val Ser Leu His Thr Gln Val Gln Ser Val Val Pro Gln	
200 205 210	
cag cta ctg aca gtc aca gct gcc ccc acg gca gcc cct gta acg acc	847
Gln Leu Leu Thr Val Thr Ala Ala Pro Thr Ala Ala Pro Val Thr Thr	
215 220 225	
act gtg acc tcg cag atc cag cag gtc ccg gtc ctg ctg cag ccc cac	895
Thr Val Thr Ser Gln Ile Gln Gln Val Pro Val Leu Leu Gln Pro His	
230 235 240	
ttc atc aag gca gac tcg ctg ctt ctg aca gcc atg aag aca gac gga	943
Phe Ile Lys Ala Asp Ser Leu Leu Leu Thr Ala Met Lys Thr Asp Gly	
245 250 255	
gcc act gtg aag gcg gca ggt ctc agt ccc ctg gtc tct ggc acc act	991
Ala Thr Val Lys Ala Ala Gly Leu Ser Pro Leu Val Ser Gly Thr Thr	
260 265 270 275	
gtg cag aca ggg cct ttg ccg acc ctg gtg agt ggc gga acc atc ttg	1039
Val Gln Thr Gly Pro Leu Pro Thr Leu Val Ser Gly Gly Thr Ile Leu	
280 285 290	
gca aca gtc cca ctg gtc gta gat gcg gag aag ctg cct atc aac cgg	1087
Ala Thr Val Pro Leu Val Val Asp Ala Glu Lys Leu Pro Ile Asn Arg	
295 300 305	
ctc gca gct ggc agc aag gcc ccg gcc tct gcc cag agc cgt gga gag	1135
Leu Ala Ala Gly Ser Lys Ala Pro Ala Ser Ala Gln Ser Arg Gly Glu	
310 315 320	
aag cgc aca gcc cac aac gcc att gag aag cgc tac cgc tcc tcc atc	1183
Lys Arg Thr Ala His Asn Ala Ile Glu Lys Arg Tyr Arg Ser Ser Ile	
325 330 335	
aat gac aaa atc att gag ctc aag gat ctg gtg gtg ggc act gag gca	1231
Asn Asp Lys Ile Ile Glu Leu Lys Asp Leu Val Val Gly Thr Glu Ala	
340 345 350 355	

aag ctg aat aaa tct gct gtc ttg cgc aag gcc atc gac tac att cgc	1279
Lys Leu Asn Lys Ser Ala Val Leu Arg Lys Ala Ile Asp Tyr Ile Arg	
360 365 370	
ttt ctg caa cac agc aac cag aaa ctc aag cag gag aac cta agt ctg	1327
Phe Leu Gln His Ser Asn Gln Lys Leu Lys Gln Glu Asn Leu Ser Leu	
375 380 385	
cgc act gct gtc cac aaa agc aaa tct ctg aag gat ctg gtg tcg gcc	1375
Arg Thr Ala Val His Lys Ser Lys Ser Leu Lys Asp Leu Val Ser Ala	
390 395 400	
tgt ggc agt gga ggg aac aca gac gtg ctc atg gag ggc gtg aag act	1423
Cys Gly Ser Gly Gly Asn Thr Asp Val Leu Met Glu Gly Val Lys Thr	
405 410 415	
gag gtg gag gac aca ctg acc cca ccc ccc tcg gat gct ggc tca cct	1471
Glu Val Glu Asp Thr Leu Thr Pro Pro Pro Ser Asp Ala Gly Ser Pro	
420 425 430 435	
ttc cag agc agc ccc ttg tcc ctt ggc agc agg ggc agt ggc agc ggt	1519
Phe Gln Ser Ser Pro Leu Ser Leu Gly Ser Arg Gly Ser Gly Ser Gly	
440 445 450	
ggc agt ggc agt gac tcg gag cct gac agc cca gtc ttt gag gac agc	1567
Gly Ser Gly Ser Asp Ser Glu Pro Asp Ser Pro Val Phe Glu Asp Ser	
455 460 465	
aag gca aag cca gag cag cgg ccg tct ctg cac agc cgg ggc atg ctg	1615
Lys Ala Lys Pro Glu Gln Arg Pro Ser Leu His Ser Arg Gly Met Leu	
470 475 480	
gac cgc tcc cgc ctg gcc ctg tgc acg ctc gtc ttc ctc tgc ctg tcc	1663
Asp Arg Ser Arg Leu Ala Leu Cys Thr Leu Val Phe Leu Cys Leu Ser	
485 490 495	
tgc aac ccc ttg gcc tcc ttg ctg ggg gcc cgg ggg ctt ccc agc ccc	1711
Cys Asn Pro Leu Ala Ser Leu Leu Gly Ala Arg Gly Leu Pro Ser Pro	
500 505 510 515	
tca gat acc acc agc gtc tac cat agc cct ggg cgc aac gtg ctg ggc	1759
Ser Asp Thr Thr Ser Val Tyr His Ser Pro Gly Arg Asn Val Leu Gly	
520 525 530	
acc gag agc aga gat ggc cct ggc tgg gcc cag tgg ctg ctg ccc cca	1807
Thr Glu Ser Arg Asp Gly Pro Gly Trp Ala Gln Trp Leu Leu Pro Pro	
535 540 545	
gtg gtc tgg ctg ctc aat ggg ctg ttg gtg ctc gtc tcc ttg gtg ctt	1855
Val Val Trp Leu Leu Asn Gly Leu Leu Val Leu Val Ser Leu Val Leu	
550 555 560	
ctc ttt gtc tac ggt gag cca gtc aca cgg ccc cac tca ggc ccc gcc	1903
Leu Phe Val Tyr Gly Glu Pro Val Thr Arg Pro His Ser Gly Pro Ala	
565 570 575	
gtg tac ttc tgg agg cat cgc aag cag gct gac ctg gac ctg gcc cgg	1951
Val Tyr Phe Trp Arg His Arg Lys Gln Ala Asp Leu Asp Leu Ala Arg	
580 585 590 595	
gga gac ttt gcc cag gct gcc cag cag ctg tgg ctg gcc ctg cgg gca	1999
Gly Asp Phe Ala Gln Ala Ala Gln Gln Leu Trp Leu Ala Leu Arg Ala	
600 605 610	

ctg ggc cgg ccc ctg ccc acc tcc cac ctg gac ctg gct tgt agc ctc	2047
Leu Gly Arg Pro Leu Pro Thr Ser His Leu Asp Leu Ala Cys Ser Leu	
615 620 625	
ctc tgg aac ctc atc cgt cac ctg ctg cag cgt ctc tgg gtg ggc cgc	2095
Leu Trp Asn Leu Ile Arg His Leu Leu Gln Arg Leu Trp Val Gly Arg	
630 635 640	
tgg ctg gca ggc cgg gca ggg ggc ctg cag cag gac tgt gct ctg cga	2143
Trp Leu Ala Gly Arg Ala Gly Gly Leu Gln Gln Asp Cys Ala Leu Arg	
645 650 655	
gtg gat gct agc gcc agc gcc cga gac gca gcc ctg gtc tac cat aag	2191
Val Asp Ala Ser Ala Ser Ala Arg Asp Ala Ala Leu Val Tyr His Lys	
660 665 670 675	
ctg cac cag ctg cac acc atg ggg aag cac aca ggc ggg cac ctc act	2239
Leu His Gln Leu His Thr Met Gly Lys His Thr Gly Gly His Leu Thr	
680 685 690	
gcc acc aac ctg gcg ctg agt gcc ctg aac ctg gca gag tgt gca ggg	2287
Ala Thr Asn Leu Ala Leu Ser Ala Leu Asn Leu Ala Glu Cys Ala Gly	
695 700 705	
gat gcc gtg tct gtg gcg acg ctg gcc gag atc tat gtg gcg gct gca	2335
Asp Ala Val Ser Val Ala Thr Leu Ala Glu Ile Tyr Val Ala Ala Ala	
710 715 720	
ttg aga gtg aag acc agt ctc cca cgg gcc ttg cat ttt ctg aca cgc	2383
Leu Arg Val Lys Thr Ser Leu Pro Arg Ala Leu His Phe Leu Thr Arg	
725 730 735	
ttc ttc ctg agc agt gcc cgc cag gcc tgc ctg gca cag agt ggc tca	2431
Phe Phe Leu Ser Ser Ala Arg Gln Ala Cys Leu Ala Gln Ser Gly Ser	
740 745 750 755	
gtg cct cct gcc atg cag tgg ctc tgc cac ccc gtg ggc cac cgt ttc	2479
Val Pro Pro Ala Met Gln Trp Leu Cys His Pro Val Gly His Arg Phe	
760 765 770	
ttc gtg gat ggg gac tgg tcc gtg ctc agt acc cca tgg gag agc ctg	2527
Phe Val Asp Gly Asp Trp Ser Val Leu Ser Thr Pro Trp Glu Ser Leu	
775 780 785	
tac agc ttg gcc ggg aac cca gtg gac ccc ctg gcc cag gtg act cag	2575
Tyr Ser Leu Ala Gly Asn Pro Val Asp Pro Leu Ala Gln Val Thr Gln	
790 795 800	
cta ttc cgg gaa cat ctc tta gag cga gca ctg aac tgt gtg acc cag	2623
Leu Phe Arg Glu His Leu Leu Glu Arg Ala Leu Asn Cys Val Thr Gln	
805 810 815	
ccc aac ccc agc cct ggg tca gct gat ggg gac aag gaa ttc tcg gat	2671
Pro Asn Pro Ser Pro Gly Ser Ala Asp Gly Asp Lys Glu Phe Ser Asp	
820 825 830 835	
gcc ctc ggg tac ctg cag ctg ctg aac agc tgt tct gat gct gcg ggg	2719
Ala Leu Gly Tyr Leu Gln Leu Leu Asn Ser Cys Ser Asp Ala Ala Gly	
840 845 850	
gct cct gcc tac agc ttc tcc atc agt tcc agc atg gcc acc acc acc	2767
Ala Pro Ala Tyr Ser Phe Ser Ile Ser Ser Ser Met Ala Thr Thr Thr	
855 860 865	

ggc gta gac ccg gtg gcc aag tgg tgg gcc tct ctg aca gct gtg gtg	2815
Gly Val Asp Pro Val Ala Lys Trp Trp Ala Ser Leu Thr Ala Val Val	
870 875 880	
atc cac tgg ctg cgg cgg gat gag gag gcg gct gag cgg ctg tgc ccg	2863
Ile His Trp Leu Arg Arg Asp Glu Glu Ala Ala Glu Arg Leu Cys Pro	
885 890 895	
ctg gtg gag cac ctg ccc cgg gtg ctg cag gag tct gag aga ccc ctg	2911
Leu Val Glu His Leu Pro Arg Val Leu Gln Glu Ser Glu Arg Pro Leu	
900 905 910 915	
ccc agg gca gct ctg cac tcc ttc aag gct gcc cgg gcc ctg ctg ggc	2959
Pro Arg Ala Ala Leu His Ser Phe Lys Ala Ala Arg Ala Leu Leu Gly	
920 925 930	
tgt gcc aag gca gag tct ggt cca gcc agc ctg acc atc tgt gag aag	3007
Cys Ala Lys Ala Glu Ser Gly Pro Ala Ser Leu Thr Ile Cys Glu Lys	
935 940 945	
gcc agt ggg tac ctg cag gac agc ctg gct acc aca cca gcc agc agc	3055
Ala Ser Gly Tyr Leu Gln Asp Ser Leu Ala Thr Thr Pro Ala Ser Ser	
950 955 960	
tcc att gac aag gcc gtg cag ctg ttc ctg tgt gac ctg ctt ctt gtg	3103
Ser Ile Asp Lys Ala Val Gln Leu Phe Leu Cys Asp Leu Leu Leu Val	
965 970 975	
gtg cgc acc agc ctg tgg cgg cag cag cag ccc ccg gcc ccg gcc cca	3151
Val Arg Thr Ser Leu Trp Arg Gln Gln Gln Pro Pro Ala Pro Ala Pro	
980 985 990 995	
gca gcc cag ggc gcc agc agc agg ccc cag gct tcc gcc ctt gag ctg	3199
Ala Ala Gln Gly Ala Ser Ser Arg Pro Gln Ala Ser Ala Leu Glu Leu	
1000 1005 1010	
cgt ggc ttc caa cgg gac ctg agc agc ctg agg cgg ctg gca cag agc	3247
Arg Gly Phe Gln Arg Asp Leu Ser Ser Leu Arg Arg Leu Ala Gln Ser	
1015 1020 1025	
ttc cgg ccc gcc atg cgg agg gtg ttc cta cat gag gcc acg gcc cgg	3295
Phe Arg Pro Ala Met Arg Arg Val Phe Leu His Glu Ala Thr Ala Arg	
1030 1035 1040	
ctg atg gcg ggg gcc agc ccc aca cgg aca cac cag ctc ctc gac cgc	3343
Leu Met Ala Gly Ala Ser Pro Thr Arg Thr His Gln Leu Leu Asp Arg	
1045 1050 1055	
agt ctg agg cgg cgg gca ggc ccc ggt ggc aaa gga ggc gcg gtg gcg	3391
Ser Leu Arg Arg Arg Ala Gly Pro Gly Gly Lys Gly Gly Ala Val Ala	
1060 1065 1070 1075	
gag ctg gag ccg cgg ccc acg cgg cgg gag cac gcg gag gcc ttg ctg	3439
Glu Leu Glu Pro Arg Pro Thr Arg Arg Glu His Ala Glu Ala Leu Leu	
1080 1085 1090	
ctg gcc tcc tgc tac ctg ccc ccc ggc ttc ctg tcg gcg ccc ggg cag	3487
Leu Ala Ser Cys Tyr Leu Pro Pro Gly Phe Leu Ser Ala Pro Gly Gln	
1095 1100 1105	
cgc gtg ggc atg ctg gct gag gcg gcg cgc aca ctc gag aag ctt ggc	3535
Arg Val Gly Met Leu Ala Glu Ala Ala Arg Thr Leu Glu Lys Leu Gly	
1110 1115 1120	

gat cgc cgg ctg ctg cac gac tgt cag cag atg ctc atg cgc ctg ggc 3583  
Asp Arg Arg Leu Leu His Asp Cys Gln Gln Met Leu Met Arg Leu Gly  
1125 1130 1135

ggg ggg acc act gtc act tcc agc tag accccgtgtc cccggcctca 3630  
Gly Gly Thr Thr Val Thr Ser Ser  
1140 1145

gcaccctgt ctctagccac tttgggtccg tgcagcttct gtcctgcgtc gaagctttga 3690

aggccgaagg cagtgaaga gactctggcc tccacagttc gacctgcggc tgctgtgtgc 3750

cttcgcggtg gaaggccga ggggcgcgat cttgacccta agaccggcgg ccatgatggt 3810

gctgacctct ggtggccgat cggggcactg caggggcca gccattttgg ggggcccccc 3870

tccttgctct gcaggcacct tagtggcttt tttcctcctg tgtacaggga agagaggggt 3930

acatttcct gtgctgacgg aagccaactt ggctttcccg gactgcaagc agggctctgc 3990

cccagaggcc tctctctccg tcgtgggaga gagacgtgta catagtgtag gtcagcgtgc 4050

ttagcctcct gacctgaggc tcctgtgcta ctttgccttt tgcaaaacttt attttcatag 4110

attgagaagt tttgtacaga gaattaaaaa tgaaattatt tata 4154

&lt;210&gt; 21

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 21

tgtctgcaca gtggtgccag

20

&lt;210&gt; 22

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 22

ctccgagtca ctgccactgc

20

&lt;210&gt; 23

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 23

tgaagcatgt cttcgaaagt

20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 24

gtcactgtct tggttgttga

20

<210> 25

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 25

gggaagtcac tgtcttggtt

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 26

ggccagggaa gtcactgtct

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 27

gagtctgcct tgatgaagtg

20

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 28  
gccttgctgc cagctgcgag 20

<210> 29  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 29  
gcagatttat tcagctttgc 20

<210> 30  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 30  
agacagcaga tttattcagc 20

<210> 31  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 31  
gcgcaagaca gcagatttat 20

<210> 32  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 32  
gccttgcgca agacagcaga 20

<210> 33  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 33  
cgatggcctt gcgcaagaca 20

<210> 34  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 34  
gtagtcgatg gccttgcgca 20

<210> 35  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 35  
aggcgggagc ggtccagcat 20

<210> 36  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 36  
ggcagagcca ctgcatggca 20

<210> 37  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 37  
gaggccacc acttgccac 20

<210> 38  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>



<223> Antisense Oligonucleotide

<400> 38

gccagtggat caccacagct

20

<210> 39

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 39

ccgggcagcc ttgaaggagt

20

<210> 40

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 40

actggccttc tcacagatgg

20

<210> 41

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 41

gcaggtaccc actggccttc

20

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 42

ctatgaaaat aaagtttgca

20

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 43

gccgacttca cctgtcaagg

20

<210> 44

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 44

ggagggttc ctgcagaaat

20

<210> 45

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 45

atttattcag ctgcacggtg

20

<210> 46

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 46

gtgcttcctt ggaaggcaag

20

<210> 47

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 47

gcaccagcct tggccaggag

20

<210> 48

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 48

ccctgtggaa ggagagagct

20

<210> 49

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 49

gggtctacgc ctgcagaaga

20

<210> 50

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 50

gggcactcac cctccgcatg

20

<210> 51

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 51

gtccaggccg ttggccctac

20

<210> 52

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 52

agtgcaatcc atggctccgc

20

<210> 53

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 53

gataagctga agcatgtctt

20

<210> 54

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 54

gtcctgccct ggcctcagag

20

<210> 55

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 55

tggctcgtcc atggcgcagc

20

<210> 56

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 56

cgcctcgctg aagggtggct

20

<210> 57

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 57

ctgaagcatg tcttcgatgt

20

<210> 58

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 58

ctcaatgtgg caggaggtgg

20

<210> 59

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 59

tgggaagctc tgtggcagga

20

<210> 60

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 60

ccagtggcag gccaggcagc

20

<210> 61

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 61

agggtcggca aaggccctgt

20

<210> 62

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 62

tgcgagccgg ttgataggca

20

<210> 63

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 63

gctgtgcgct tctctccacg

20

<210> 64

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 64

tgcccaccac cagatccttg

20

<210> 65

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 65

cgcagactta gggttctcctg

20

<210> 66

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 66

tgcttttgtg gacagcagtg

20

<210> 67

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 67

ctgccacagg ccgacaccag

20

<210> 68

<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 68  
cagcctgctt gcgatgcctc

20

<210> 69  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 69  
ccaggtccag gtcagcctgc

20

<210> 70  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 70  
gcttatggta gaccagggct

20

<210> 71  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 71  
gtgtgcttcc ccatggtgtg

20

<210> 72  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 72  
cgccacatag atctcggcca

20

<210> 73  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 73  
atgcagccgc cacatagatc 20

<210> 74  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 74  
ctcgctctaa gagatgttcc 20

<210> 75  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 75  
atcagctgac ccagggctgg 20

<210> 76  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 76  
ggcatccgag aattccttgt 20

<210> 77  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 77  
tacgccggtg gtggtggcca 20



<210> 78  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 78  
gctggaccag actctgcctt 20

<210> 79  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 79  
agctgctggc tgggtgtgta 20

<210> 80  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 80  
cgcagctcaa gggcggaagc 20

<210> 81  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 81  
tctgctgaca gtcgtgcagc 20

<210> 82  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 82  
aggcgcatga gcatctgctg 20

<210> 83  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 83  
ggaagtgaca gtggtccac 20

<210> 84  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 84  
gggtctagct ggaagtgaca 20

<210> 85  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 85  
cacgggacca aagtggctag 20

<210> 86  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 86  
caggacagaa gctgcacggg 20

<210> 87  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 87

ggcacacagc agccgcaggt

20

<210> 88

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 88

cttccaccgc gaaggcacac

20

<210> 89

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 89

atggccgccg gtcttagggt

20

<210> 90

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 90

cagcaccatc atggccgccg

20

<210> 91

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 91

ctaaggtgcc tgcagagcaa

20

<210> 92

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 92  
acagggaaat gtacccctct 20

<210> 93  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 93  
tggcttccgt cagcacaggg 20

<210> 94  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 94  
tccgggaaag ccaagttggc 20

<210> 95  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 95  
tcaggaggct aagcacgctg 20

<210> 96  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 96  
agtttgcaaa aggcaaagta 20

<210> 97  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 97  
ttaattctct gtacaaaact

20

<210> 98  
<211> 616  
<212> DNA  
<213> M. musculus

<220>

<400> 98  
ggatccagaa ctggatcatc agccccccc tccttgaaac aagtgttctc atcctggggc 60  
gctctgctag ctagatgacc ctgcaccacc aactgccact atctaaaggc agctattggc 120  
cttcctcaga ctgtaggcaa atcttgctgc tgccattcga tgcgaagggc caggagtggg 180  
taaactgagg ctaaaatggt ccaggcaagt tctgggtgtg tgcgaacgaa ccagcgggtg 240  
gaacacagag cttccgggat caaagccaga cgccgtccgg attccggacc caggctcttt 300  
tcggggatgg ttgcctgtgc ggcaggggtt gggacgacag tgaccgccag taaccccagc 360  
gcgcgctggc gcagacgcgg ttaaaggcgg acgcccgcga gtaaccccgg cccatttcag 420  
agcaccggga gaaacccgag ctgccgccgt cgggggtggg cggggcccta atggggcgcg 480  
gcgcggctgc tgattggcca tgtgcgctca cccgaggggc ggggcacgga ggcgatcggc 540  
gggctttaa gctcgcggg gcctgacagg tgaaatcggc gcggaagctg tcggggtagc 600  
gtctgcacgc ctagg 616

<210> 99  
<211> 491  
<212> DNA  
<213> M. musculus

<220>

<221> unsure  
<222> 352  
<223> unknown

<221> unsure  
<222> 415  
<223> unknown

<223>

<400> 99  
aaaatcggcg cggaagctgt cggggtagcg tctgcacgcc ctaggggcgg ggcgcggacc 60  
acggagccat ggattgcaca ttgaagaca tgctccagct catcaacaac caagacagtg 120  
acttcccggg cctgtttgac gcccctatg ctgggggtga gacaggggac acaggcccca 180  
gcagcccagg tgccaactct cctgagagct tctcttctgc ttctctggcc tcctctctgg 240

aagccttcct gggaggaccc aaggtagacac ctgcaccctt gtcccctcca ccatcggcac 300  
ccgctgcttt aaagatgtac ccgtccgtgt cccctttttc ccctgggcct gngatcaaag 360  
aggagccagt gccactcacc atcctacagc ctgcagcgcc acagccgtca ccgngaccc 420  
tcctgcctcc gagcttcccc gcaccacccg tacagctcag ccctgcgccc gtgctgggtt 480  
actcgagcct g 491

<210> 100  
<211> 8128  
<212> DNA  
<213> M. musculus

<220>

<221> unsure  
<222> 3861  
<223> unknown

<221> unsure  
<222> 3862  
<223> unknown

<221> unsure  
<222> 3863  
<223> unknown

<221> unsure  
<222> 3864  
<223> unknown

<221> unsure  
<222> 3865  
<223> unknown

<221> unsure  
<222> 3866  
<223> unknown

<221> unsure  
<222> 3867  
<223> unknown

<221> unsure  
<222> 3868  
<223> unknown

<221> unsure  
<222> 3869  
<223> unknown

<221> unsure  
<222> 3870  
<223> unknown

<221> unsure  
<222> 3871  
<223> unknown

<221> unsure

<222> 3872  
<223> unknown

<221> unsure  
<222> 3873  
<223> unknown

<221> unsure  
<222> 3874  
<223> unknown

<221> unsure  
<222> 3875  
<223> unknown

<221> unsure  
<222> 3876  
<223> unknown

<221> unsure  
<222> 3877  
<223> unknown

<221> unsure  
<222> 3878  
<223> unknown

<221> unsure  
<222> 3879  
<223> unknown

<221> unsure  
<222> 3880  
<223> unknown

<221> unsure  
<222> 3881  
<223> unknown

<221> unsure  
<222> 3882  
<223> unknown

<221> unsure  
<222> 3883  
<223> unknown

<221> unsure  
<222> 3884  
<223> unknown

<221> unsure  
<222> 3885  
<223> unknown

<221> unsure  
<222> 3886  
<223> unknown

<221> unsure  
<222> 3887  
<223> unknown

<221> unsure

<222> 3888  
<223> unknown

<221> unsure  
<222> 3889  
<223> unknown

<221> unsure  
<222> 3890  
<223> unknown

<221> unsure  
<222> 3891  
<223> unknown

<221> unsure  
<222> 3892  
<223> unknown

<221> unsure  
<222> 3893  
<223> unknown

<221> unsure  
<222> 3894  
<223> unknown

<221> unsure  
<222> 3895  
<223> unknown

<221> unsure  
<222> 3896  
<223> unknown

<221> unsure  
<222> 3897  
<223> unknown

<221> unsure  
<222> 3898  
<223> unknown

<221> unsure  
<222> 3899  
<223> unknown

<221> unsure  
<222> 3900  
<223> unknown

<221> unsure  
<222> 3901  
<223> unknown

<221> unsure  
<222> 3902  
<223> unknown

<221> unsure  
<222> 3903  
<223> unknown

<221> unsure



<222> 3904  
<223> unknown

<221> unsure  
<222> 3905  
<223> unknown

<221> unsure  
<222> 3906  
<223> unknown

<221> unsure  
<222> 3907  
<223> unknown

<221> unsure  
<222> 3908  
<223> unknown

<221> unsure  
<222> 3909  
<223> unknown

<221> unsure  
<222> 3910  
<223> unknown

<221> unsure  
<222> 3911  
<223> unknown

<221> unsure  
<222> 3912  
<223> unknown

<221> unsure  
<222> 3913  
<223> unknown

<221> unsure  
<222> 3914  
<223> unknown

<221> unsure  
<222> 3915  
<223> unknown

<221> unsure  
<222> 3916  
<223> unknown

<221> unsure  
<222> 3917  
<223> unknown

<221> unsure  
<222> 3918  
<223> unknown

<221> unsure  
<222> 3919  
<223> unknown

<221> unsure

<222> 3920  
<223> unknown

<221> unsure  
<222> 3921  
<223> unknown

<221> unsure  
<222> 3922  
<223> unknown

<221> unsure  
<222> 3923  
<223> unknown

<221> unsure  
<222> 3924  
<223> unknown

<221> unsure  
<222> 3925  
<223> unknown

<221> unsure  
<222> 3926  
<223> unknown

<221> unsure  
<222> 3927  
<223> unknown

<221> unsure  
<222> 3928  
<223> unknown

<221> unsure  
<222> 3929  
<223> unknown

<221> unsure  
<222> 3930  
<223> unknown

<221> unsure  
<222> 3931  
<223> unknown

<221> unsure  
<222> 3932  
<223> unknown

<221> unsure  
<222> 3933  
<223> unknown

<221> unsure  
<222> 3934  
<223> unknown

<221> unsure  
<222> 3935  
<223> unknown

<221> unsure

<222> 3936  
<223> unknown

<221> unsure  
<222> 3937  
<223> unknown

<221> unsure  
<222> 3938  
<223> unknown

<221> unsure  
<222> 3939  
<223> unknown

<221> unsure  
<222> 3940  
<223> unknown

<221> unsure  
<222> 3941  
<223> unknown

<221> unsure  
<222> 3942  
<223> unknown

<221> unsure  
<222> 3943  
<223> unknown

<221> unsure  
<222> 3944  
<223> unknown

<221> unsure  
<222> 3945  
<223> unknown

<221> unsure  
<222> 3946  
<223> unknown

<221> unsure  
<222> 3947  
<223> unknown

<221> unsure  
<222> 3948  
<223> unknown

<221> unsure  
<222> 3949  
<223> unknown

<221> unsure  
<222> 3950  
<223> unknown

<221> unsure  
<222> 3951  
<223> unknown

<221> unsure

<222> 3952  
<223> unknown

<221> unsure  
<222> 3953  
<223> unknown

<221> unsure  
<222> 3954  
<223> unknown

<221> unsure  
<222> 3955  
<223> unknown

<221> unsure  
<222> 3956  
<223> unknown

<221> unsure  
<222> 3957  
<223> unknown

<221> unsure  
<222> 3958  
<223> unknown

<221> unsure  
<222> 3959  
<223> unknown

<221> unsure  
<222> 3960  
<223> unknown

<223>

<400> 100  
cagctcacaa attgactaca aaggcagttt ggccatcaaa caaggaatgt ccttgtgcag 60  
cccctcagac ctgagattat aagcatcagc tgtcataccc ggttcccca cccacctcc 120  
ccctgctttt taaatttatt ttttgcttct ttatttttct atacctggct ttttgtggg 180  
gttaaaactcg ggtccctccc tttgcctgca cagcaagcac ccactaatgg agctgtcttc 240  
ccagcccctc tgcataagtg gggcttgctg tgtaagtggg tgaggcccag atgactgtgg 300  
gccttttcgg aggctgcca cagcaccctg tgctgtctct ctgcatatac gaaggcgata 360  
aaggctgctt ggcccagggc tcacctcagg ccgtgactga ctatatagga gcagactgta 420  
taggcaccgt ggatcagcag aactgagcca gggctcctcaag tgcttcccga ggccactgag 480  
ggctcttgat ccttctctgg accttggtgt cctcactggg aagaggctcct gagcacaagc 540  
gtgactgttt catcagcctg cgtgtagcct atccccttcc aggaagaacc acattctttt 600  
aatgccctgg agcagggcct ttgagtgcac aaaaggcagt ctatacccct gtgccctggc 660  
accatacga cagccaagga ccagagtgcc tgccagggac ttctgaggag taagggcctg 720

gggagcagca gggcaggctg catgcctgaa aaaacagtga gccatagccc agtcctctaa 780  
cctgcaagtc cccaagcagg gggcactgtc ctgtgtcctc ggtgggaggt ggtgccactt 840  
ctctatgcag cctgtctccc ttctctctcc tgcgtctcctt caggggatgg gatag'ggttg 900  
aaatcctgta ggctcactgg gatcccagca taacctgtcc ttacccgagc cactgtttct 960  
gcctctgccc tcacacctag cttgtacggg ttccgtcttt ggctttgcct tttcttctgg 1020  
ccagagagtt ttccctccct tgtagcccta tttattcaga ctacactcaa gtgtcacgtc 1080  
cccaggcagc cttgataccc acctgtcttt gcttgcccag cctctcacct ctgccactcg 1140  
tctcacatcc ctcccccaac cccaccccga gcatgtgcgc agctggttcc ttgggtggagt 1200  
ggaagtatcc accaggggct ggatctctcg tgttgtcccc agcaagtggc tttcacctag 1260  
gatggtcctt tgattctggt ggggaggggc agccgaggct tcaggtttcc ggttgaagcc 1320  
agataggatc agggcttgag aaggagat agaggcttg tgcccggtc cccttttgtc 1380  
cttttgcttc aaatcacata tgtgacctgg aagtctgtgc acggttggtga gaagtcagta 1440  
ttcagcatgc cctgatggct cgtagcttgg ttactgtggg gccctttcc agactgcagg 1500  
acctactgag ccctagtcct tcctaggggt aggcaaggaa cactctcacg ttaggtgtgt 1560  
agcgtgttag gtgtgtagcg tgctggctga tgtctccct cagttcttgg gtggccctac 1620  
tcattccctt taaaatgtta aaaacctacc aggtgccag gactgactca gtcctgcagc 1680  
tcagggtcta gtttgaggt ctagccaatt ccagcggctg ttgagaggaa acacctttgc 1740  
tgaaaccttt ttgagtgggt agattcttta ttaacttgtt ctggaatcgc caccacagg 1800  
aggggtagag tctggacctg ggggtcttta gaggcacccg gctcccgatg catagctgg 1860  
ggggaaaaga aaagaaaggc cgcagcacac agctgcagat ccttggcaag gcttattctc 1920  
aaggagcttg caaagctggc ttttaaggctc cgtttcctct caagacttcc ccctggccac 1980  
cagcatctac agacatgagc tagcgaccog gctcagaagg tggtagaggg ggaggccagg 2040  
cagcatggac acacattctg ctagtgtgca ggcctgcccc cgggtccagt cttgactaag 2100  
gcttttgtac tcacaagcgt gccacatgc ttgggtcaca cttgtccagt gtccagatac 2160  
ggacaggggt ggggagacgt gacccacact gtacggagtt tcgatgagcc tccccgcctc 2220  
tgcaagtctt tctgtattcg ggactcagat gtcagaagga gcagagtagg gtcaacactg 2280  
ggaagcctca tgcctggact ccagcccccc ccccccccc cgtgttgggg tcagggtctt 2340  
tccctgcctt cagttgggtg aggtcagagg ttttcccagg agctgtgcat ggtttgggga 2400  
ctctcgagca cttgcaggct ggacagaacg gtgtcataaa aagatgtttt ctttggaaatg 2460  
aacctcctat gaggatgtga aaagacctag aaaggggatc aggggaatgt cagacacacg 2520  
tgtctgtttc ccagacaaga ctctgaaaag agagatgggc cacaagtccc tgacacacat 2580  
aaggtgacta cttggctcgt ggaccctca cagactgtgt gagtccctgg tctgccaact 2640

aggctgccag accttgctgg gccactgcca cagaagctag gttgctggcc atcactgtgt 2700  
ggtgatggta atggcgggag tatgtgtgtg cacatgcttg tgtgtgcaca ggtatgaaag 2760  
ctttcaattt gccagcaagg gacagggaca gatttggcat acccttaata tccactgcct 2820  
ttcccttctg tcccagagac tggttcctgt gcaggccttt gcagagtgtc ataagagaat 2880  
cgagtaaggc ttcacttggt gactgctggg ggctgtgata cctggaggga agacactgac 2940  
ccagcctagg ggcacagag ctgagagcag gatatcctgg acgctgtgatt tgaggaagga 3000  
tttccctagc tcaactcctga aggcagtttc atgagggatc cagaactgga tcatcagccc 3060  
ccccctcctt gaaacaagtg ttctcatcct ggggcgctct gctagctaga tgaccctgca 3120  
ccaccaactg ccactatcta aaggcaacta ttggccttcc tcagactgta ggcaaactct 3180  
gctgctgcca ttcgatgcga agggccagga gtgggtaaac tgaggctaaa atggtccagg 3240  
caagtcttgg gtgtgtgcga acgaaccagc ggtgggaaca cagagcttcc gggatcaaag 3300  
ccagacgccg tccggattcc ggaccaggc tcttttcggg gatggttgcc tgtgcggcag 3360  
gggttgggac gacagtgacc gccagtaacc ccagcgcgcg ctggcgcaga cgcggttaaa 3420  
ggcggacgcc cgctagtaac cccggcccca ttcagagcac cgggagaaac ccgagctgcc 3480  
gccgtcgggg gtgggcgggg ccctaattgg gcgcggcgcg gctgctgatt ggccatgtgc 3540  
gctcaccgga ggggcggggc acggaggcga tcggcgggct ttaaagcctc gcggggcctg 3600  
acaggtgaaa tcggcgcgga agctgtcggg gtagcgtctg cacgccctag gggcggggcg 3660  
cggaccacgg agccatggat tgcacatttg aaggtacttt ggggaggacc ctgcactcta 3720  
ttactttgcc agggctctctg cagcggactg cagtacggtg ttctaacaga gaatgcagga 3780  
cggcccttcc ccaccttggg ctggaaattg gtgggcctct ttatcctgct taaggaccga 3840  
caccttgcaa tttgcaactt nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 3900  
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 3960  
gagcctgcct tcaggcttct caggtgagcg agtgatggaa gaagagtggc cgctgtgctc 4020  
ttacagagga attcccaggc ttcagaagtt aggtggtcat cctgcgacct gagatgcctc 4080  
ttggttctgg gccagtgca tcccccaac cccagttgt gcagctggaa ggtgacatgt 4140  
gcagggtctg tctgtctatg aagtaatggg gatagttatg tgaggccagt cggggtaaag 4200  
gtcggcaagg cagcctgtgc cagcaacctt aaactctgtc tctgcaggga cccttcagg 4260  
aaacactcag cagccaccat ctagcctgcc gctggcccct gcaccaggag tcttgccac 4320  
ccctgccctg cacaccagg tccaaagctt ggcctcccag cagccgctgc cagcctcagc 4380  
agcccctaga acaaactg tgacctcaca ggtccagcag gtcccagtga gtgggtctga 4440  
ccaggaaggt ggggggtggg gacgcctggc ttggatgctg ctcgcttaca gcttggcccc 4500  
tcccatccag gttgtactgc agccacactt catcaaggca gactcactgc tgctgacagc 4560

tgtgaagaca gatgcaggag ccaccgtgaa gactgcaggc atcagcacc tggctcctgg 4620  
cacagccgtg caggcaggtc ccctgcagggt agatgggtca ggcacaaggg agactatggg 4680  
ggggggggga ggggttggtg cgcattgtgc tgtccacctg gtgagatgca tctgacccca 4740  
cagaccctgg tgagtggagg gaccatcttg gccacagtac ctttggttgt ggacacagac 4800  
aaactgcca tccaccgact cgcagctggc agcaaggccc taggctcagc tcagagccgt 4860  
ggtgagaagc gcacagcca caatgccatt gagaagcgct accggtcttc tatcaatgac 4920  
aagattgtgg agctcaaaga cctgggtggg ggcactgaag caaaggtagc gccaaaggcc 4980  
tcgcgagactc aggtcagggt gaccaggga gaaatggggc acatcagcca gccggggatg 5040  
ggattaggtc agtcctcgtc acttagtcat atgcatcaac ttgtctgggt ctaggcagtc 5100  
ccgtttgcgg agttaggtct tatcaagggc agcctggata aagaaagctg gtctatgcat 5160  
tgagggggcg tggatgatgaa gcacagaaat cctgtcctgg aggaactgac tccctagggg 5220  
agtagtggga attgcagcgg ctggctccca tgttcgggga agaaaccagg accagtgaag 5280  
gttgtggttg tgaactgggt ggtcaaggaa ggtctcaccg tagagagctg aggggtgtagg 5340  
gaatgtgagg tggagacagc aggggcccga gctgggagac accgttgtga gtattcacag 5400  
ggtgactttt atctctgccc tgtggagtgg gtactgtcag gagacagcag cataggagag 5460  
ttgtagttag aaggaaccgt cccgtccaga ggccccgagg cagctgtgac gcagagcggc 5520  
tcttacctgc tctcgtacct gtggtcagggt ccacttggtt ggctgagccc tctccctctc 5580  
ctcacagctg aataaatctg ctgtcttgcg caaggccatc gactacatcc gcttcttgca 5640  
gcacagcaac cagaagctca agcaggagaa cctgacccta cgaagtgcac acaaaagcag 5700  
tgagtcccag cccctcccc cggcccccc cccctgctg tccctggccac tatgccgttg 5760  
ctgtgaagac actatgacca tggtcagggt tattaaaggc ttacagtctc aggggtgaac 5820  
ccatgaccac agtgggtggc gcaggcagac aggcttggcg cttggagcag tagccgagag 5880  
ctcaaataatt gagacagcca caaggccaag agaaagagct agctgagaat agtgtgggtt 5940  
tttgaaattt caaagcctac cacagtgaac cccctcctcc agcaaggcca cacctcccaa 6000  
tccttcccaa acaggaatgg gaaccaagcg gtcaaacggg accctctgaa agccattctc 6060  
attcagattg ccaccctgat gctgccttct ctatccctgc ccaaccttgt ctctggctct 6120  
caccctacct tggccctgt tttgagcata acagaaccat ccaagtcctg gcgcttggcg 6180  
gccaggcctc tctcaccagc cctgttcttt ctgcctacag aatcactgaa ggacctgggtg 6240  
tcagcttgtg gcagtggagg aggcacagat gtgtctatgg agggcatgaa acccgaagtg 6300  
gtggagacgc ttacccctcc accctcagac gccggctcac cctcccagag tagccccttg 6360  
tcttttggca gcagagctag cagcagtgggt ggtagtgact ctgagcccga cagtccagcc 6420  
tttgaggata gccagggttg actctgcaat atggccctt ccctctccca gcagccctgc 6480

agtctcctcc accttttagc ctgcctttg gggctagctg agctctatgc ccttacctcc 6540  
cttgctccct gccaggtcaa agcccagcgg ctgccttcac acagccgagg catgctggac 6600  
cgctcccgcc tggccctgtg tgtactggcc tttctgtgtc tgacctgcaa tcctttggcc 6660  
tcgcttttcg gctggggcat tctcactccc tctgatgcta cgggtacaca ccgtagttct 6720  
gggcgagca tgetggaggc agagagcaga ggtgagtcag gtcagcccag gtgttgctcg 6780  
cagagacctt tgggactttg gatttccgga gaactgagtt ctcagacctt ttctttgcct 6840  
gtagatggct ctaattggac ccagtggttg ctgccacccc tagtctggct ggccaatgga 6900  
ctactagtgt tggcctgctt ggctcttctc tttgtctatg gggaacctgt gactaggcca 6960  
cactctggcc cggctgtaca cttctggaga catcgcaaac aagctgacct ggatttggcc 7020  
cgggtaaggg gctgacctg aggaggcggg gtggggcccc gggcctggaa ggtgctgggt 7080  
gcctctgctc acttcatttt ctccagtctg tctcatcccc cgccttcaga gtcctgact 7140  
ctagggggccc agacaagggg gtaccctgct gccatccctg ctgccatttt tcttactgag 7200  
aatcttttct ctagggagat ttccccagg ctgctcaaca gctgtggctg gccctgcaag 7260  
cgctgggccc gcccctgccc acctcaaacc tggatctggc ctgcagtctg ctttgggaacc 7320  
tcatccgcca cctgctccag cgtctctggg tgggccgctg gctggcaggc caggccgggg 7380  
gcctgctgag ggaccgtggg ctgaggaagg atgcccgtgc cagtgcccg gatgaggctg 7440  
ttgtctacca taagctgcac cagctgcatg ccatgggtat ggctggctgg gagctgggct 7500  
ccgaggggtcc ccaccacacc gtcacctcct gtcctcatgc ctcacccact ttgcaggcaa 7560  
gtacacagga ggacatcttg ctgcttctaa cctggcacta agtgccctca acctggctga 7620  
gtgcgcagga gatgctatct ccatggcaac actggcagag atctatgtgg cagcggccct 7680  
gagggtcaaa accagcctcc caagagccct gcatttcttg acagtgagta ggctgatggg 7740  
gacagggctg ggggctcctc tttaacaactc tcaacctgtc acttccaggg caaggggcta 7800  
aacaggatgt ggcagtgggt agcagggtgg ctgtaggccc tcctgggatc caactgggag 7860  
ccagtgtgac agttctgttc cttccctaca gcgtttcttc ctgagcagcg cccgccaggc 7920  
ctgcctagca cagagcggct cgggtgcctct tgccatgcag tggctctgcc accctgtagg 7980  
tcaccgtttc tttgtggacg gggactgggc cgtgcacggt gcccccccg agagcctgta 8040  
cagcgtggct gggaaccag gtgctttctc gttctgttct taccctgcc tcatccctgt 8100  
ccctatgtca cattgcactg tcccctct 8128

&lt;210&gt; 101

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;



<223> Antisense Oligonucleotide

<400> 101

tggagcatgt cttcaaagt

20

<210> 102

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 102

tgtgcaatcc atggctccgt

20

<210> 103

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 103

aagagaagct ctcaggagag

20

<210> 104

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 104

ccttggtcc tcccaggaag

20

<210> 105

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 105

ggacaagggt gcaggtgtca

20

<210> 106

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 106

gatggtgagt ggcactggct

20

<210> 107

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 107

ggatgggcag tttgtctgtg

20

<210> 108

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 108

gctgtgcgct tctcaccacg

20

<210> 109

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 109

gcttctcaat ggcattgtgg

20

<210> 110

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 110

cactgccaca agctgacacc

20

<210> 111

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 111

ccatagacac atctgtgcct

20

<210> 112

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 112

gctcagagtc actgccacca

20

<210> 113

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 113

gggctttgac ctggctatcc

20

<210> 114

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 114

ttagagccat ctctgctctc

20

<210> 115

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 115

gcagcaacca ctgggtccaa

20

<210> 116

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 116  
agtccattgg ccagccagac 20

<210> 117

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 117  
ccaagcaggc caacactagt 20

<210> 118

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 118  
tgcgatgtct ccagaagtgt 20

<210> 119

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 119  
gccagatcca ggtttgaggt 20

<210> 120

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 120  
tggcctgcca gccagcggcc 20

<210> 121

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 121

gtgtacttgc ccatggcatg

20

<210> 122

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 122

agatctctgc cagtgttgcc

20

<210> 123

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 123

gacctacagg gtggcagagc

20

<210> 124

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 124

ctgggttccc agccacgctg

20

<210> 125

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 125

ggcatctgag aactccctgt

20

<210> 126

<211> 20

<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 126  
ccacttggcc actgggtctg 20

<210> 127  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 127  
agccttgaag gagtacagag 20

<210> 128  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 128  
cacctttctg tggctccagca 20

<210> 129  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 129  
atggccaggc tggctgggct 20

<210> 130  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 130  
tcacacagga gcagctgcat 20

<210> 131

<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 131  
caagaagtag atcacacagg

20

<210> 132  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 132  
cattgctggt accgtgagct

20

<210> 133  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 133  
ctccagagca gaggcctggg

20

<210> 134  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 134  
aaccacgcag ctccagagca

20

<210> 135  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 135  
tcatgttgga aaccacgcag

20

<210> 136  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 136  
gctgctcagg tcatgttgga

20

<210> 137  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 137  
gctgtggcct catgtaggaa

20

<210> 138  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 138  
catcagccga gctgtggcct

20

<210> 139  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 139  
ccgggcagga cttgctcctg

20

<210> 140  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 140  
tttgccactg gaacctgccc

20



<210> 141  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 141  
gtgtgctccc gccatgtggg

20

<210> 142  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 142  
caggagcatc tgctggcagt

20

<210> 143  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 143  
gggtctagct ggaagtgcg

20

<210> 144  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 144  
tctgccacta gaggtcggca

20

<210> 145  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 145  
gcctacagag caagaggggtg

20

<210> 146  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 146  
aaaatttctc aacctatgaa

20

<210> 147  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 147  
tgagaacact tgtttcaagg

20

<210> 148  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 148  
gccaatagct gcctttagat

20

<210> 149  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 149  
gtgttcccac cgctggttcg

20

<210> 150  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 150

ttactggcgg tcactgtcgt

20

<210> 151  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 151  
ttggccgtac ctttgcttca

20

<210> 152  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 152  
ccacactatt ctcagctagc

20

<210> 153  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 153  
agaaggcagc atcaggggtg

20

<210> 154  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 154  
ttcagtgtatt ctgttaggcag

20

<210> 155  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 155  
agagtccaac ctggctatcc

20

<210> 156  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 156  
cttaccgccc ccaaattccag

20

<210> 157  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 157  
gggatgagac agactggaga

20

<210> 158  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 158  
gtgtacttgc ctgcaaagtg

20

<210> 159  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 159  
ctggcaccac tgtgcagaca

20

<210> 160  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 160  
gcagtggcag tgactcggag

20

<210> 161  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 161  
tcaacaacca agacagtgac

20

<210> 162  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 162  
aaccaagaca gtgacttccc

20

<210> 163  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 163  
agacagtgac ttccctggcc

20

<210> 164  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 164  
cacttcatca aggcagactc

20

<210> 165  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 165  
ctcgcagctg gcagcaaggc

20

<210> 166  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 166

gcaaagctga ataaatctgc

20

<210> 167  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 167  
gctgaataaa tctgctgtct

20

<210> 168  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 168  
ataaatctgc tgtcttgcg

20

<210> 169  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 169  
tctgctgtct tgcgcaaggc

20

<210> 170  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 170  
tgtcttgcg aaggccatcg

20

<210> 171  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 171  
tgcgcaaggc catcgactac

20

<210> 172  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 172  
atgctggacc gctcccgct

20

<210> 173  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 173  
tgccatgcag tggctctgcc

20

<210> 174  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 174  
gtggccaagt ggtgggcctc

20

<210> 175  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 175  
agctgtggtg atccactggc

20

<210> 176  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 176  
actccttcaa ggctgcccgg

20

<210> 177  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 177  
ccatctgtga gaaggccagt

20

<210> 178  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 178

gaaggccagt gggtagctgc

20

<210> 179

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 179

tgcaaaccttt attttcatag

20

<210> 180

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 180

ccttgacagg tgaagtcggc

20

<210> 181

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 181

atttctgcag gaagccctcc

20

<210> 182

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 182

caccgtgcag ctgaataaat

20

<210> 183

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 183

ctcctggcca aggctggtgc

20

<210> 184

<211> 20



<212> DNA  
<213> H. sapiens

<220>

<400> 184  
catgcggagg gtgagtgcc

20

<210> 185  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 185  
gtagggccaa cggcctggac

20

<210> 186  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 186  
gcggagccat ggattgcact

20

<210> 187  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 187  
aagacatgct tcagcttata

20

<210> 188  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 188  
ctctgaggcc agggcaggac

20

<210> 189  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 189  
gctgcgcat ggacgagcca

20

<210> 190  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 190  
agccaccctt cagcgaggcg

20

<210> 191  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 191  
acatcgaaga catgcttcag

20

<210> 192  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 192  
ccacctcctg ccacattgag

20

<210> 193  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 193  
tcctgccaca gagcttccca

20

<210> 194  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 194  
gctgcctggc ctgccactgg

20

<210> 195  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 195  
acagggcctt tgccgaccct

20

<210> 196  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 196  
tgcctatcaa ccggctcgca

20

<210> 197  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 197  
cgtggagaga agcgcacagc

20

<210> 198  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 198  
caaggatctg gtggtgggca

20

<210> 199  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 199  
caggagaacc taagtctgcg

20

<210> 200  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 200  
cactgctgtc cacaaaagca

20

<210> 201  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 201  
ctggtgtcgg cctgtggcag

20

<210> 202  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 202  
gaggcatcgc aagcaggctg

20

<210> 203  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 203  
gcaggctgac ctggacctgg

20

<210> 204  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 204  
agccctggtc taccataagc

20

<210> 205  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 205  
tggccgagat ctatgtggcg

20

<210> 206  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 206  
gatctatgtg gcggctgcat

20

<210> 207  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 207

ggaacatctc ttagagcgag

20

<210> 208

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 208

ccagccctgg gtcagctgat

20

<210> 209

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 209

aaggcagagt ctggtccagc

20

<210> 210

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 210

taccacacca gccagcagct

20

<210> 211

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 211

gcttccgccc ttgagctgcg

20

<210> 212

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 212

cagcagatgc tcatgcgccct

20

<210> 213

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 213

gtgggaccac tgtcacttcc

20

<210> 214

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 214

tgtcacttcc agctagaccc

20

<210> 215

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 215

ctagccactt tgggtcccgtg

20

<210> 216

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 216

cccgtgcagc ttctgtcctg

20

<210> 217

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 217

acctgcggct gctgtgtgcc

20

<210> 218

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 218

gtgtgccttc gcggtggaag

20

<210> 219

<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 219  
cggcggccat gatggtgctg

20

<210> 220  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 220  
ttgctctgca ggcaccttag

20

<210> 221  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 221  
agaggggtac atttccctgt

20

<210> 222  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 222  
ccctgtgctg acggaagcca

20

<210> 223  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 223  
gccaaacttgg ctttcccgga

20

<210> 224  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 224  
cagcgtgctt agcctcctga

20

<210> 225  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 225  
tactttgcct ttgcaaact

20

<210> 226  
<211> 20  
<212> DNA  
<213> H. sapiens

<220>

<400> 226  
agttttgtac agagaattaa

20

<210> 227  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 227  
acggagccat ggattgcaca

20

<210> 228  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 228  
cttcctggga ggaccaagg

20

<210> 229  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 229  
tgacacctgc acccttgtcc

20

<210> 230  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 230



agccagtgcc actcaccatc

20

<210> 231  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 231  
cacagacaaa ctgcccatcc

20

<210> 232  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 232  
cgtggtgaga agcgcacagc

20

<210> 233  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 233  
ccacaatgcc attgagaagc

20

<210> 234  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 234  
ggtgtcagct tgtggcagtg

20

<210> 235  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 235  
aggcacagat gtgtctatgg

20

<210> 236  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 236  
tggtggcagt gactctgagc

20

<210> 237  
<211> 20  
<212> DNA  
<213> M. musculus

&lt;220&gt;

<400> 237  
ggatagccag gtcaaagccc

20

<210> 238  
<211> 20  
<212> DNA  
<213> M. musculus

&lt;220&gt;

<400> 238  
ttggaccag tggttgctgc

20

<210> 239  
<211> 20  
<212> DNA  
<213> M. musculus

&lt;220&gt;

<400> 239  
gtctggctgg ccaatggact

20

<210> 240  
<211> 20  
<212> DNA  
<213> M. musculus

&lt;220&gt;

<400> 240  
actagtgttg gcctgcttgg

20

<210> 241  
<211> 20  
<212> DNA  
<213> M. musculus

&lt;220&gt;

<400> 241  
acacttctgg agacatcgca

20

<210> 242  
<211> 20  
<212> DNA  
<213> M. musculus

&lt;220&gt;

&lt;400&gt; 242

acctcaaacc tggatctggc

20

&lt;210&gt; 243

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; M. musculus

&lt;220&gt;

&lt;400&gt; 243

ggccgctggc tggcaggcca

20

&lt;210&gt; 244

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; M. musculus

&lt;220&gt;

&lt;400&gt; 244

catgccatgg gcaagtacac

20

&lt;210&gt; 245

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; M. musculus

&lt;220&gt;

&lt;400&gt; 245

ggcaacactg gcagagatct

20

&lt;210&gt; 246

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; M. musculus

&lt;220&gt;

&lt;400&gt; 246

gctctgccac cctgtaggtc

20

&lt;210&gt; 247

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; M. musculus

&lt;220&gt;

&lt;400&gt; 247

cagcgtggct gggaaccag

20

&lt;210&gt; 248

&lt;211&gt; 20

<212> DNA  
<213> M. musculus

<220>

<400> 248  
acagggagtt ctcagatgcc

20

<210> 249  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 249  
cagacccagt ggccaagtgg

20

<210> 250  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 250  
ctctgtactc cttcaaggct

20

<210> 251  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 251  
tgctggacca cagaaagggtg

20

<210> 252  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 252  
atgcagctgc tcctgtgtga

20

<210> 253  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 253  
cctgtgtgat ctacttcttg

20

<210> 254  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 254  
agctcacggt accagcaatg

20

<210> 255  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 255  
tgctctggag ctgcgtggtt

20

<210> 256  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 256  
ctgcgtggtt tccaacatga

20

<210> 257  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 257  
ttcctacatg aggccacagc

20

<210> 258  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 258  
aggccacagc tcggctgatg

20

<210> 259  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 259  
caggagcaag tcctgcccgg

20

<210> 260  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 260  
gggcagggttc cagtggcaaa

20

<210> 261  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 261  
cccacatggc gggagcacac

20

<210> 262  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 262  
tgccgacctc tagtggcaga

20

<210> 263  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 263  
caccctcttg ctctgtaggc

20

<210> 264  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 264  
ttcataggtt gagaaatttt

20

<210> 265  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 265  
ccttgaaaca agtgttctca

20

<210> 266  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 266  
atctaaaggc agctattggc

20

<210> 267  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 267  
acgacagtga ccgccagtaa

20

<210> 268  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 268  
tgaagcaaag gtacggccaa

20

<210> 269  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 269  
gctagctgag aatagtgtgg

20

<210> 270  
<211> 20  
<212> DNA  
<213> M. musculus

<220>

<400> 270  
ccaccctgat gctgccttct

20

<210> 271  
<211> 20  
<212> DNA  
<213> M. musculus

&lt;220&gt;

&lt;400&gt; 271

ggatagccag gttggactct

20

&lt;210&gt; 272

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; M. musculus

&lt;220&gt;

&lt;400&gt; 272

ctggatttgg cccgggtaag

20

&lt;210&gt; 273

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; M. musculus

&lt;220&gt;

&lt;400&gt; 273

cactttgcag gcaagtacac

20